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I hope that none of you are yet tired of playing with bubbles because… there is more in a 
common bubble than those who have only played with them generally imagine. 
 
-C.V. Boys “Soap Bubbles and the Forces which Mold Them” 
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ABSTRACT 
 Tissues arising late in evolutionary time, such as lung alveoli that are unique to air 
breathing organisms, have been challenging to generate in vitro from pluripotent stem 
cells (PSCs), in part because there are limited lower organism model systems available to 
provide the necessary developmental roadmaps to guide in vitro differentiation. 
Furthermore, pulmonary alveolar epithelial type II cell (AEC2) dysfunction has been 
implicated as a primary cause of pathogenesis in many poorly understood lung diseases 
that lack effective therapies, including interstitial lung disease (ILD) and emphysema. 
Here we report the successful directed differentiation in vitro of human PSCs into 
AEC2s, the facultative progenitors of lung alveoli. Using gene editing to engineer 
multicolored fluorescent reporter PSC lines (NKX2-1GFP;SFTPCtdTomato), we track and 
purify human SFTPC+ alveolar progenitors as they emerge from NKX2-1+ endodermal 
developmental precursors in response to stimulation of Wnt and FGF signaling. Purified 
PSC-derived SFTPC+ cells are able to form monolayered epithelial spheres 
(“alveolospheres”) in 3D cultures without the need for mesenchymal co-culture support, 
		 xi 
exhibit extensive self-renewal capacity, and display additional canonical AEC2 
functional capacities, including innate immune responsiveness, the production of lamellar 
bodies able to package surfactant, and the ability to undergo squamous cell differentiation 
while upregulating type 1 alveolar cell markers. Guided by time-series global 
transcriptomic profiling we find that AEC2 maturation involves downregulation of Wnt 
signaling activity, and the highest differentially expressed transcripts in the resulting 
SFTPC+ cells encode genes associated with lamellar body and surfactant biogenesis. 
Finally, we apply this novel model system to generate patient-specific AEC2s from 
induced PSCs (iPSCs) carrying homozygous surfactant mutations (SFTPB121ins2), and we 
employ footprint-free CRISPR-based gene editing to observe that correction of this 
genetic lesion restores surfactant processing in the cells responsible for their disease. 
Thus we provide an approach for disease modeling and future functional regeneration of 
a cell type unique to air-breathing organisms. 
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INTRODUCTION 
The Alveolar Epithelial Type II cell and its role in the lung 
 The evolution of air breathing in vertebrate animals is closely aligned with the 
appearance of particular cell types in the fish swim bladder, which was conserved in its 
evolutionary derivative, the lung. More specifically, alveolar epithelial cells (AEC) are 
present on a microscopic scale at the air/blood interface in all air-breathing animals, 
despite extreme variations in gross lung architecture between reptiles, birds, amphibians, 
and mammals. 
The major role of the alveolar epithelium is to interface with the pulmonary 
vasculature and facilitate oxygen and carbon dioxide exchange with the circulatory 
system. The alveolar epithelium consists of two cell types: the type I cell (AEC1) and the 
type II cell (AEC2). Large, squamous AEC1s represent around 40% of alveolar epithelial 
cells and cover around 95 % of the alveolar surface area and play the primary role in 
alveolar gas exchange. In contrast, smaller cuboidal AEC2s represent around 60% of 
alveolar epithelial cells, covering only around 5% of the alveolar space (Stone et al. 
1992). AEC2s are highly metabolically active and serve multiple functions, including 
synthesizing and secreting pulmonary surfactant, serving as a progenitor of both AEC1s 
and AEC2s in response to alveolar damage, maintaining the alveolar fluid lining, and 
protecting the thin-walled alveolus from toxins and pathogens by mediating the innate 
immune response (Mason 2006).  
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The AEC2: A Surfactant Factory 
The most well characterized function of the AEC2 is its ability to synthesize, 
secrete, and recycle pulmonary surfactant. Surfactant, or “surface active agent,” is a lipid-
rich substance that lines the alveolar wall and reduces surface tension within the alveolus 
to near-zero values during expiration. This prevents alveolar collapses and eases the work 
of breathing. Surfactant production is essential to air breathing; indeed, all air breathing 
animals have surfactant present in their lungs. 
Early Days in Surfactant Biology 
The existence of functional surfactant was first conclusively proven in 1959, with 
the seminal work by Avery and Mead showing that premature infants with “hyaline 
membrane disease,” at that time the number one cause of infant mortality, lacked 
surfactant in their lungs. Since this finding launched the entire field of AEC2 and 
surfactant biology, it is important to place it in historical context and comment on the 
visionary physicists, biologists, and physicians who brought it to fruition, (reviewed in 
Comroe 1977).  
The discovery of surfactant’s role in lung biology was built upon observations 
made as early as 1929 by von Neergaard that first suggested that surface tension was as 
important a force as elastic recoil in respiratory mechanics, which went unnoticed for 25 
years until it was rediscovered and confirmed by Radford in 1954. Also in 1954, a key 
observation was made by Macklin, who hypothesized that AEC2s, or “granular 
pneumonocytes,” were the most likely source of the thin, mucoid film in the alveolus, 
which played a role in reduction of alveolar surface tension (Macklin 1954). Meanwhile, 
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Pattle, a physicist focused on studying the properties of alveolar foam in the context of 
chemical warfare, showed that unlike foam from the serum or other sites, foam from the 
lungs did not shrink when submerged in water, surprisingly suggesting a surface tension 
within the lung “bubbles” of close to zero (Pattle 1955). Finally, the quantitative 
confirmation of the existence of surfactant in the lung came in 1957, when Clements 
reported a remarkably low surface tension in surface films made from lung extracts (1-10 
dynes/cm2, compared to >50dynes/cm2 in plasma extracts) after compression (Clements 
1957). Two years later, Avery and Mead reported that when compared to the low surface 
tension in lung extract surface films from patients who died of other causes (<10 
dynes/cm2), films from infants with hyaline membrane disease had a surface tension of 
>30 dynes/cm2. Hyaline membrane disease was not, as was previously thought, caused by 
an increase in eosinophilic exudate or alveolar “stickiness,” but by a lack of surfactant 
(Avery & Mead 1959).  
Up to this point, the cell of origin for surfactant had been postulated to be the 
AEC2 by Macklin, but without conclusive proof. In the late 1950s and early 1960s, 
researchers found an association between the appearance of lipid-rich lamellated 
inclusions, or “lamellar bodies” in AEC2s and the earliest detection of surfactant in lung 
lysates at around E17-18 in fetal mice (Woodside & Dalton 1958; Buckingham & Avery 
1962). Electron micrograph images showing the release of lamellar bodies from the 
AEC2 into the alveolar space and continuities between lamellar bodies and tubular 
myelin that lines the alveolar space further confirmed that AEC2s were the source of 
surfactant (Williams 1977).  
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Figure 1.1. Lamellar body secretion.   
Left panel shows a lamellar body being extruded from an AEC2 into the alveolar space in a 21-day fetal rat lung 
(Comroe 1977). Right panel shows lamellar body that was extruded into the alveolar space of 21-day fetal rat lung. 
Continuities between the membranes of the lamellar body and tubular myelin suggest surfactant takes on a new 
conformation in the alveolar space (Williams 1977).  
 
Taken together, these studies showed that surfactant, arising from the late-fetal 
AEC2 was necessary for prevention of atelectasis after birth.  An additional study by 
Liggins in 1969 showed that lambs delivered prematurely had normal lung function when 
their mother was given a dexamethasone infusion, suggesting that AEC2 maturation was 
accelerated by corticosteroids (Liggins 1969). This was confirmed in humans (Liggins & 
Howie 1972), and is now a mainstay of care for pregnancies likely to result in premature 
delivery.  
Surfactant Composition: Lipids and Proteins 
With the knowledge of the importance of surfactant in lung biology, and the 
existence of a cell type uniquely involved in its synthesis, molecular biologists went on to 
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study surfactant biosynthesis and composition. In 1972, Chevalier and Collet first 
demonstrated the series of biosynthesis, processing, and trafficking events that results in 
surfactant secretion by AEC2s. They showed that after injection into the adult mouse, 
both radiolabeled choline and radiolabels leucine (surfactant phosphatidylcholine and 
protein precursors, respectively) could be traced first to the AEC2 endoplasmic 
reticulum, then to the Golgi, next to multivesicular bodies, and finally to mature lamellar 
bodies before being secreted into the alveolar space (Chevalier & Collet 1972).  
Surfactant is comprised primarily (~90%) of phospholipids (PLs), including a 
high proportion of phospatidylcholine (~66%), and more specifically, a high 
concentration of a surfactant-specific PL, dipalmitoylphosphatidylcholine (DPPC; ~41%) 
(Parra & Perez-Gil 2015). In general, surfactant phospholipids form a monolayer at the 
alveolar air/liquid interface with the hydrophilic head group positioned near the aqueous 
cell surface and the hydrophobic tails pointing toward the luminal air. During the 
dynamic process of alveolar compression and expansion during breathing, the surface 
monolayer is maintained in conjunction with a phospholipid bilayer within the 
“hypophase,” or the aqueous region between the monolayer and the cell (Wright & 
Clements 1987). As the alveoli expand, phospholipids from the hypophase transition into 
the monolayer, and when the alveoli contract, these lipids return to the hypophase 
without disrupting the surface monolayer. DPPC is uniquely suited for surfactant film 
because it consists of two saturated palmitic acid tails, which can be tightly compressed 
during exhalation, in the process eliminating water molecules in the alveolar lining and 
reducing surface tension (Possmayer 1991). Other lipid species, including 
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phosphatidylgylcerol (PG), phosphatidylinositol (PI), and neutral lipids such as 
cholesterol also contribute to the composition of surfactant (Parra & Perez-Gil 2015).  
Though the functional components of surfactant were initially though to be 
entirely composed of phospholipids, when phospholipid-based mixtures failed to replace 
surfactant in vivo, attention turned to the possibility that the minor protein component of 
surfactant also played an essential role in surfactant function. Tubular myelin, the 
surfactant layer visible on EM, has a specific lattice-like structure that could not result 
from a simple mixture of phospholipids. Indeed, King and Clements showed that when 
the protein fraction of surfactant was removed, the surface film did not develop as rapidly 
(King & Clements 1972). The same group identified the first known surfactant protein, 
surfactant protein A (SFTPA), a 36 kD glycoprotein (King et al. 1973). Subsequently, 
other researchers identified the two hydrophobic surfactant proteins B and C (SFTPB and 
SFTPC) (Suzuki et al. 1982; Phizackerley et al. 1979), and surfactant preparations that 
contained these two proteins were shown to be effective in reducing surface tension in the 
lungs of  infants with “hyaline membrane disease” (Fujiwara et al. 1980).  
SFTPB plays a critical role in establishing the surface film, and the absence of 
SFTPB, either in humans with SFTPB mutations or in SFTPB knockout mice, is 
incompatible with air breathing (Nogee et al. 1993; Clark et al. 1995). SFTPB is first 
translated as a 42kD protein, which, in AEC2s specifically, is cleaved sequentially in the 
Golgi and multivesicular body (MVB)/ lamellar body (LB) into its 8kD mature form 
(Guttentag et al. 1998). SFTPB is comprised of 52% hydrophobic residues and forms 
homodimers that are amphipathic in nature, and are found in the phospholipid headgroup 
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region of surfactant (Weinhold & Feldman 1995). This essential protein stabilizes the 
surfactant film and facilitates the transition from lamellar body to tubular myelin, and 
subsequently from tubular myelin to the phospholipid monolayer (Serrano et al. 2006).  
SFTPC, unlike SFTPB, is not essential for air-breathing; however, deficiency or 
abberant expression of SFTPC has been associated with increased susceptibility to 
infection and pulmonary fibrosis. Importantly, SFTPC is the only surfactant component 
that is specific to the adult AEC2, though it is expressed as early as week 12-15 of human 
development in the distal lung bud. SFTPC is an extremely hydrophobic protein (69% 
hydrophobic residues) that resides primarily in the integral membrane region of 
surfactant bilayer. SFTPC-/- mice exhibit normal lamellar bodies and tubular myelin, 
though their surfactant film becomes unstable at low lung volumes, suggesting a role for 
SFTPC in maintaining the connection between the phospholipid reservoir and the surface 
monolayer at low compression volumes (Glasser et al. 2001; Serrano & Perez-Gil 2006).  
Unlike the lung-specific hydrophobic surfactant proteins, SFTPA and SFTPD are 
C-type lectins that generally form hydrophilic multimers and do not play an essential role 
in maintenance of the surface film, though SFTPA has been shown to form the protein 
foundation for the net-like tubular myelin structure (Suzuki et al. 1989; Korfhagen et al. 
1996). SFTPA has been shown to enhance adsorption of phospholipid vesicles to the 
surface film (Sáenz et al. 2007). The primary roles of SFTPA and SFTPD are in innate 
immunity and will be discussed in a subsequent section. A summary of the proposed 
effects of surfactant proteins is below, originally from (Parra & Perez-Gil 2015):  
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Figure 1.2. Roles of surfactant proteins in maintaining the surface film. 
SFTPA octadecamer depicted in green aiding in vesicle adsorption, SFTPB depicted in red stabilizing surfactant 
bilayers and facilitating transfer between hypophase bilayers and surface monolayer, and SFTPC depicted in blue 
positioned to remove phospholipids from the monolayer in high compression states. (Adapted from Parra & Perez-Gil 
2015) 
 
Surfactant Trafficking: Synthesis to the Lamellar Body 
 AEC2s can be recognized easily on electron microscopy by their characteristic 
organelles, lysosome-related structures called lamellar bodies (LBs). LBs are among the 
largest intracellular secretory granules in any cell type, ranging in diameter from 100-
2000nm (Weaver et al. 2002). LBs share several features with lysosomes, including 
expression of soluble enzymes, lysosomal proteins like LAMP1 and LAMP3, and acidic 
contents. LBs are thought to be formed from multivesicular bodies, or MVBs (Stahlman 
et al. 2000), which in turn form from early endosomes (Piper & Luzio 2001). The protein 
components in LBs are translated in the ER, then move to the Golgi, MVB, and finally 
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Air
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the LB. Proteins are also endocytosed from the alveolar surface, recycled in endosomes, 
and brought into LBs.  
 
Figure 1.3. Multivesicular bodies and lamellar bodies (from Weaver 2000) 
Left panel shows pro-SFTPC immunogold staining on cryo-EM sections of a fetal mouse lung, with arrows showing 
positive labeling. Scale bar 200nm. Right panel shows MVB transition to LB, with a shared limiting membrane. Scale 
bar 500nm.  
Within MVBs and LBs, SFTPB is cleaved into its mature 8kD form through the action of 
the enzymes napsin A, cathepsin H, and pepsinogen C, and mature SFTPB is required for 
the formation of LBs and the processing and transport of SFTPC (Mulugeta et al. 2015).  
Pepsinogen C is expressed specifically in AEC2s post week 22 human gestation, just 
before the expression of 8kD SFTPB, suggesting an important role in LB biogenesis 
(Foster et al. 2004).  
 Surfactant lipids are synthesized in the ER as well, but unlike surfactant proteins, 
they do not require trafficking through the Golgi and MVBs to enter LBs (Osanai et al. 
2001) and the enzymes involved in their synthesis, including the rate limiting enzyme in 
generating phophatidylcholine, phosphocholine cytidyl transferase, are found only in the 
ER and cytosol (Feldman et al. 1990). The appearance and disappearance of large 
cytoplasmic pools of glycogen near end-gestation, coincident with production of 
surfactant suggests that glycogen may provide the initial substrate for phospholipid 
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synthesis in the developing AEC2 (Kikkawa et al. 1971). Once synthesized in the cytosol 
or ER, phospholipids must enter the LB through an active process in order to be packaged 
into surfactant bilayers. ATP-binding cassette A3 (ABCA3) is an AEC2-specific protein 
in the lung found on the limiting membrane of the MVB/LB that enables transfer of 
surfactant phospholipids into the MVB/LB (Yamano et al. 2001). ABCA3-/- mice lacked 
LBs in their AEC2s, had reduced production of PC species, and died of neonatal 
respiratory distress, a phenotype apparent in human infants with ABCA3 deficiency as 
well (Shulenin et al. 2004; Cheong et al. 2007; Brasch et al. 2006).  
 
Surfactant Trafficking: The Lamellar Body to the Alveolar Surface and Back 
 LBs are secreted into the alveolar hypophase by regulated exocytosis. AEC2s 
express several SNARE proteins, annexins (II, VII, and A2), and P2X4 receptors that are 
associated with calcium-induced exocytosis, and both increased intracellular and 
extracellular calcium promotes surfactant secretion (Bruni et al. 1988; Miklavc et al. 
2011). Hyperventilation has been shown to rapidly induce surfactant secretion via 
calcium-mediated exocytosis, highlighting the effect of mechanical stretch (Patel et al. 
2005; Nicholas & Barr 1983; Wirtz & Dobbs 1990). In addition, activation of b-
adrenergic receptors (cAMP/PKA pathway; active during labor), activation of PKC via 
phorbol esters, DAG, or purinergic activation of PLC, and stimulation of calmodulin-
dependent protein kinase are known to increase surfactant secretion (Mason & Voelker 
1998). Molecules that activate these pathways, therefore, can be referred to as 
“secretagogues.” 
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 Finally, removal of inactivated surfactant from the surface film is important in 
maintaining alveolar surface tension. The alveolar macrophage plays an important role in 
surfactant uptake and catabolism, as evidenced by genetic mouse models of GM-CSF 
deficiency resulting in dysfunctional alveolar macrophages and an accumulation of 
surfactant proteins and phospholipid in the alveolar space, similar to the human disease 
pulmonary alveolar proteinosis thought to result from altered GM-CSF signaling 
(Ikegami et al. 1996; Trapnell et al. 2003; Kitamura et al. 1999). AEC2s also endocytose 
used surfactant either recycling SFTPB, SFTPC, and phospholipids into late endosomes, 
MVBs, composite bodies, and ultimately back into LBs for secretion or targeting them 
for degradation (Rückert et al. 2003). Though there is no known role for SFTPD in 
surfactant stabilization, SFTPD-/- mice do exhibit reduced surfactant endocytosis, 
possibly via a GPR116 receptor mediated pathway (Poulain et al. 1999; Fukuzawa et al. 
2013).  
  
The proper expression and regulation of all components of the surfactant 
synthesis, secretion, and recycling pathways are important for normal AEC2 function, 
and in our attempt to generate mature AEC2s in vitro, it is important that we first 
characterize them.   
AEC2s: The “Defender of the Alveolus” 
In the process of bringing oxygen into the lungs from the outside air, the alveolar 
epithelium is exposed to a wide variety of insults, from airborne toxins to disease-causing 
organisms. If the lung were to mount an immune response to every foreign exposure, it 
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would likely be in a state of chronic inflammation (Mason 2006). In order to avoid 
having to mount this full-fledged adaptive immune response, both the lung resident 
immune cells and lung epithelial cells play innate immune roles that keep infectious or 
irritant agents at bay. It is possible, indeed likely, that AEC1s are involved in immune 
signaling, but because AEC1s are more difficult to isolate and culture in-vitro, research to 
this point has primarily focused on the role of the AEC2 in innate immunity (Mason 
2006). Beyond the epithelial cells that make up the alveolar wall, the alveolar 
macrophage situated inside the air space is the resident immune cell of the alveolus.  
Surfactant as an innate immune molecule 
In their resting state, AEC2s secrete several antimicrobial molecules, leading the 
pre-eminent AEC2 biologists Robert J. Mason and Mary C. Williams to refer to the 
AEC2 as the “defender of the alveolus.” (Mason & Williams 1977) The alveolar lining 
fluid, produced primarily by AEC2s has been known to play a key role in innate 
immunity since LaForce and colleagues showed in 1973 that alveolar macrophages were 
only capable of inactivating phagocytosed Staphylococcus aureus after pre-incubation of 
the bacteria with alveolar lining fluid (LaForce et al. 1973). Since then, researchers have 
identified many of the AEC2-related soluble factors that are involved in pulmonary host 
defense.  
AEC2s are known to be highly biosynthetically active, synthesizing both lipids 
and proteins that make up surfactant, including surfactant proteins A, B, C, and D 
(SFTPA, SFTPB, SFTPC, and SFTPD). SFTPB and SFTPC are classically thought of as 
structural components of the surfactant film that lines the alveolus and reduces surface 
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tension, though studies suggest that they may have an immune function as well. SFTPC 
knockout mice exhibit increased inflammation when challenged with LPS or respiratory 
syncytial virus (RSV), suggesting an anti-inflammatory role for SFTPC protein (Glasser 
et al. 2013; Glasser et al. 2009). SFTPB has been shown to have direct antimicrobial 
activity as well (Ryan et al. 2006).  SFTPA and SFTPD, however, are better characterized 
as members of the collectin family of C-type lectin proteins, involved in recognition, 
binding, and clearance of pathogens (van Iwaarden et al. 1990; Tenner et al. 1989). Both 
pulmonary collectins have been shown to stimulate alveolar macrophage chemotaxis and 
bind pathogens, ranging from viruses to bacteria, fungi, and yeast (Schagat et al. 2001) . 
In particular, SFTPA knockout mice exhibit a decrease in alveolar macrophage binding 
and phagocytosis of both bacteria and viruses, as well as an increase in pro-inflammatory 
cytokine release in response to infection (LeVine et al. 2000). SFTPD knockout mice 
develop emphysema (Wert et al. 2000), exhibit deficiencies in viral clearance, increased 
macrophage apoptosis, and increased release of pro-inflammatory cytokines in response 
to infection (LeVine et al. 2000). Even in the absence of immune cells, pulmonary 
collectins can inhibit bacterial growth in vitro (Wu et al. 2003).  
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Figure 1.4. Roles of SFTPA and SFTPD in innate immunity (Wright 2005).   
As summarized in figure 1.4 (Wright 2005), the direct-killing, pro-phagocytotic, 
and anti-inflammatory properties of the pulmonary collectins have been well 
documented.  
AEC2 as mediators of innate and adaptive immune response 
In addition to the pulmonary collectins, AEC2s synthesize and secrete several 
immune complement proteins, including C2, C3, C4, and C5, as well as cytokines and 
chemokines, including IL-1a, IL-1b, TNF, IL-6, IL-8, GM-CSF, and RANTES (Strunk et 
al. 1988; Mason 2006). AEC2s also express toll-like receptors such as TLR2 and TLR4, 
making them capable of responding to pathogen-associated molecular patterns (PAMPs) 
expressed on many pathogenic microorganisms (Whitsett & Alenghat 2014), including 
pneumococcal pneumonia, influenza virus, and Mycobacterium tuberculosis. In response 
to pneumococcal pneumonia, cytokines secreted by AEC2s, including IL-6 and TNF, 
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increase neutrophil recruitment to the alveolar space and bacterial killing (Quinton et al. 
2008) (Quinton et al. 2007). After exposure to influenza virus, AEC2s have been shown 
to secrete GM-CSF, attracting both CD103+ dendritic cells and CD4+ and CD8+ T cells 
to the site of infection, thereby aiding both innate and adaptive immunity (Unkel et al. 
2012). In a final example, AEC2s are also involved in host response to Mycobacterium 
tuberculosis (MTB), recruiting macrophages and adaptive immune cells, as well as 
possibly serving as a site of latent MTB infection (Scordo et al. 2016). Considering the 
burden of lower respiratory tract infection on public health and the likely role of the 
AEC2 in both detecting pathogenic organisms and interacting with immune mediator 
cells, more studies are needed to elucidate the details of these interactions.  
AEC2s, Inflammation, and Pulmonary Fibrosis 
Beyond their role in acute infection, it is also possible that AEC2s contribute to a 
chronic inflammatory state that underlies the pathogenesis of fibrotic lung disease. 
Mutations in genes such as SFTPA and SFTPC, the latter of which is extremely specific 
to the AEC2, are known to cause familial interstitial lung disease likely mediated by an 
overactive unfolded protein response and endoplasmic reticulum (ER) stress (Maguire et 
al. 2012). Chronic inflammation of any etiology could promote fibrosis, and in one study, 
at least one herpesvirus was found in lung samples of 97% of subjects with idiopathic 
pulmonary fibrosis (IPF) compared with 36% of healthy controls (Tang et al. 2003). 
Since herpesviruses have also been shown to induce ER stress in-vitro (Isler et al. 2005) 
and to be associated with ER stress in the alveolar epithelium of IPF patients (W. E. 
Lawson et al. 2008), it is conceivable that chronic infection could lead to fibrosis as well. 
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The exact mechanism by which ER stress in the AEC2 leads to cellular dysfunction, local 
inflammation, and fibrosis is unknown, and new models are needed to clarify how the 
initial epithelial insult propagates to lung mesenchymal and immune cells. 
The Facultative Progenitor Cell of the Alveolus 
 Another way in which AEC2s “defend” the alveolus is by responding to alveolar 
injury by re-entering cell-cycle to re-establish the alveolar barrier. Since the large 
diameter of AEC1s makes them highly susceptible to toxins and pathogens, AEC2s play 
an important role in replacing damaged AEC1s as well as in self-replicating.  
 Experiments in alveolar injury date back to the early 1970s, when Evans and 
colleagues injured mice with toxic doses of nitrous oxide and observed an increase in 
AEC2 proliferation and differentiation into AEC1s (Evans et al. 1972). Since then, 
models have included hyperoxia, pneumonectomy, bleomycin, acid, and infection, among 
others (Matute-Bello et al. 2008). Though histopathology of injured alveoli can suggest 
the mechanism of injury and re-epithelialization, lineage tracing studies are necessary to 
conclusively show which populations of cells have regenerative capacity.  
 The intratracheal bleomycin model is one of the most commonly used alveolar 
injuries, causing acute pulmonary inflammation and AEC1 necrosis followed by AEC2 
proliferation and reversible fibrosis (Moore & Hogaboam 2007). After intratracheal 
bleomycin instillation, both Scgb1a1 trace+ cells and Sftpc trace+ cells contribute to 
repopulation of the alveolar epithelium, with cells labeled by both reporters generating 
AEC1s and AEC2s (Rock et al. 2011). Since both club cells and some AEC2s express 
Scgb1a1, AEC2s could be responsible for the entire injury response. Another putative 
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alveolar progenitor cell, the Integrin a6/b4+ Stpc- distal cell, has been shown to be 
capable of differentiation into Sftpc+ AEC2s ex vivo and to increase in number after 
intratracheal bleomycin injury (Chapman et al. 2011). Finally, in epithelial-specific 
injury, wherein Sftpc+ AEC2s are genetically engineered to express a tamoxifen-
inducible diphtheria toxin cassette, Sftpc trace+ cells proliferate clonally after dTA-
induced injury (Barkauskas et al. 2013). Though AEC2s are quiescent at the steady state, 
since they can self-renew and differentiate into AEC1s in response to alveolar injury, 
they can be referred to as the “facultative progenitor” of the alveolus. The mechanism by 
which AEC2s regenerate the alveolar epithelium is unknown, but reports have suggested 
that perturbations in WNT signaling alter normal post-bleomycin AEC2 injury repair 
(Tanjore et al. 2013; Henderson et al. 2010), and that exogenous KGF, a well-studied 
lung epithelial mitogen, improves bleomycin induced fibrosis in mice (Sakamoto et al. 
2011).  
 The influenza infection model is an attractive alveolar injury model because, 
unlike intratracheal bleomycin, it represents a well-known mechanism of human disease. 
In response to influenza A infection, in areas of the lung where AEC2s are left intact, 
Sftpc trace+ cells do differentiate into AEC1s (Yee et al. 2017); however, in areas of the 
lung with profound epithelial injury, previously lineage negative “LNEPs,” when 
intranasally instilled into influenza-exposed mice, upregulate keratin 5, migrate to the 
injured area, and, after downregulation of Notch signaling, are claimed to repopulate the 
alveolar epithelium, including Sftpc+ AEC2s (Vaughan et al. 2015). It has not been 
shown yet that these cells play a role in endogenous injury repair, however, and the 
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existence of alternative sources of AEC2s remain controversial and have yet to be 
reproduced in other labs.  
 One important question that remains is whether the regenerative capacity of 
AEC2s is common to all AEC2s or specific to a particular subpopulation. Studies have 
suggested that there may be a more proliferative AEC2 subtype, with Sca1+ AEC2s 
proliferating preferentially in response to infection with Pseudomonas aeruginosa (Liu et 
al. 2011), and Axin2+ AEC2s proliferating preferentially in response to  ex vivo culture 
conditions (Frank et al. 2016). Further studies are needed, especially leveraging single 
cell RNA-sequencing technologies, to understand which AEC2 subpopulations might 
exist, and how they differ in injury-response capacity.  
  
Current approaches to modeling alveolar disease 
 AEC2s have been notoriously difficult to study, both in vivo and in vitro. Since 
lung alveoli developed late in evolutionary time, lower organism models fail to 
recapitulate some key aspects of human AEC2 biology, especially because mice and 
humans vary in alveolar innate immune response, with differences in expression of toll-
like receptors and various cytokines and chemokines, including IL-8, as well as 
expression of pulmonary intravascular macrophages (Matute-Bello et al. 2008).  Alveoli 
are situated in the distal lung, not easily accessible during techniques like bronchoscopy, 
an important obstacle to human ex vivo AEC2 models. Access to human alveolar primary 
cells requires lung biopsy, an extremely invasive procedure, and human primary AEC2s 
have been shown to proliferate and maintain AEC2 phenotype for no more than 1 week 
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in-vitro without the addition of mesenchymal feeders, limiting the time in which 
experiments could be conducted (Dobbs 1990) (Gonzales et al. 2002). Primary AEC2s 
can be maintained in 3D culture for multiple passages, but only with mesenchymal feeder 
co-culture, complicating the study of AEC2-specific biology (Barkauskas et al. 2013).  
Murine models of alveolar disease 
Though most of our current knowledge of lung developmental biology comes 
from invaluable mouse genetic models, mouse injury response models have sometimes 
failed to recapitulate human disease progression. In some fields, such as cystic fibrosis 
biology, this has led researchers to focus on alternate model organisms, such as ferrets or 
pigs. Looking at pulmonary fibrosis models specifically, both drug and genetics-based 
insults result in pathology that differs from that seen in human patients. The most well 
characterized mouse model of pulmonary fibrosis is the intratracheal or intraperitoneal 
bleomycin injury model. In humans, bleomycin is a chemotherapeutic that has a known 
side effect of causing irreversible, progressive pulmonary fibrosis. In mice, though 
fibrosis does develop after around 4 weeks of bleomycin treatment, it is generally a non-
progressive, self-limiting injury that varies in severity based on mouse strain (Moore & 
Hogaboam 2007). Similarly, mouse genetic models of human monogenic diseases known 
to cause early onset pulmonary fibrosis show variable consistency in disease progression 
with their human disease counterparts. For example, mice that express transgenic L188Q 
mutation in the SFTPC BRICHOS domain, known to cause familial interstitial 
pneumonitis in humans, do not develop fibrosis without an additional profibrotic insult 
(W. E. Lawson et al. 2011). It is certainly likely that mice expressing a fibrosis-causing 
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mutation from the endogenous SFTPC locus would better phenocopy human disease, and  
that humans also experience a “second hit” that leads to development of fibrosis. 
However, despite the obvious utility of mouse models in showing the phenotypic effects 
of genetic mutations in vivo, mouse models have sometimes diverged from human 
models of lung disease. Thus, it is important that valuable findings from murine models 
need to be validated in human alveolar cells. 
Primary AEC2 culture 
When researchers first attempted to isolate AEC2s and culture them ex vivo, they 
found that despite their known role as a progenitor cell in the alveolus, they had a limited 
capacity to proliferate in culture (Dobbs 1990). Furthermore, they adopted a flattened, 
more AEC1-like morphology, downregulated surfactant protein genes, and upregulated 
AEC1 genes. With the addition of glucocorticoids and cAMP agonists, AEC2 phenotype 
could be maintained for up to 7 days (J. Wang et al. 2007; Gonzales et al. 2002), but 
AEC2s cultured in either AEC2 or AEC1 conditions are transcriptionally very different 
than primary AEC2s or AEC1s (Gonzalez et al. 2005; Ballard et al. 2010). Though 
primary AEC2s can maintain their phenotype for several weeks in 3D matrigel culture, 
they do not proliferate without the addition of mesenchymal feeders at a ratio of between 
1 epithelial cell: 10-20 fibroblasts or endothelial cells (Barkauskas et al. 2013; Frank et 
al. 2016; Lee et al. 2014).  Studying AEC2-specific biology in the presence of 
mesenchymal feeders is complicated; since it would be challenging to dissect which 
experimental perturbation acted directly on AEC2s vs indirectly through effects on the 
feeder cells. Furthermore, AEC2s cultured in these “organoid” systems have not been 
		
21 
profiled transcriptionally or functionally compared to primary AEC2s, making it 
impossible to know their relevance as a primary cell surrogate. Finally, none of these ex-
vivo AEC2 culture models have been employed to model genetic human alveolar disease, 
and none have been shown to be amenable to gene-editing technologies.  
Studying alveolar disease with heterologous cell lines 
 Finally, faced with the lack of an easily accessible and expandable primary cell 
source, researchers have resorted to using overexpression of alveolar genes in 
heterolologous cell lines to provide insight into genetic drivers of alveolar injury. Human 
cell lines like HEK293s and HELA cells are known to be unrelated to the lung, but even 
lung-derived cell lines like A549 cells do not express surfactant proteins or lamellar 
bodies and are a poor surrogate for primary AEC2s (Mason & Williams 1980). Important 
findings from these systems include studies of mistrafficking of artificially overexpressed 
SFTPC dominant negative mutant proteins (Mulugeta et al. 2005; Maguire et al. 2012) 
and studies of the functional defects of artificially overexpressed ABCA3 mutant proteins 
(Weichert et al. 2011). While these reports show how mutant proteins would be trafficked 
in any cell, since AEC2s express such unique biosynthetic pathways and organelles, it is 
important that these studies are performed in a cell that spontaneously expresses 
surfactant proteins, lipids, and relevant organelles at levels similar to those in primary 
AEC2s.  
 Though many advances have been made in AEC2 biology and disease since the 
initial discovery of surfactant in the 1950s, a major obstacle to understanding disease 
mechanisms and finding therapeutics has been the lack of an accessible source of 
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expandable primary-like cells that can be studied in isolation. Understanding the culture 
conditions that promote the maintenance of AEC2 phenotype and developing a new 
method to generate mature AEC2s in vitro would be important steps toward solving this 
problem.  
Embryological origins of the AEC2 
The lung epithelium develops embryologically from an outpouching of the 
endoderm gut tube, specifically the anterior foregut endoderm. A small pool of 
endodermal NKX2-1+ primordial progenitor cells is specified early in development (E9.5 
in mice and week 4 in humans), and these cells are thought to divide and differentiate 
into all cells of the lung epithelium. AEC2s are one of the last cells in mammalian 
gestation to become fully mature, continuing to develop after birth in both mice and 
humans. Therefore, the roadmap of AEC2 differentiation spans quite a breadth of time, 
and recapitulating this roadmap in vitro proves to be nuanced and challenging.  
Developmental specification of foregut endoderm into primordial lung epithelium 
After gastrulation (E6.5 in mice), once the definitive endoderm has been 
specified, the endodermal gut tube begins to form, surrounded by signaling mesenchymal 
cells, and divided on an anterior/posterior axis into the foregut (most anterior, HHEX+, 
SOX2+), midgut, and hindgut (most posterior, CDX1-4+). By E8.0-9.5, organ-specific 
domains emerge, defined by transcription factors such as NKX2-1 (lung, thyroid), PDX1 
(pancreas), and HHEX (thyroid, liver), and the NKX2-1+ lung primordium separates 
from the SOX2+ esophageal primordium on the dorsal/ventral axis. The Nkx2-1+ cells of 
the lung primordium formed by E9.0 are hypothesized to represent the progenitor pool 
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from which all cells of the lung epithelium derive, since Nkx2-1 is the first gene known 
to be expressed in the endodermal lung primordium and appears to mark all the epithelial 
cells of the primordium (Lazzaro et al. 1991; Kimura et al. 1996), and NKX2-1 null mice 
exhibit hypoplastic lungs and lack of branching morphogenesis and mature lung markers 
(Minoo 1999). But what are the key regulators that result in specification of these cells?  
There have been several signaling pathways implicated in orchestrating 
differentiation of anterior foregut endoderm toward a lung epithelial fate, including 
WNT, fibroblast growth factor (FGF), bone morphogenic protein 4 (BMP), retinoic acid 
(RA), and sonic hedgehog (SHH) (Cardoso & Lü 2006). WNT signaling is required for 
lung specification, as shown in vivo, with WNT2/2B null mutant mice and foregut-
endoderm knockdown of beta-catenin both resulting in lung agenesis (Goss et al. 2009; 
Harris-Johnson et al. 2009), and forced overexpression of beta-catenin resulting in 
spreading of the lung field into the stomach. Furthermore, in vitro, our group and others 
have demonstrated that without addition of WNT agonists in mouse directed 
differentiation or WNT activators in human directed differentiation, NKX2-1+ lung 
progenitors are not specified. The roles of the other signaling pathways are less clear.  
Though BMP4 signaling via BMPRR1a/b has been shown to play a key role in 
tracheal development, this pathway seems to play a contradictory role in specification of 
the distal lung. In vivo, expression of SFTPC in the distal lung is reduced but not absent 
in BMP4 receptor knockout mice, and distal budding is increased (Domyan et al. 2011). 
In ex vivo foregut explant culture, however, BMP4 agonism is required for specification 
of both NKX2-1+ and SFTPC+ cells (Rankin et al. 2016). We have found that while 
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BMP4 is required for specification of mouse lung epithelial cells, it is not consistently 
required for sNKX2-1 induction in human endodermal cells.  
RA deficiency during lung development has been shown to result in reduced 
expression of NKX2-1 in the lung field and agenesis of lung buds (Desai et al. 2004). In 
ex vivo foregut explants, RA receptor knockouts showed abnormalities in expression of 
NKX2-1+ in the lung progenitor field, and lack of expression of SFTPC (Desai et al. 
2004; Chen et al. 2010). Recent work in the xenopus foregut explant model showed that 
RA likely has multiple roles in lung development: (1) prior to lung progenitor 
specification, RA induces endodermal SHH ligand expression that leads to mesenchymal 
WNT2/2b and BMP4 expression, promoting NKX2-1 lung specification,  (2) RA also 
regulates the competence of the foregut endoderm to respond to these mesenchymal 
signals, and (3) after lung progenitor specification, RA acts upstream of FGF10 and 
WNT2/2b to maintain the NKX2-1+ lung epithelium and promote further differentiation 
into the distal bud (Rankin et al. 2016). In this same study, human ESCs differentiate into 
NKX2-1+ lung progenitors when treated first with RA, and subsequently with CHIR (a 
WNT agonist) and BMP4. Our base media for PSC differentiation includes RA, but in the 
human differentiation protocol, we have found that supplementation of RA is required for 
lung specification.  
Finally, though there have been studies that show a role for FGF signaling in 
initial formation of the lung bud (Serls et al. 2005), we have found in both mouse and 
human developmental models that FGF signaling is dispensable for lung specification. 
Though there is a clear role for SHH signaling in lung development, with downstream 
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target Gli2/3 null mutant mice exhibiting lung agenesis (Motoyama et al. 1998), all 
current studies indicate the SHH secreted by the foregut and lung epithelium acts directly 
on the surrounding mesenchyme and mesenchymal signals in return act to specify the 
lung epithelium, as described above.  
Distalization of the early lung primordium 
After lung bud specification, during the pseudoglandular stage of development 
(E10.5-16.0 in mice, Week 5-17 in human), the lung primordium undergoes highly 
coordinated branching morphogenesis (Metzger et al. 2008) and is patterned into 
proximal and distal domains that are precursors to the airway and alveolar epithelia, 
respectively. In the mouse lung, by E10, proximal progenitors are identified by 
expression of the transcription factor Sox2, and distal progenitors are defined by 
expression of the transcription factor Sox9 (Alanis et al. 2014). As the Sox9+ distal bud 
proliferates and branches in response to signals from the distal mesenchyme, previously 
Sox9+ cells rapidly adopt a Sox2+ proximal fate. At early timepoints in fetal lung 
development, the proximal and distal buds are still plastic, as evidenced by the fact that 
ex vivo distal buds can be reprogrammed into trachea via co-culture with proximal lung 
mesenchyme, and vice-versa (Shannon et al. 1998). Accordingly, early in the 
pseudoglandular stage of development (E11.5) Sox9+/Id2 lineage label+ distal bud cells 
give rise to both proximal and distal cells in the adult; whereas during the cannalicular 
stage (E16.5), Id2 lineage label+ cells only give rise to alveolar cells in the adult 
(Rawlins et al. 2009). Though Sox9+/Id2+/Sftpc+ distal bud cells are likely very plastic 
early in development, they eventually commit to a distal lung fate in vivo.  
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Several signaling pathways are likely involved in distalization of the lung 
primordium, but the preponderance of evidence points to WNT and FGF signaling as 
being key factors. Severe defects in branching morphogenesis occur in mice when either 
FGF10 or FGFR2b is deleted post-lung specification (Min et al. 1998; Sekine et al. 
1999), with expansion of the Sox2+ proximal program and loss of the Sox9+ distal 
progenitor pool (Chang et al. 2013). Ex vivo, tracheal epithelium can differentiate into 
SFTPC+ distal cells when exposed to recombinant FGF10 (Hyatt et al. 2004), and 
overexpression of FGF10 in E10.5-E13.5 lungs prevents distal-to-proximal 
differentiation, with SFTPC expression evident in proximal regions of the lung, possibly 
via upregulation of beta-catenin.(Volckaert et al. 2013). While FGF10 has been studied 
extensively both in vivo and ex vivo, SFTPC expression in E11.5 lung explants was 
induced at significantly higher levels in response to FGF7, or keratinocyte growth factor 
(KGF), than to a 10-fold higher concentration of FGF10 (Liu et al. 2003). Furthermore, 
KGF has been shown to specifically enhance AEC2 proliferation both in the resting lung 
and after pneumonectomy (Ulich et al. 1994; Kaza et al. 2002). Taken together, these 
findings suggest that FGF signaling via ligands that bind FGFR2 promotes a distal cell 
fate. 
WNT/b-catenin signaling also plays a well-described role in distalization of the 
lung epithelium. When activated b-catenin overexpression was driven by a proximal club 
cell secretory protein (CCSP) promoter (active at E14.5), airspaces were enlarged and 
distal SFTPC+ cells occupied the bronchiolar epithelium (Mucenski et al. 2005). 
Conversely, either overexpression of DKK1, a WNT signaling inhibitor, or deletion of b-
		
27 
catenin driven by the SFTPC promoter (active at E10.5) resulted in expansion of CCSP+ 
proximal airway cells and attenuation of SFTPC expression in the distal lung buds (Shu 
et al. 2005). In the same study, WNT signaling was shown to promote distalization by 
acting upstream of BMP4 and FGF signaling as well. Finally, in in-vitro human directed 
differentiation, our group demonstrated that CHIR, a WNT signaling activator, promoted 
distalization of human lung primordial progenitors at the expense of proximal lineages 
(McCauley et al. 2017).  
Though other signaling pathways, such as SHH, BMP4, TGFb, and RA, have 
been implicated in the complex promixo-distal patterning decisions made in the 
developing lung, they are currently less well characterized and require further study. 
Alveolarization and AEC2 maturation 
SFTPC, the most specific marker of the AEC2 in adults, is expressed as early as 
E10.5 in mice and week 12-15 in humans, marking the developing distal bud. As the lung 
develops, the alveoli enter the cannalicular (E16.0-17.5/ week 16-26) and saccular 
(E17.5-birth/ week 26-36) stages before birth, and only reach full maturity postnatally 
(alveolar stage; P1-P20/ week 36-adolescence). During this period, the branches formed 
during the pseudoglandular stage narrow, vascular networks surround the epithelial cells, 
and terminal sacs, the precursors to air-filled alveoli, begin to septate into smaller units to 
increase the surface area over which gas exchange can occur. By adulthood, human lungs 
contain 300 million alveoli, representing a gas exchanging surface area of 75m2 (Ochs et 
al. 2004).  
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Figure 1.5. Postnatal alveolar development. 
Scanning EM images of postnatal Day 1 (left) and adult (right) mouse distal lung at the same magnification (300x). 
Note smaller, more numerous alveoli in adult lung (Amy et al. 1977). 
 
Specification of AEC2s and AEC1s 
The saccular and alveolar stages of lung development are less well understood 
than the pseudoglandular stage, in part because mouse and human postnatal lung 
development vary greatly in timing, with mice born during the saccular stage of 
development and humans born during the alveolar stage (Herring et al. 2014). In mouse 
models, both AEC2s and AEC1s are thought to arise from the Sox9+/Id2+/Sftpc+ distal 
bud progenitors of the developing lung. Though the signaling pathways involved in 
committing these distal bud cells to an alveolar fate are unknown, one report has 
suggested that downregulation of Sox9, downstream of an increase in FGF signaling, 
slows branching morphogenesis and allows for alveolar maturation. Indeed, in a lung 
lineage specific (Shh) Sox9 conditional knockout mouse model, alveolar differentiation 
was initiated prematurely after deletion of Sox9 from the lung epithelium (Chang et al. 
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2013). Another recent report showed that after a period of reduced WNT signaling in the 
saccular stage, a wave of high WNT signaling coincides with the onset of alveologenesis 
in mice (Frank et al. 2016).  
There is some controversy as to whether the AEC1 and AEC2 lineages arise 
independently from immature distal bud tip cells, via early AEC2 proliferation and 
transdifferentiation into AEC1s, or from a “bipotent progenitor.” Frank et al. show that a 
subpopulation of Axin2+ AEC2s have a higher clonal growth potential within the 
growing mouse alveolus, that AEC2s have a higher potential to self renew in response to 
WNT signaling, and they tend to differentiate into AEC1s  when WNT signaling is 
inhibited (Frank et al. 2016). Though cells coexpressing Pdpn and Sftpc transcripts have 
been identified in the distal bud tip as early as E16.5 (Desai et al. 2014; Treutlein et al. 
2014), lineage tracing using specific markers for these cells needs to be performed to 
validate whether these distal marker expressing cells are deserving of the term “bipotent 
progenitor” as claimed by these authors.  There is abundant data showing that in 
pneumonectomy, hyperoxia, and bleomycin injury models as well as in in-vitro culture 
models, AEC2s can transdifferentiate into AEC1s (Perl et al. 2002; Kaza et al. 2002; 
Adamson & Bowden 1975; Adamson & Bowden 1974; Evans et al. 1972; Rock et al. 
2011), but at the resting state, both AEC2s and AEC1s are relatively quiescent 
(Barkauskas et al. 2013).  
Non-epithelial Cells of the Alveolus 
Much of the study of alveologenesis has been driven by the pathophysiology of 
bronchopulmonary dysplasia, a chronic lung disorder that is associated with premature 
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delivery and alveolar simplification.  Another recent insight into the mechanism of 
alveologenesis relates to the involvement of smooth muscle actin (SMA)+ 
myofibroblasts. During the peak of alveologenesis (mouse P4-12), these SMA+ cells 
create a “fishnet” pattern around the terminal sacs, the network from which the alveolar 
ridges arise (Branchfield et al. 2016). The same group found that myofibroblast networks 
were disordered in several known mouse models of bronchopulmonary dysplasia 
(Branchfield et al. 2016). The development of mature alveoli involves not only 
maturation of AEC2s and AEC1s, but also development of the alveolar niche, which 
includes lipofibroblasts, myofibroblasts, endothelial cells, alveolar macrophages, and the 
appropriate extracellular matrix to support this delicate structure. Some of these lineages, 
including lipofibroblasts and endothelial cells are known to support the growth and 
differentiation of AEC2s ex vivo (Lee et al. 2014; Barkauskas et al. 2013). Epithelial-
mesenchymal interactions late in alveologenesis are currently poorly understood, but this 
burgeoning field will likely provide key insights into the pathogenesis of diseases from 
bronchopulmonary dysplasia to pulmonary fibrosis and COPD.  
Directed Differentiation of Pluripotent Stem Cells 
Directed Differentiation of PSCs into Endodermal Lineages 
Pluripotent stem cells are self-renewing cells capable of differentiation into the 
mature cells of all three germ layers (ectoderm, mesoderm, and endoderm).  Cultured 
pluripotent stem cells (embryonic stem cells, or ESCs) derive from the inner cell mass of 
the blastocyst and express pluripotency markers (Oct4, Sox2, Nanog, SSEA1 or 4). 
Furthermore, in a process called blastocyst complementation, mouse pluripotent stem 
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cells that are injected into blastocysts and implanted into a pregnant mouse can contribute 
to all germ layers of of the resulting mouse progeny (Robertson et al. 1986). In tetraploid 
complementation assays, mouse pluripotent stem cells injected into nonviable tetraploid 
blastocyst actually generate all cells of the resulting progeny  (Nagy et al. 1990). Mouse 
ESC in-vitro culture was first established in 1981 (Evans & Kaufman 1981; Martin 
1981), human ESC culture in 1998 (Thomson et al. 1998). While the human ESC field 
was highly enticing to researchers, generation of human ESCs required access to unused 
human blastocysts, an ethically charged issue. Very few human ESC lines were approved 
for research in the United States, limiting the utility of ESC-derived cells for 
transplantation and genetic disease modeling. In 2006, Shinya Yamanaka and Kazutoshi 
Takahashi developed a method to reprogram embryonic or adult mouse fibroblasts into 
induced pluripotent stem cells (iPSCs) via exogenous expression of 4 key transcription 
factors: Oct4, Sox2, Klf4, and cMyc (Takahashi & Yamanaka 2006). This method was 
soon reproduced in human cells (Takahashi et al. 2007; Yu et al. 2007) and ushered in a 
new era of iPSC research unhindered by ethical considerations and capable of 
representing the genetic background of any living person. iPSC-derived tissues 
potentially could be used for many applications, including disease modeling (Soldner et 
al. 2011), personalized drug screening (Terrenoire et al. 2013), and autologous cell-based 
therapy (Mandai et al. 2017).  
Though ESCs and iPSCs are similar in their morphology, expression of 
pluripotency markers, and ability to contribute to all three primary germ layers 
(Christodoulou et al. 2011), differences between different ESC lines may be as significant 
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as differences between ESCs and iPSCs (Osafune et al. 2008). Towards the goal of 
generating a protocol to make a particular mature cell type, it is still important to validate 
that the protocol works in multiple PSC lines, including both ESCs and iPSCs.  
 Though pluripotent stem cells can generate any mature cell type in blastocyst 
complementation assays, their utility in research in many cases hinges on their ability to 
generate mature cell types in vitro. The process of recapitulating key signals learned from 
developmental biology in-vitro to generate cells of interest from PSCs is termed “directed 
differentiation” (Keller et al. 1993; Murry & Keller 2008). Though directed 
differentiation to ectodermal and mesodermal lineages was established soon after the 
establishment of ESC culture, the signals required to generate definitive endoderm from 
PSCs remained elusive. In early embryogenesis, epiblast cells go through gastrulation 
and form the “primitive streak,” a region through which epiblast cells migrate and 
eventually give rise to the mesodermal (posterior primitive streak) and endodermal 
(anterior primitive streak) germ layers (K. A. Lawson & Pedersen 1987). Tgfb 
(Activin/Nodal) signaling agonists promote differentiation of ESCs into anterior 
primitive streak definitive endoderm cells marked by Bry+/Foxa2hi expression (Gadue et 
al. 2006; Kubo et al. 2004; Zorn & Wells 2007) or by Ckit/Cxcr4 expression (Gouon-
Evans, Boussemart, Gadue, Nierhoff, Koehler, Kubo, Shafritz & Keller 2006a; Yasunaga 
et al. 2005; D'Amour et al. 2005). Importantly, ESCs and iPSCs show a similar ability to 
differentiate into endoderm and endodermal derivatives in vitro (Christodoulou et al. 
2011).  
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 Once protocols to derive definitive endoderm from PSCs were well established, 
researchers rapidly developed techniques to differentiate PSC-derived endoderm into 
immature intestinal, hepatic, and pancreatic cells (Gouon-Evans, Boussemart, Gadue, 
Nierhoff, Koehler, Kubo, Shafritz & Keller 2006b; Kroon et al. 2008; Ameri et al. 2010). 
Protocols to derive Nkx2-1+ lung or thyroid progenitors, however, were not developed 
until Snoeck and colleagues’ key finding that a brief period of Tgfb and Bmp4 inhibition 
after definitive endoderm induction was required to specify anterior foregut endoderm 
(Green et al. 2011). Finally, several protocols were developed that by culturing PSC-
derived anterior foregut endoderm in media containing various combinations of Fgf, Wnt,  
Bmp4, Egf, retinoic acid. These protocols reported robust generation of Nkx2-1+ mouse 
and human putative lung or thyroid progenitor cells from PSCs (Longmire et al. 2012; 
Mou et al. 2012; Huang et al. 2013). Since these early studies, more attention in the 
directed differentiation field has focused on 3 dimensional culture systems, and other 
groups, including ours, have developed lung “organoid” culture systems (McCauley et al. 
2017; Dye et al. 2015; Gotoh et al. 2014)Serra et al. in revision; Hawkins et al. 2017). 
However, the resulting efficiency and relative abundance of mature cell types like AEC2s 
were not quantified in these studies.  
Previous Attempts to Generate AEC2s from PSCs 
 Because of the obvious utility of PSC-derived AEC2s, several groups have 
focused on developing a protocol to generate these cells. Studies that came before the 
Green et al. paper that detailed a protocol to generate Nkx2-1+ lung progenitor cells in 
serum-free differentiation conditions or did not use a similar framework for generation of 
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progenitor cells are unlikely to be reproducible, since we have shown that Sftpc+ cells in 
both the mouse and human system derive from an Nkx2-1+ progenitor cell (Longmire et 
al. 2012)(Serra et al. in revision; Hawkins et al. 2017). Evaluation of PSC-derived AEC2s 
is made difficult by the fact that (1) the most specific marker of the mature AEC2, 
SFTPC, is an extremely hydrophobic protein difficult to detect with commercially 
available antibodies; (2) primary AEC2s are difficult to isolate and culture, making 
comparisons to phenotypically mature AEC2s difficult, and (3) reliance on the 
appearance of lamellar bodies via EM analysis despite the fact that many non-LB 
inclusions can resemble LBs in fibroblasts and cell lines like A549s.  
Anne Bishop and colleagues were the first group that reported generation of 
mouse ESC-derived SFTPC+ cells in 2002 and they have published several studies on the 
topic; however, their protocol involved embryoid body (EB) formation followed by 
culture in small airway growth medium (SAGM) without progression through an NKX2-
1 progenitor fate, and expression of a single marker (SFTPC) was the only metric used to 
substantiate the claim that lung epithelial cells had been produced (Ali et al. 2002). In 
2006, Mollard and colleagues cultured mouse ESCs with E11.5 mouse lung tissue and 
claimed to see expression of Sftpc mRNA in the resulting ESC derivatives (Denham et al. 
2006). Rick Wetsel and colleagues attempted to generate pure populations of human 
AEC2s from PSCs by engineering a transgenic SFTPC promoter driven-neomycin 
resistance PSC line, treating EBs with serum containing media, and finally adding 
neomycin such that only resistant cells, claimed to be human ES-derived AEC2s survived 
(D. Wang et al. 2007). Another study from Finck and colleagues did focus on 
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differentiating EBs into endoderm before further manipulation of the media, using 
Activin A, serum, and A549 conditioned media to generate definitive endoderm and 
subsequently culturing cells in FGF2 to generate cells that were claimed to express 
SFTPC mRNA and protein (Roszell et al. 2009).  
None of these groups compared PSC-derived AEC2s to primary AEC2 controls, 
and, the Wetsel group concluded that PSC-derived AEC2s were similar in phenotype to 
the A549 cell line, which does not express SFTPC or contain lamellar bodies. All studies 
relied on qPCR for SFTPC mRNA without primary controls, immunostaining for SFTPC 
protein, notorious for high background staining, and EM for lamellar bodies without 
further evaluation of the functionality of the structures they saw.  
Since a protocol was established that could generate NKX2-1+ lung progenitor 
cells from PSCs (Green et al. 2011), there have been additional attempts to derive AEC2s 
from this population. Snoeck and colleagues were the first to claim efficient generation of 
alveolar cells from NKX2-1+ progenitors after culture in CHIR (WNT agonist), FGF10, 
KGF, and DCI ; however, they did not quantify the percent of SFTPC+ cells they 
generated, only focusing on an SFTPB uptake assay not specific to AEC2s (Huang et al. 
2013). Niklason and colleagues next claimed to generate a population of nearly 100% 
SFTPC+ cells from NKX2-1+ progenitors, though they relied on quantification of 
intracellular SFTPC protein expression, a technique prone to artifact, and qPCR 
compared to a primary control that the authors do not describe well enough to establish 
its utility as an AEC2 surrogate (Ghaedi et al. 2013). More recently, Gotoh et al. 
described a protocol to generate AEC2s from a relatively pure population of NKX2-1+ 
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progenitors using the caboxypeptidase M (CPM) sort marker. CPM+ cells were plated in 
3D culture with fetal human lung fibroblasts, and efficiency of AEC2 differentiation was 
evaluated using an SFTPCGFP knockin reporter. Around 4% of the resulting cells were 
GFP+, and when the entire CPM+ population was analyzed, SFTPC mRNA and protein 
seemed to be expressed, along with more convincing lamellar bodies by EM. Levels of 
expression of AEC2 mRNA were 5-1000 fold lower than that seen in primary AEC2s, 
suggesting that the primary controls used were appropriate (Gotoh et al. 2014). Though 
the Gotoh et al study shows likely generation of a population of AEC2-like cells from 
lung progenitors, it relies on coculture with fetal fibroblasts, suggesting that the 
maturation media lacks an essential component.  
 
Figure 1.6. Electron Microscopy of PSC-derived AEC2s, primary rat AEC2s, and A549 cells (left panels from 
papers as listed, right panels from Mary Williams, BUSM Pulmonary center images) 
Overall, great strides have been made toward generation of PSC-derived AEC2s, 
and the field has a relatively strong understanding of the signals required to make 
endoderm (Activin; (Kubo et al. 2004; Gadue et al. 2006)), anterior foregut endoderm 
Ali 2002! Wang 2007!
Roszell 2009!
Huang 2013!
Gotoh 2014!
Ghaedi 2013!
AEC2s via EBs! AEC2s possibly via 
NKX2-1+ progenitor!
A549!
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(TGF beta and BMP4 inhibition; Green et al. 2011), lung progenitors (WNT, BMP4, and 
retinoic acid; Rankin et al. 2016), and distal lung progenitors (WNT; McCauley et al. 
2017). At the beginning of my thesis work, the specific signals required to generate 
AEC2s at a level of maturity similar to primary AEC2s were not well understood, and a 
pure population of PSC-derived AEC2s had not been analyzed.  
Gene Editing in Pluripotent Stem Cells 
iPSCs can be generated with relative ease and efficiency from patient blood 
samples (Gianotti-Sommer et al. 2008), resulting in an inexhaustible supply of patient-
specific pluripotent stem cells that can theoretically be differentiated into any mature cell 
type in the body. This provides an unprecedented opportunity for modeling human 
disease in-vitro in relevant cell types. The advent of gene-editing technologies that can be 
used to manipulate the genome of PSCs with relative ease only magnifies their research 
utility. Because PSC lines vary greatly in genetic background and propensity to 
differentiate into different lineages (Boulting et al. 2011; Kyttälä et al. 2016), disease 
modeling is best studied in monogenic diseases that can be gene-corrected and controlled 
for this variable . Gene editing technology, including zinc-finger nucleases (ZFNs) 
transcription activator-like effector nucleases (TALENs) and CRISPR/Cas9, enables site-
specific manipulation of the genome. Using ZFNs, TALENs or CRISPR/Cas9 in PSCs, 
reporter genes can be knocked into specific gene loci (homology directed repair), single 
nucleotides can be mutated or corrected (via homology directed repair), and entire genes 
can be knocked out with either indel mutations (via non-homologous end joining) or 
large fragment deletions (Doudna & Charpentier 2014).  
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TALENs in particular consist of a DNA binding domain (DBD), made up of a 
series of 15-20 amino acid sequences with “repeat variable diresidues” that recognize 
specific base pairs of DNA, fused to a nuclease effector domain such as Fok1 that creates 
a site-specific double stranded break (DSB) after dimerization (Boch et al. 2009). Two 
TALENs must bind to the same region of DNA to generate the DSB, and designing one 
TALEN requires generation of a DBD with 500-700 specific amino acids, making 
TALEN generation rather laborious (time spent cloning) while also less prone to off 
target effects (requirement of 2 adjacent TALENs binding for a DSB) (Boettcher & 
McManus 2015).  
CRISPR/Cas9, on the other hand, relies on the activity of Cas9 protein to generate 
a DSB along with a single guide RNA with a constant region that binds Cas9 and a 
variable region (17-20 nucleotides) that binds to the DNA of interest (Jinek et al. 2012). 
Since only 17-20 nucleotides need to be altered to generate a specific CRISPR gRNA vs. 
1500-2000 to generate a specific TALEN, CRISPR/Cas9 is a more easily customizable 
method to generate the same site-specific DSB. Both TALEN and CRISPR/Cas9 
technology has been used to edit the PSC genomes, particularly valuable in allowing for 
the generation of lineage-specific reporter knockins and correction of monogenic disease-
causing mutations, among other applications (Hockemeyer et al. 2011; Mali et al. 2013; 
Ran et al. 2013). To date, mutations in monogenic lung disease that have been corrected 
in PSCs include the CFTR mutation causing cystic fibrosis (Crane et al. 2015), and the 
SERPINA1 mutation causing PiZZ alpha 1 antitrypsin deficiency (Yusa et al. 2011). 
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AEC2s in Lung Disease 
Epithelial injury in pulmonary fibrosis 
 Because inflammatory infiltrates are often seen in lung biopsies of patients with 
idiopathic pulmonary fibrosis (IPF), it is important to examine the role of the immune 
response in initiating fibrosis. Interestingly, evidence from mouse models shows that 
depleting neutrophils from rabbits treated with bleomycin actually increased the degree 
of pulmonary fibrosis (Thrall et al. 1981), and that dampening anti-inflammatory 
signaling through knockout of IL-10 decreased the degree of silica- induced pulmonary 
fibrosis (Huaux et al. 1998). Furthermore, treating IPF patients with anti-inflammatory 
agents has not proven to alter the course of disease progression (Flaherty et al. 2001; 
Richeldi 2013). Though immune signals very likely play some role in the pro-fibrotic 
injury response, these findings suggest that other cells are involved.  
 In 1979, Haschek and Witschi showed that when mice were exposed to inhaled 
butylated hydroxytoluene, an injury that affects primarily AEC1s and is resolved with 
AEC2 proliferation and transdifferentiation, followed by hyperoxia, delaying the AEC2 
proliferation response, collagen deposits could be seen in the denuded alveolar 
epithelium, resulting in pulmonary fibrosis (Haschek et al. 1981). This lead the authors to 
develop the “Witschi hypothesis,” the idea that pulmonary fibrosis may be initiated by 
alveolar epithelial dysfunction (Haschek & Witschi 1979).  
After alveolar epithelial injury, it is the role of the AEC2 to proliferate and re-
form the alveolar capillary barrier. When this repair process goes awry, fibrosis can 
result, as evidenced by the dysplastic, hyperplastic, or apoptotic AEC2s seen in IPF 
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patient lung sections. Activating apoptosis in mouse AEC2s and bronchiolar cells with 
aerosolized Fas ligand results in spontaneous pulmonary fibrosis as well (Hagimoto et al. 
1997). In an SFTPC promoter driven diphtheria toxin receptor (DTR) transgenic mouse, 
administration of diphtheria toxin induced AEC2 apoptosis, resulting in alveolar fibrosis 
without an additional insult, strongly suggesting that AEC2s can drive fibrotic 
pathogenesis (Sisson et al. 2010). A more recent study using an AEC2-specific inducible 
DTA knockin mouse did not find an increase in lung collagen content, however 
(Barkauskas et al. 2013). Though one study showed that after 3 weeks of profibrotic Tgf-
beta overexpression in transgenic SFTPC promoter-driven beta-Gal expressing mice, 
beta-Gal-expressing cells also expressed markers of mesenchymal lineages (Kim et al. 
2006), subsequent studies that used knockin Sftpc and Scgb1a1 reporters did not show 
evidence of epithelial-to-mesenchymal transition during the initiation of fibrotic change 
in the lung (Rock et al. 2011). AEC2s can, however, secrete mesenchymal proteins like 
collagen that may exacerbate IPF (Yang et al. 2013). Though the precise AEC2-specific 
pro-fibrotic signals are unknown, upregulation of the TGF-beta (via binding epithelial 
integrin avb6), EGF, CTGF, SHH, and WNT signaling pathways has been observed in 
IPF lungs (reviewed in (Sakai & Tager 2013)).  
The most convincing evidence of an epithelial role in promoting pulmonary 
fibrosis is that mutations in surfactant protein C result in early-onset pulmonary fibrosis. 
Postnatally, SFTPC is the most specific marker of the AEC2, and autosomal dominant 
gain of function mutations in this gene have been shown to induce AEC2 stress and 
apoptosis ultimately resulting in interstitial lung disease (Nogee et al. 2001; Maguire et 
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al. 2012; Mulugeta et al. 2005). The fact that these patients have pulmonary fibrosis 
resulting from mutations in genes expressed only in AEC2s suggests a key role for 
AEC2s in IPF pathogenesis.  
Mutations in several additional genes that are expressed in AEC2s, including 
SFTPA2, TERT, TERC, SLC34A2, HPS1, and HPS4, have been implicated in familial 
pulmonary fibrosis (FPF).  SFTPA2 mutations are associated with increased risk of lung 
adenocarcinoma and familial pulmonary fibrosis (PF) (Y. Wang et al. 2009). Telomerase 
mutations, also autosomal dominant but with variable penetrance, are associated with 
adult onset PF, possibly related to senescence in the AEC2 progenitor population, making 
it incapable of appropriate injury response (Alder et al. 2015; Armanios et al. 2007; 
Tsakiri et al. 2007). Importantly, patients with IPF are significantly more likely to have 
shortened telomeres in their AEC2s than the general population (Kropski et al. 2015). 
Pulmonary microlithiasis is caused by an autosomal recessive mutation in the phosphate 
transporter SLC34A2 that causes accumulation of calcium phosphate in the alveolar 
space. Importantly, SLC34A2 is expressed in AEC2s, and pulmonary microlithiasis also 
leads to pulmonary fibrosis (Huqun et al. 2007). Hermansky-Pudlak syndrome, an 
autosomal recessive disorder that causes ocular albinism and increased bleeding, is 
caused by a variety of mutations. Two in particular, HPS1 and HPS4, are also associated 
with pulmonary fibrosis, most likely through dysfunctional lamellar body biogenesis and 
subsequent AEC2 apoptosis (Nakatani et al. 2000). Taken together, all these genetic 
mutations lead directly to AEC2 dysfunction and death, and ultimately increased 
susceptibility to PF. 
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Children’s Interstitial Lung Disease  
 Though the pathogenesis of adult onset pulmonary fibrosis is poorly understood, 
early onset pulmonary fibrosis or interstitial lung disease can be caused by mutations in 
genes expressed in AEC2s: SFTPC, SFTPB, ABCA3, and NKX2-1.  
Surfactant Protein C Mutations 
SFTPC mutations are autosomal dominant mutations, both inherited and 
spontaneous, that result in misfolding and mistrafficking of the pro-SFTPC protein 
(Maguire et al. 2012). Though there is significant variability in disease presentation and 
progression, patients often present with thick alveolar septae, hyperplastic AEC2s, and 
lymphocytic/myofibroblast infiltrates (Nogee et al. 2001; Hamvas 2010). There is no 
mechanism-specific treatment for SFTPC mutation-related disease, with most patients 
consigned to lung transplantation, which leads to significant short-term and long-term 
consequences for quality of life and a notoriously low 5-year success rate of only 50% 
(Hamvas 2010).   
Mature SFTPC is an extremely hydrophobic 3.4 kd protein that is processed 
primarily as a 21 kd proprotein to facilitate trafficking in the hydrophilic environment of 
the cell (Beers & Mulugeta 2005). Most SFTPC mutations lead to the accumulation of 
misfolded pro-SFTPC, resulting in cell dysfunction and even death, as in other 
conformational diseases such as alpha-1-antitrypsin deficiency, Huntington’s disease, and 
systemic amyloidosis (Knight et al. 2013).  
SFTPC mutations fall into two major categories, one affecting the highly 
conserved carboxy-terminal BRICHOS domain that is present in several proteins 
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implicated in conformational disease, and one affecting a more proximal juxtamembrane 
region (non-BRICHOS mutations). The most common SFTPC mutation is the non-
BRICHOS I73T mutation, present in  >25% of all SFTPC mutation related disease 
(Cameron et al. 2005). Previous studies in heterologous cell lines have shown that 
overexpression of the BRICHOS mutants for 48 hours leads to activation of all three 
arms of the UPR pathway: ATF6, IRE1/XBP1, and PERK/eIF2, as well as downstream 
caspase activation resulting in apoptosis (Mulugeta et al. 2007; Mulugeta et al. 2005; 
Maguire et al. 2012). In contrast, studies that use a cell lines stably transfected with 
BRICHOS mutant pro-SFTPC proteins showed accumulation of aggregates but no ER 
stress markers (Thurm et al. 2013). Non-BRICHOS studies in similar cell lines have used 
a model of overexpression of non-BRICHOS I73T mutant GFP/SFTPC fusions that 
fluorescently mark the cellular compartments where pro-SFTPC is accumulating. These 
models have shown that non-BRICHOS mutant pro-SFTPC does not induce the UPR or 
ER stress, instead leading to mistrafficking of pro-SFTPC to the plasma membrane and 
early endosomes, resulting in impaired uptake and degradation of surfactant 
phospholipids and alveolar lipoproteinosis, as well as blocking macroautophagy and 
mitophagy (Beers et al. 2011; Hawkins et al. 2015).  
 Mouse models of SFTPC mutations have shown increased ER stress levels, but 
have not thus far resulted in spontaneous progressive pulmonary fibrosis (W. E. Lawson 
et al. 2011); though there is one preliminary report in mice expressing SFTPC I73T 
mutant protein develop fibrosis without an additional insult (Beers, unpublished data). 
Considering that SFTPC mutations were present in 25% of patients in one familial 
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pulmonary fibrosis cohort (van Moorsel et al. 2010), and that SFTPC is specific to the 
AEC2 in mature lungs, understanding the mechanisms by which SFTPC mutations cause 
pulmonary fibrosis could provide great insights into the pathogenesis of both children’s 
interstitial lung disease, and adult PF.  
Surfactant Protein B Mutations 
 Unlike SFTPC mutations, SFTPB deficiency results from autosomal recessive 
loss-of-function mutations. All known SFTPB deficiency cases are inherited, and 
approximately 70% of SFTPB deficiency cases involve the “121ins2” mutation (Hamvas 
et al. 2001), in which a GAA is substituted for a C in exon 4, resulting in mRNA 
instability, lack of expression of SFTPB protein, misprocessing of proSFTPC, and 
inability to form mature lamellar bodies (Nogee et al. 1994; Ballard et al. 1995; Nogee et 
al. 1993). SFTPB deficiency causes lethal neonatal respiratory distress in both humans 
and mice (Melton et al. 2003; Stahlman et al. 2000; Clark et al. 1995), though 
heterozygotes are phenotypically normal, suggesting that 50% of normal SFTPB 
expression is sufficient for alveolar function (Ballard et al. 1995). Histopathology 
typically shows pulmonary alveolar proteinosis or desquamative interstitial pneumonitis, 
though it is unclear whether this pathology is a direct result of the protein deficiency or 
the subsequent medical interventions (ventilation, hyperoxia) (Whitsett et al. 2015). Since 
SFTPB protein has a known function to stabilize the alveolar surface film and the 
bilayers in the hypophase, as well as to package surfactant protein and phospholipids into 
lamellar bodies, it is not surprising that loss of SFTPB leads to such dramatic phenotypes. 
However, surfactant replacement therapy is not effective in these infants, so SFTPB 
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deficiency does not phenocopy neonatal respiratory distress caused by surfactant 
deficiency. Though pure populations of SFTPB-deficient AEC2s have not been studied in 
vitro or in vivo, this suggests that there may be an additional insult in the SFTPB 
deficient lung, likely involving AEC2 dysfunction.  
 Children’s interstitial lung disease can also be caused by autosomal recessive 
inherited loss of function mutations in ABCA3, the lipid transporter that brings 
phospholipids from the cytoplasm to the lamellar body, that result in lethal neonatal 
respiratory distress (Shulenin et al. 2004; Bullard et al. 2005). Additionally, autosomal 
dominant inherited or spontaneous mutations in NKX2-1 can cause NKX2-1 
haploinsufficiency leading to brain-lung-thyroid syndrome, which can manifest in the 
lung as recurring respiratory infections and eventual pulmonary fibrosis (Krude et al. 
2002).  
AEC2 involvement in other lung diseases 
Though the role of AEC2 dysfunction in pulmonary fibrosis is particularly 
enticing to researchers considering the lack of mechanistic advances in this field and the 
preponderance of data suggesting that AEC2s are the cell of origin, AEC2s are likely 
involved in other diseases processes as well. Both CFTR and SERPINA1 are expressed at 
low levels in AEC2s, suggesting that these cells could contribute to the pathology of 
cystic fibrosis or alpha-1-antrypsin deficiency despite not being the primary drivers of 
these diseases (Brochiero et al. 2004; Ballard et al. 2010). Chronic obstructive pulmonary 
disease (COPD) and emphysema are characterized by progressive destruction of alveolar 
architecture, and their strong association with cigarette smoking suggests that the effect 
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of cigarette smoke on AEC2s may be an important initiator of COPD pathogenesis (Hogg 
& Timens 2009). Acute respiratory distress syndrome (ARDS) is often caused by 
pneumonia, sepsis, or trauma, among others, and results in destruction of the alveolar 
barrier, leading to fluid leak into the alveolar spaces and atelectasis (Matthay et al. 2012). 
AEC2s play a key role in repairing the alveolar/endothelial barrier after epithelial injury, 
and understanding what types of injury overwhelm AEC2 proliferative capacity or inhibit 
alveolar differentiation could inform the treatment of ARDS. Finally, AEC2s are thought 
to be the cell of origin of lung adenocarcinoma because overexpression of K-Ras, a 
known driver of lung adenocarcinoma, in Sftpc+ cells in several mouse models resulted 
in the growth of alveolar adenocarcinomas  (Desai et al. 2014; Lin et al. 2012; X. Xu et 
al. 2012). Studying the initial events that lead to oncogenic transformation of AEC2s 
would be informative in understanding lung adenocarcinoma biology as well.  
Taken together, most pulmonary diseases involved dysfunction of AEC2s either 
as part of the initiation of pathology or as a consequence. Limitations in access to primary 
human AEC2s and in AEC2 in vitro culture have contributed to the lack of understanding 
of disease and mechanism-specific therapeutics for lung disease. Addressing these 
limitations will facilitate studies in alveolar development and disease, and will hopefully 
represent a major advance toward alveolar regeneration.   	
Specific Aims 
Aim 1: Create fluorescent reporter PSC lines that will enable isolation of a pure 
population of putative AEC2s. We will insert fluorescent reporters into the SFTPC 
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locus of PSC lines, making it possible to isolate a pure population of SFTPC-expressing 
putative AEC2s after differentiation, and we will characterize the global transcriptomes, 
lamellar body ultrastructure, and surfactant content of these cells compared to primary 
AEC2 controls. 
Aim 2: Generate a global transcriptomic profile of PSC-derived putative AEC2s. 
We will perform RNA-sequencing analysis of PSC-derived AEC2s and AEC2 
progenitors as well as primary fetal and adult AEC2s to determine the pathways that 
regulate AEC2 differentiation and the similarities and differences between engineered 
and primary AEC2s.   
Aim 3: Use PSC-derived AEC2s to model alveolar disease in-vitro. We will gene-edit 
iPSCs from a patient homozygous for the SFTPB121ins2 mutation so that we have pre- and 
post- correction iPSCs from the same genetic background. We will differentiate these 
iPSCS into “alveolospheres” and analyze SFTPB mRNA and protein expression, SFTPC 
processing, and lamellar body expression in pre- and post- correction alveolospheres to 
determine whether these cells recapitulate known aspects of the disease.   	
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GENERATION OF MATURE AEC2S FROM HUMAN PLURIPOTENT STEM 
CELLS 
Rationale 
Pulmonary alveolar epithelial type II cell (AEC2) dysfunction has been implicated 
as a primary cause of pathogenesis in many poorly understood lung diseases that lack 
effective therapies, including interstitial lung disease (ILD) and emphysema. In 
particular, studies have shown that mutations affecting genes highly expressed in AEC2s, 
such as SFTPC, SFTPB, and ABCA3, cause children’s interstitial lung disease (chILD), 
which can result in neonatal respiratory distress or early-onset pulmonary fibrosis 
(reviewed in (Whitsett et al. 2015). Mutations in genes that affect AEC2s have also been 
implicated in both familial adult-onset pulmonary fibrosis (W. E. Lawson et al. 2004; van 
Moorsel et al. 2010; Mulugeta et al. 2015) as well as in some sporadic variants (Brasch, 
Griese, et al. 2004). Hence, studying AEC2s from patients with these mutations might 
provide insight into the mechanisms by which early AEC2 dysfunction can lead to a wide 
variety of lung diseases.  
Despite the broadly acknowledged need for human AEC2 in primary cell culture, 
a pure source of expandable AEC2s has not been previously achieved. Reports have 
shown that AEC2s proliferate poorly ex-vivo and transdifferentiate into type I alveolar 
epithelial cells (AEC1s) when isolated from human lungs and cultured (Foster et al. 2007; 
Borok et al. 1998). Methods that do show maintenance of the AEC2 phenotype in culture 
require addition of mesenchymal feeders (Barkauskas et al. 2013), complicating the study 
of AEC2-specific biology in vitro. Since AEC2s are also relatively inaccessible to study 
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in the developing human embryo, it is difficult to correlate findings in mice with human 
lung development. These obstacles to AEC2 study have limited research in alveolar 
development and disease, and have prevented the engineering of approaches to correct 
the genetic lesions that cause AEC2-initiated lung diseases.  
Using induced pluripotent stem cell (iPSC) technology and directed 
differentiation to generate AEC2s de novo would provide novel opportunities to study 
normal human AEC2 development and to understand the pathogenesis of monogenic 
alveolar diseases. Several groups have reported differentiation protocols that result in 
early lung progenitors expressing the transcriptional regulator NKX2-1, as well as more 
differentiated populations containing cells expressing alveolar marker genes such as 
SFTPC (Huang et al. 2013; Gotoh et al. 2014; Dye et al. 2015; McCauley et al. 2017). 
Yet, important hurdles remain in the field, such as analysis of pure populations of iPSC-
derived putative AEC2s (iAEC2s) in comparison to primary controls, assessment of the 
maturation state of iAEC2s relative to the developing human lung, and evaluation of the 
ability of iAEC2s to model human alveolar disease in vitro.  
AEC2s have several critical roles in the distal lung. First, they are the facultative 
progenitors of the alveolus (Barkauskas et al. 2013; Desai et al. 2014; Mason & Williams 
1977), responding to lung parenchymal injury in mice by self-renewing or differentiating 
into AEC1s. AEC2s also function to synthesize and secrete surfactant, modulating 
alveolar surface tension (Kikkawa et al. 1975), and are able to respond to innate immune 
stimuli, protecting against infection (Juers et al. 1976; O'Brien et al. 1998). Several 
surfactant proteins are expressed in AEC2s, but only one, surfactant protein C (SFTPC), 
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is reported to be highly specific to the AEC2 in humans (Kalina et al. 1992; Wohlford-
Lenane et al. 1992). Even then, though SFTPC may be specific to the AEC2s in adults, it 
is expressed as early as week 12-15 in human development (Otto-Verberne et al. 1988; 
Khoor et al. 1994) and E10.5 in mouse development in the distal lung bud (Wert et al. 
1993). Mature AEC2s are characterized not only by expression of SFTPC, but also by the 
ability to assemble functional lamellar bodies (Williams & Mason 1977; Sorokin 1966), 
the organelle in which surfactant proteins and phospholipids are processed, stored, and 
secreted, a benchmark that has not yet been evaluated in iPSC-derived lung epithelial 
cells.  
In this study, we engineer human pluripotent stem cell (PSC) lines with 
fluorescent reporters (GFP and/or tdTomato) targeted to the endogenous NKX2-1 and 
SFTPC loci, respectively. We employ these tools to quantify the efficiency of alveolar 
directed differentiation in response to various inductive signals and isolate putative 
SFTPC+ alveolar cells for transcriptomic analysis compared to primary controls. We find 
that differentiating NKX2-1+ lung epithelial progenitor cells without mesenchymal co-
culture in media containing activators of Wnt and FGF signaling promotes differentiation 
of epithelial spheres containing SFTPC+ cells (“alveolospheres”). These alveolospheres 
display canonical AEC2 functional capacities, including innate immune responsiveness 
and the production of lamellar bodies able to package surfactant. Guided by time-series 
global transcriptomic profiling of PSC-derivatives, we find that AEC2 maturation 
involves downregulation of Wnt signaling activity and that the highest differentially 
expressed transcripts in iPSC-derived AEC2s encode genes associated with lamellar body 
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and surfactant biogenesis. This human model system thus is likely to facilitate disease 
modeling, developmental studies, drug screening, and future regenerative gene or cell 
therapies for a variety of adult and childhood lung diseases affecting lung alveoli.  
Methods 
PSC Line Generation and Maintenance 
All experiments involving the differentiation of human iPSC lines were 
performed with the approval of the Institutional Review Board of Boston University 
(protocol H33122). BU3 and C17 iPSC lines carrying the NKX2-1GFP reporter were 
obtained from our prior studies (Hawkins et al. 2017). These lines were derived from a 
normal donor (BU3) (Kurmann et al. 2015) and an individual with cystic fibrosis (C17) 
carrying a published compound heterozygous CFTR genotype (Crane et al. 2015), 
respectively. The human embryonic stem cell line RUES2 was a generous gift from Dr. 
Ali H. Brivanlou of The Rockefeller University. 
All PSC lines used in this study (BU3, C17, RUES2) displayed a normal 
karyotype when analyzed by G-banding both before and after gene-editing (Cell Line 
Genetics, Madison, WI). Culture conditions used for maintenance and editing of 
undifferentiated PSCs were as follows: for TALENs targeting, PSC lines were 
maintained on mitomycin C-inactivated MEFs in human iPSC media (WiCell feeder 
dependent protocol). For CRISPR targeting and prior to directed differentiation, all PSC 
lines were maintained in feeder-free conditions, on growth factor reduced matrigel 
(Corning, Corning, NY) in 6-well tissue culture dishes (Corning), in mTeSR1 medium 
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(StemCell Technologies, Vancouver, Canada) using gentle cell dissociation reagent for 
passaging.  
SFTPCtdTomato Reporter PSC Line Generation 
To generate SFTPCtdTomato knock-in reporter ESCs, TALENs were designed to 
target the sequences close to the translation initiation (ATG) site of the human SFTPC 
gene. The SFTPC TALEN recognition sequences are: left TALEN 5’-TAG CAC CTG 
CAG CAA GAT GG-3’ and right TALEN 5’-TCA CCG GCG GGC TCT CCA TC-3’. 
Between the two binding sites is a 22 bp spacer (ATG TGG GCA GCA AAG AGG TCC 
T). TALENs were constructed using EZ-TAL TALE Assembly Kit (System Bioscience, 
Palo Alto, CA), according to manufacturer’s instruction, and the resulting SFTPC 
TALENS encoding plasmids were named: EF1a-TALEN_NN (SPC left) and EF1a-
TALEN_HD (SPC right), respectively. 
To deliver the donor template to the SFTPC locus, we generated a donor vector 
(p1303 DV-SFTPC-tdTomato; map and sequence available at www.kottonlab.com) 
containing the tdTomato coding sequence and a floxed PGK promoter-driven puromycin 
resistance cassette, flanked by left and right arms of homology to the human endogenous 
SFTPC locus, as follows: we first modified the CReM’s targeting vector, TVGIP-eGFP-
puro (generous gift of Gustavo Mostoslavsky and Cesar Sommer, CReM of Boston 
University and Boston Medical Center; www.bumc.bu.edu/stemcells). The GIP-eGFP 
sequence was replaced with the tdTomato coding sequence. 5’ and 3’ arms of homology 
to the SFTPC locus were generated by PCR cloning using gDNA extracts of human ES 
cells (RUES2) as templates. The 5’ arm of homology extends 750 base pairs upstream of 
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the SFTPC ATG start site, and the 3’ arm of homology extends 750 base pairs 
downstream of the ATG start site. 
The TALENs and donor vector plasmids were co-transfected into the following 
PSC lines: RUES2, C17 NKX2-1GFP, and BU3 NKX2-1GFP (Hawkins et al. 2017, in 
press) using a lipofectamine based transfection protocol. Each line was plated onto a 
mitomycin C-inactivated DR4 mouse embryonic fibroblast (MEF) feeder layer and 
cultured in human iPSC media (WiCell) in a 6 well plate. After the cells reached 50% 
confluence, they were transfected with the two TALENs and tdTomato donor vector as 
follows: 3ug of donor vector and 1.2ug of each TALEN were added to 275ul of IMDM 
and 4ul of Plus reagent from the Lipofectamine LTX kit (Thermo Fisher), and this 
mixture was incubated at room temperature for 5 minutes. 16ul of lipofectmine LTX 
from the same kit was added to another 275 ul of IMDM. 275ul of the DNA mixture was 
added to 275ul of the LTX mixture and incubated at room temperature for 30 minutes. 
550ul of the total mixture was added drop by drop to 1 well of a 6 well plate. 5 hours 
later, the media was changed, and 48 hours later, 0.7ug/ml puromycin (Fisher Scientific) 
was added to the media for 4 days to select antibiotic resistant colonies. After 10 days 
individual colonies from each line were picked and screened for targeting using the 
following primer pairs (Figure S1): GGG TGA GTG AGC TGA TTC GAG, TGA CCT 
CCT CGC CCT TGC  TCA CCA TG. To confirm heterozygous targeting, colonies were 
screened for a remaining intact SFTPC gene using the following primers:  CTA CGG 
ACA CAT ATA AGA CCC TGG TC, GCT GTG CAT CCC ACA CCT. DNA 
sequencing using a primer binding in the genome outside any regions included in 
		
54 
targeting plasmids confirmed targeting into the endogenous SFTPC locus (GGG TGA 
GTG AGC TGA TTC GAG).  
Cre-mediated excision of the floxed puromycin resistance cassette was performed 
using a plasmid containing Cre-recombinase and neomycin resistance (PHAGE2 EF1a-
Cre-IRES-NeoR-W; www.kottonlab.com) using the same lipofectamine-based protocol 
described above, with 4 days of 200ng/ul geneticin-based (Life Tech) selection for clones 
that were transfected with Cre-containing plasmid. Excision of the puromycin cassette 
was confirmed by PCR using the following primers: ATG ACC GAG TAC AAG CCC 
ACG, TCA GGC ACC GGG CCT GC.  
Directed Differentiation of PSCs into NKX2-1+ lung progenitors 
PSC directed differentiation into NKX2-1 lung progenitors was performed as 
described previously (Hawkins, et al. 2017; (Rankin et al. 2016)). Briefly, cells 
maintained on mTESR1 media were differentiated into definitive endoderm using the 
STEMdiff Definitive Endoderm Kit (StemCell Technologies), with 1 day addition of 
supplement A and B, and 2 days addition of supplements B only (Day 4 in the STEMdiff 
kit protocol). After the endoderm-induction stage, cells were dissociated using GCDR 
and passaged at a ratio between 1:2 to 1:6 into 6 well plates coated with growth factor 
reduced matrigel in “DS/SB” anteriorization media, consisting of complete serum-free 
differentiation medium (cSFDM) base, including IMDM (ThermoFisher, Waltham, MA) 
and Ham’s F12 (ThermoFisher) with B27 Supplement with retinoic acid (Invitrogen, 
Waltham, MA), N2 Supplement (Invitrogen), 0.1% bovine serum albumin Fraction V 
(Invitrogen), monothioglycerol (Sigma, St. Louis, MO),  Glutamax (ThermoFisher), 
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ascorbic acid (Sigma), and primocin with supplements of 10 µM SB431542 (“SB”; 
Tocris, Bristol, United Kingdom) and 2 µM Dorsomorphin (“DS”; Stemgent, Lexington, 
MA). For the first 24 hours after passaging, 10µM Y-27632 was added to the media. 
After anteriorization for 3 days (72 hours), cells were cultured in “CBRa” lung 
progenitor-induction media for 9-11 days. “CBRa” media consists of cSFDM containing 
CHIR99021 (Tocris), 10 ng/mL recombinant human BMP4 (rhBMP4, R&D Systems), 
and 50 nM retinoid acid (RA, Sigma), as previously described (Rankin, et al., 2016). On 
Day 15 of differentiaton, efficiency of specification of NKX2-1+ lung progenitors was 
evaluated either by flow cytometry for intracellular NKX2-1 protein, NKX2-1GFP 
reporter expression, or by expression of surrogate cell surface markers CD47hi/CD26 
based on the method of Hawkins and Kotton (Hawkins et al., 2017). 
Purification of NKX2-1+ Lung Progenitors by Cell Sorting 
On day 15 of differentiation, cells were incubated at 37°C in 0.05% trypsin-
EDTA (Invitrogen) for 7-15 minutes, until they reached single cell suspension. Cells 
were then washed in media containing 10% fetal bovine serum (FBS, ThermoFisher), 
centrifuged at 300g x 5 minutes, and resuspended in sort buffer containing Hank’s 
Balanced Salt Solution (ThermoFisher), 2% FBS, 10µM Y-27632, and 10 uM calcein 
blue AM (Life Technologies) for dead cell exclusion. Cells not containing the NKX2-
1GFP reporter were subsequently stained with CD47-PerCPCy5.5 and CD26-PE 
antibodies (mouse monoclonal; Biolegend 1:200; 1 x 106 cells in 100ul) for 30 minutes at 
4°C, washed with PBS, and resuspended in sort buffer. Cells were passed through a 40um 
strainer prior to sorting (Falcon). Various live cell populations indicated in the text (i.e. 
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GFP+, GFP-, CD47hi/CD26-,CD47lo) were sorted on a high-speed cell sorter (MoFlo 
Legacy).  
Directed Differentiation of NKX2-1+ Lung Progenitor Outgrowth into iAEC2s 
Day 15 cells, either sorted (as described above) or unsorted (dissociated as 
described above), were resuspended in undiluted growth factor-reduced matrigel 
(Corning) at a dilution of 50-100 cells/ul, with droplets ranging in size from 20ul in 96 
well plates to 1ml in 10cm tissue culture-treated dishes (Corning). Cells in matrigel 
suspension were incubated at 37°C for 20-30 minutes, then warm media was added to the 
plates.  
Where indicated in the text, outgrowth and distal/alveolar differentiation of cells 
after day 15 was performed in “CK+DCI” medium, consisting of cSFDM base, with 3 
μM CHIR99021, 10 ng/mL rhKGF, and 50 nM dexamethasone (Sigma), 0.1 mM 8-
Bromoadenosine 3′,5′-cyclic monophosphate sodium salt (Sigma) and 0.1 mM 3-
Isobutyl-1-methylxanthine (IBMX) (Sigma) (DCI). Immediately after replating cells on 
Day 15 10µM Y-27632 was added to the medium for 24 hours. Additional growth factors 
or cytokines were added or withdrawn as indicated in the text, including FGF10, TGFb, 
EGF, OSM (20ng/ml), TNFa (10ng/ml), and IL-1b (10ng/ml) with other concentrations 
listed in figure legends (Figures S2A, B).  
Alveolosphere Long Term Culture, Dissociation, and Differentiation 
Alveolospheres developed in 3D matrigel culture outgrowths within 3-7 days after 
day 15 replating, and were maintained in CK+DCI media for weeks to months, as 
indicated in the text. These spheres were analyzed as follows: Z-stack images of live 
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alveolospheres were taken and processed on a Keyence (Osaka, Japan) BZ-X700 
fluorescence microscope. For some analyses (RT-qPCR, Western blot, lipidomic 
analysis) alveolospheres were released from matrigel droplets, and for other techniques 
(flow cytometry, cell sorting), they were dissociated into single cell suspension. To 
release alveolospheres from matrigel, droplets were incubated in dispase (2mg/ml, 
Fisher) at 37°C for 1 hour, centrifuged at 300g x 1 minute, washed in 1x PBS, then 
centrifuged again at 300g x 1 minute. To generate single cell suspensions, cell pellets 
were incubated in 0.05% trypsin and continued through the trypsin-based dissociation 
protocol described above, after which they could be passaged into fresh matrigel, 
analyzed by flow cytometry, or sorted as described above. Sorted cells from 
alveolospheres were replated into matrigel droplets for serial passaging where indicated 
in the text. For AEC1 differentiation experiments approximately 20,000 sorted 
SFTPCtdTomato+ cells were plated in 96 well tissue culture plates in Dulbecco’s 
Modified Eagle Medium (DMEM), 10% FBS, glutamax, and primocin for 4-7 days, then 
harvested for analysis. For EdU labeling, alveolospheres in 3D culture were incubated in 
CK+DCI media with 5uM EdU for 24 hours, then dissociated as described above, fixed, 
and processed according to the manufacturer’s instructions (Click-iT® EdU Alexa 
Fluor® 488 Imaging Kit, Thermo Fisher).  
Electron Microscopy of Alveolospheres (Anne Hinds) 
Alveolospheres were fixed for 3 hours total in 2.5% glutaraldehyde (Ladd 
Research, Williston, VT) in 0.1% cacodylate buffer pH 7.4 at room temperature. An 
equal volume of 5% glutaraldehyde/.1M cacodylate was added to the Eppendorf tube 
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with alveolospheres in known volume of media, fixed for 1.5 hours, and spun down 
gently (300g x 1 minute). Fresh 2.5% glutaraldehyde/ 0.1M cacodylate was added, and 
the sample was fixed for an additional 1.5 hours at room temperature. The sample was 
then washed in 0.1M cacodylate three times, post-fixed in 1% Tannic Acid in cacodylate 
buffer for 5 minutes at room temperature, washed again 3 times in cacodylate buffer, and 
post fixed overnight in 1.5% osmium tetroxide (Polysciences, Warrington, PA) in 0.1M 
cacodylate buffer in dark at 4°C. The sample was washed 3-4 times in 0.05M Na Maleate 
buffer pH 5.2 and block stained in 1.5% Uranyl acetate (Electron Miscropscopy Sciences, 
(EMS), Hatfield, PA) in 0.025M Na Maleate buffer pH 6.0. Next, the sample was 
dehydrated quickly through acetone on ice, from 70% to 80% to 90%. Then, it was 
incubated 2 times in 100% acetone at room temperature for 10 minutes each, and in 
propylene oxide at room temperature for 15 minutes each. Finally, the sample was 
changed into EMbed 812 (EMS), left for 2 hours at RT, changed into fresh EMbed and 
left overnight at room temperature, after which it was embedded in fresh EMbed 812 and 
polymerized overnight at 60°C. Plastic embedded samples were thin sectioned at 70nm 
and grids were stained in 4% aqueous Uranyl Acetate for 5 minutes at 60°C followed by 
Lead Citrate for 10 mins at room temperature. 
Sections on grids were imaged on a CM12 Transmission Electron Microscope 
(Philips, Amsterdam, Netherlands), using a TEMCAM F216 camera (TVIPS, Oslo, 
Norway) at an original magnification of 7875x and and a Morgagni 268 (FEI, Eindhoven, 
Netherlands), using a Veleta camera (Olympus SIS, Münster, Germany) at original 
magnifications of 7200x and 14000x. 
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Immunogold Staining of Alveolospheres (Tim Weaver, Cheng-Lun Na, Jeff Whitsett) 
Human iPSC-derived AEC2s were processed for immunogold labeling described 
previously (Ridsdale et al. 2011). Cultured iPSC were first fixed in situ with 4% 
paraformaldehyde (Electron Microscopy Sciences), 0.1% glularaldehyde (EMS, Hatfield, 
PA), 75 mM L-lysine (Sigma), 10 mM INaO4 (Sigma), and 0.1% CaCl2 in 0.2M HEPES 
(Sigma), pH 7.2 at room temperature for 10 min, followed by postfixation with fresh 
fixative at 4°C overnight. They were embedded with 10% gelatin, cryoprotected with 
2.3M Polyvinylpyrrolidone (PVP; M.W. 10,000; Sigma)/sucrose (Sigma) in 0.2M 
HEPES, pH 7.2, and frozen in liquid nitrogen for cryoultramicrotomy. 70 to 80 nm frozen 
sections were picked up with mixture of 1.15M PVP/sucrose, 1% methyl cellulose 
(Sigma), 0.2% uranyl acetate (EMS, Hatfield, PA), and 0.1% glutatraldehyde, transferred 
to 200 mesh Butvar® coated nickel grids (EMS), and stored at -20 °C until they were 
ready for immunogold labeling. To localize SFTPB or SFTPC proteins, thawed frozen 
sections were stained with rabbit polyclonal Ab directed against mature SFTPB (Seven 
Hills; (Lin et al. 1996)) or mature SFTPC (Seven Hills; (Ross et al. 1999)),and 10 nm 
protein A gold (CMC, U. Utrecht, The Netherlands). Electron micrographs of labeled 
cells were acquired using a Hitachi TEM 7650 (Hitachi High Technologies America, 
Schaumburg, IL) with an AMT CCD camera (Advanced Microscopy Techniques, 
Woburn, MA).  
Alveolosphere staining 
Toluidine blue staining was performed as follows: 0.5um sections (from EMbed 
plastic blocks) were collected, dried for 30 minutes on a hot plate, and stained 30-60 
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seconds in 0.5% Toluidine blue + 0.5% Borax in dH20, rinsed in dH20, dried and 
coverslipped. PAS staining was performed according to manufacturer’s instructions using 
the Sigma PAS kit.  
SFTPB Protein Analyses by Western Blot (Susan Guttentag) 
Cultured cells were treated with lysis buffer (RIPA buffer and 1x Roche Complete 
Protease Inhibitor cocktail). Buffer-treated cells were removed from the well, incubated 
on ice for 30 min, and cleared by centrifugation at 15,000G for 20min. Supernatants were 
collected and stored at -80˚C until analysis. Protein was measured using the Bio-Rad DC 
Protein Assay. A total of 35 ug of alveolosphere lysate and 25 ug of lysate from AECs 
isolated from lung explants of 21 week human lung cultured for 6 d in DCI were resolved 
on pre-cast 10% NUPAGE gels (Thermo Fisher) and transferred to PVDF membrane 
(Bio-Rad). Blots were incubated with the following primary antisera: surfactant protein B 
(PT3, a rabbit polyclonal antibody against bovine mature SP-B (Beers et al. 1992); 
1:3000 dilution); NFLANK (rabbit polyclonal antibody against a synthetic peptide of 
Gln186-Gln200 of the human Pro-SPB amino acid sequence; dilution 1:5000; (Korimilli 
et al. 2000)2000; 1:2000); GAPDH (1:5000, Chemicon). Species-specific secondary 
antisera were all conjugated to IR dyes of either 680 or 800 nm wavelengths (Rockland) 
at a dilution of 1:10000. Visualization was accomplished using the Odyssey Imaging 
System (LiCOR Biosciences, Lincoln, NB). 
Lipidomic Analysis (Hillary Heins, F. Sessions Cole) 
Alveolospheres were dissociated from matrigel as described above, and incubated 
in 1 ml of trypsin for 5 minutes to break apart the alveolospheres but leave cells intact. 
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After centrifugation, the trypsin “extracellular sample” was separated from the cell pellet 
“intracellular sample,” the cell pellet was washed in PBS, and both samples were stored 
at -80C until ready to process. 
For lipid extraction, a modified Bligh & Dyer protocol was used with an internal 
standard of 14:0 PC (DMPC) from Avanti Polar Lipids, Alabaster, AL). For extracellular 
samples, we used 500 ng PC (0.738 nmol) per sample, and for intracellular samples, we 
used 2000 ng PC (2.95 nmol) PC per sample. All reagents (water, methanol, chloroform) 
used were HPLC grade. 
Internal standard was added to each disposable glass culture tube prior to addition 
of a sample. Each cell pellet and extracellular supernatant was resuspended in 1 ml water, 
transferred to a tube, and 3 ml methanol:chloroform (2:1) was added,  intracellular 
samples were sonicated for 30 seconds, and extracelullar samples were vortexed for 30 
seconds. 1 ml chloroform and 1 ml water were added to each sample, followed by 30 
seconds of vortexing. Samples were centrifuged for 5-10 minutes at 1500xg and the 
bottom layer was collected with a glass pasteur pipet and dried under nitrogen gas. 
Intracellular samples were resuspended in 300 ul methanol, and extracellular samples 
were resuspended in 100 ul methanol. 
Electrospray ionization (ESI)/tandem mass spectrometry and gas 
chromatography/mass  spectrometry (GC/MS) were used, respectively, to measure 
phosphatidylcholine (PC) composition in the samples. Results are described as “Absolute 
Quantification” based on alveolosphere DNA amount in ng or as “Relative 
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Quantification” (Absolute Quant of each individual PC species, such as PC 32:0, divided 
by total acyl PC to get a ratio).  
Isolation of primary AECs (Susan Guttentag) 
Week 21 human lung tissues were obtained in the Guttentag laboratory under 
protocols originally reviewed by the Institutional Review Board at the Children’s 
Hospital of Philadelphia and subsequently reviewed by Vanderbilt University. The cell 
stocks used in the present studies were donated to the Kotton laboratory for the purpose 
of providing reference data. “Week 21” samples were isolated by the overnight culture of 
lung explants in Waymouth media; a technique that generally yields 86 ± 2% epithelial 
cells with the remaining cells consisting of fibroblasts with <1% endothelial cells. “Week 
21 DCI” samples were prepared in a similar manner except that the lung explants were 
also cultured for 4 days in Waymouth’s media supplemented with DCI (10 nM 
Dexamethasone, 0.1mM 8-Br cAMP, and 0.1mM 3-isobutyl-1-1methylxanthine), and 
“HFL DCI-D6” samples were cultured in this media for 6 days. Week 21 epithelial cells 
do not exhibit features of alveolar type 2 cells including lamellar bodies, whereas Week 
21 DCI epithelial cells do exhibit lamellar bodies (Gonzales et al. 2002; Wade et al. 
2006).  
Isolation of Adult AEC2s (Will Zacharias, Ed Morrisey) 
For human primary lung epithelial isolation, 1x1cm pieces of distal human lung 
obtained from healthy regions of the upper lobe of non-utilized human lungs donated for 
transplantation were dissected and all airway tissue and pleura was removed. The tissue 
was then digested using dispase, collagenase I, and DNase using the gentleMACS 
		
63 
dissociator (Miltenyi) for 30 minutes at 37°C. The resulting cell suspension was passed 
over 70uM and 40uM filters to generate a single cell suspension. Purified human AEC2 
cells were obtained by magnetic bead sorting using MACS LS columns (Miltenyi) and 
the following antibodies: HT2-280 (anti-human AEC2 antibody, IgM, Terrace 
Biotechnologies) and anti-IgM magnetic beads (Miltenyi). MACS-sorted cells were 
collected into trizol.  
RNA Sequencing and Computational Analyses (Michael Morley) 
The following samples were harvested from RUES2 PSCs in Qiazol (Qiagen) for 
RNA Sequencing analysis. (1) Day 0 samples representing undifferentiated PSCs 
cultured feeder-free in mTeSR1 media, as described above. (2) Day 15 samples 
representing CD47hi/CD26lo sorted lung progenitor. Flow cytometry analysis confirmed 
that this population consisted of between 85-90% NKX2-1+ cells. (3) Day 35 
SFTPCtdTomato+ (Tom+) and SFTPCtdTomato- (Tom-) samples resulting from the 
outgrowth of the day 15 sorted progenitors. Other samples were harvested from primary 
cells: (1) Week 21 human fetal distal lung cells (as described above), (2) Week 21 human 
fetal distal lung cells, cultured in “DCI” media for 4 days (as described above), and (3) 
Adult AEC2s purified by HT2-280-based sorting (as described above). Sequencing 
libraries were prepared from total RNA samples using Illumina TruSeq RNA Sample 
Preparation Kit v2. The mRNA was isolated using magnetic beads-based poly(A) 
selection, fragmented, and randomly primed for reverse transcription, followed by 
second-strand synthesis to create double-stranded cDNA fragments. These cDNA 
fragments were then end-repaired, added with a single ‘A’ base, and ligated to Illumina® 
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Paired-End sequencing adapters. The products were purified and PCR-amplified to create 
the final cDNA library. The libraries from individual samples were pooled in groups of 
four for cluster generation on the Illumina cBot using Illumina TruSeq Paired-End 
Cluster Kit. Each sample was sequenced four per lane on the Illumina HiSeq 2500 to 
generate more than 30 million single end 100-bp reads.  
Fastq files were assessed for quality control using the FastQC program. Fastq files 
were aligned against the human reference genome (hg19/hGRC37) using the STAR 
aligner (Dobin et al. 2013). Duplicate reads were flagged using the MarkDuplicates 
program from Picard tools. Gene counts represented as counts per million (CPM) were 
computed for Ensembl (v67) gene annotations using the Rsubread R package with 
duplicate reads removed. Genes with 10% of samples having a CPM < 1 were removed 
and deemed low expressed. The resultant data was transformed using the VOOM method 
implemented in limma R package (Law et al. 2014). Voom transformed data can now be 
tested for differential gene expression using standard linear models using the limma 
package. Multiple hypothesis test correction was performed using the Benjamini–
Hochberg procedure (FDR). Heatmaps and PCA plots were generated in R. Gene Set 
Enrichment Analysis (GSEA) was performed using the camera method implemented on 
the limma package using gene sets from the Molecular Signatures database  (MSigDB). 
Raw fastq files and VOOM transformed gene expression files are available on 
line at the gene expression omnibus, GEO (accession number pending) as well as on the 
Kotton Lab’s Bioinformatics Portal at www.kottonlab.com. 
Reverse Transcriptase Quantitative Real Time Polymerase Chain Reaction (RT-qPCR) 
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RT-qPCR was performed as previously described (Hawkins et al. 2017, in press). 
Briefly, RNA was isolated according to manufacturer’s instructions using the Qiagen 
miRNeasy mini kit (Qiagen, Venlo, Netherlands). cDNA was generated by reverse 
transcription of up to 150ng RNA from each sample using the Applied Biosystems High-
Capacity cDNA Reverse Transcription Kit. For qPCR, technical triplicates of either 20ul 
reactions (for use in Applied Biosystems StepOne 96-well System) or 12ul reactions (for 
use in Applied Biosystems QuantStudio7 384-well system) were prepared with 2ul of 
diluted or undiluted cDNA and run for 40 cycles. All primers were TaqMan probes from 
Applied Biosystems (see all in Key Resources Table). Relative gene expression was 
calculated based on the average cycle (Ct) value of the technical triplicates, normalized to 
18S control, and reported as fold change (2(-ΔΔCT)), with a fold change of 1 being 
assigned to undifferentiated (day 0) iPSCs or ESCs. Undetected probes were assigned a 
Ct value of 40 to allow for fold change calculations.  
Immunofluorescence Microscopy of Cultured Cells 
Alveolospheres were dissociated as described above, washed in dPBS, and fixed 
with 4% paraformaldehyde. Alveolospheres were subsequently either processed for 
cryosectioning or whole-mount staining. For cryosectioning, fixed alveolospheres were 
first embedded in low melting temperature agarose (SeaPrep) and after incubation in 
7.5% and 30% sucrose solution, further embedded in OCT, flash frozen, and 6um 
sections were cut on a cryotome. Both whole mount alveolospheres and frozen sections 
were washed in dPBS, blocked in 4% normal donkey serum (NDS) with 0.5% Triton X-
100 (Sigma) for 30 minutes, and incubated overnight in primary antibody (see Key 
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Resources table) in 0.5% Triton X-100 and 4% NDS. Samples were then washed in 4% 
NDS and incubated with secondary antibody from Jackson Immunoresearch (1:300 anti 
rabbit IgG (H+L) or anti mouse IgG (H+L)) for 2 hours at room temperature. Nuclei were 
stained with Hoescht dye (Thermo Fisher, 1:500) and sections were mounted with 
Prolong Diamond Anti-Fade Mounting Reagent (ThermoFisher) and coverslipped, while 
whole mount alveolospheres were mounted on cavity slides. Both stained whole mount 
and cryosectioned alveolospheres were visualized with a Zeiss (Jena, Germany) confocal 
microscope. 
Statistical Methods 
In figures containing RT-qPCR, flow cytometry, or lipidomics data, data was 
presented as the mean with error bars representing the standard deviation from the mean. 
Unpaired, two-tailed Student’s t-tests were performed on 2 groups of n ≥ 3 replicates 
each, and the p-value threshold to determine significance was set at p=0.05. Replicates 
generally represent samples differentiated separately from the PSC stage, though in some 
cases they represent separate sorted populations from the same differentiation.  
Immunogold Quantification 
To determine if immunogold stained mature SFTPB and mature SFTPC localized 
to specific cellular compartments in PSC-derived cells, gold counts registered on 
biosynthetic and non-biosynthetic compartments were tabulated and analyzed by relative 
labeling index (RLI) described by Mayhew (Mayhew 2011).Briefly, a non-destructive 
counting grids generated by the grid plugin under FIJI was randomly superimposed over 
the acquired electron micrograph at magnification of 15,000.  Gold counts and sampled 
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grid points registered on the compartments of interest, i.e., multivesicular bodies/lamellar 
bodies, were collected for estimation of the expected gold counts for selected 
compartments after normalization to surface areas of selected compartment to total cell 
surface areas. To determine if gold labeling was specific to the compartments of interests, 
observed counts (n= 1160 and 2510 total gold particles for SFTPB and SFTPC, 
respectively) were compared with expected counts by χ2 statistics and contingency table 
analyses (Conover, 1999, Practical Nonparametric Statistics, 3rd ed., p179-268). Any 
cellular compartment that had RLI>1 (p-value< 0.05) and significantly higher partial χ2 
value compared to other compartments was considered labeled preferentially by SFTPB 
or SFTPC antibodies (25% of total χ2 value was arbitrarily chosen for this study). 
Results 
SFTPC reporter PSC lines allow visualization of distal lung differentiation and 
isolation of putative iAEC2s 	
During mouse lung development, AEC2s derive from SFTPC+ distal lung bud 
progenitors, which in turn arise from less differentiated NKX2-1+ foregut endoderm-
derived lung epithelial precursors that do not yet express SFTPC. To observe in real-time 
this putative sequence of AEC2 development in human cells, we first used gene editing to 
target fluorochrome reporter constructs (GFP and tdTomato) to the endogenous NKX2-1 
and SFTPC loci, respectively (Figure 2.1A, 2.2A, B). Using a published lung directed 
differentiation protocol (Figure 2.2C) established by Snoeck and colleagues (Huang et al. 
2013), we observed sequential in vitro differentiation of dual-targeted iPSC lines (C17 
and BU3) into uncolored foregut endoderm followed by NKX2-1GFP+/SFTPCtdTomato- 
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putative primordial lung progenitors, and then NKX2-1GFP+/SFTPCtdTomato+ cells (Figure 
S1C). NKX2-1 is an essential transcription factor known to bind the SFTPC promoter, is 
required for SFTPC gene expression, and is expressed in all developing lung epithelia in 
vivo, including fetal and adult AEC2s (Minoo 1999; Boggaram 2009). In keeping with 
these in vivo observations, all PSC-derived SFTPCtdTomato+ cells co-expressed the NKX2-
1GFP reporter (Figure 2.2D). Flow cytometry sorting of NKX2-1GFP+/SFTPCtdTomato+ cells 
enriched for expression of both NKX2-1 and SFTPC transcripts (Fig. 2.2D), however, 
both the efficiency of differentiation and SFTPC expression levels within the 
SFTPCtdTomato+ population when compared to primary fetal alveolar epithelial control 
cells were initially low. Similar findings were observed with this protocol in single color 
RUES2 SFTPCtdTomato+ cells (data not shown).  
To optimize SFTPC differentiation efficiency we sequentially withdrew one 
factor at a time from each stage of differentiation (NKX2-1 progenitor induction stage vs 
SFTPC+ induction stage), observing that only three factors (CHIR, BMP4, and RA; 
hereafter CBRa) were sufficient for the specification of NKX2-1+ progenitors, as 
published previously(Gotoh et al. 2014; Rankin et al. 2016). For subsequent SFTPC 
induction within this NKX2-1+ population, only two exogenous factors (CHIR and KGF; 
hereafter CK) were sufficient in the presence of previously published lung maturation 
additives (dexamethasone, cyclicAMP and IBMX; hereafter “DCI”) (Gonzales et al. 
2002) (Figure 2.3A,B). We found no consistent further SFTPC induction efficiency with 
the addition of other reported distalizing factors, such as BMP4, EGF, and FGF10 or with 
additional inhibitors of BMP, TGFβ, or Notch signaling (Figure 2.3B and data not 
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shown). Testing our optimized differentiation protocol (Figure 2.1B) on our single-color 
RUES2 SFTPCtdTomato ESC line, we observed efficient induction of endodermal NKX2-1 
with CBRa (50.67% +/- 16.05) by day 15 and rapid emergence of SFTPCtdTomato+ cells 
within 3 to 7 days of subsequent exposure to CK+DCI (Figure 2.1B,C). tdTomato+ cells 
could be visualized scattered throughout epithelial spheres in 3D cultures of all targeted 
PSC lines (Figure 2.1C), and by day 30 of differentiation these tdTomato+ cells were 
highly enriched in transcripts encoding surfactant proteins as well as transcripts 
associated with lamellar body biogenesis, SFTPC, SFTPB, ABCA3, LAMP3, and 
LPCAT1 (Figure  1D). Notably SFTPC, SFTPB, and ABCA3 were expressed at levels 
higher than primary fetal lung controls (week 21 gestation fetal alveolar epithelial cells 
~85-90% SFPTC+). At the protein level, epithelial spheres that included tdTomato+ cells 
also expressed NKX2-1 nuclear protein, membranous EPCAM, punctate cytoplasmic 
ProSFTPC, and intracellular as well as secreted SFTPB protein (Figure 2.1E).  
		
70 
 
Figure 2.1. NKX2-1GFP and SFTPCtdTomato reporters allow visualization of distal lung differentiation and 
isolation of putative iAEC2s.  
(a) Schematics showing TALENs targeting strategy and edited NKX2-1GFP and SFTPCtdTomato loci post Cre-
mediated antibiotic cassette excision. (b) Schematic showing differentiation protocol from PSC to putative iAEC2s 
used in subsequent panels. (c) Representative images of “alveolospheres” late in differentiation showing expression of 
endogenous NKX2-1GFP and SFTPCtdTomato (C17, Day 50 and RUES2 Day 30 panels are representative 3D whole 
mount confocal fluorescence microscopy reconstructions; BU3 Day 35 panel was acquired by live alveolosphere 
imaging on an inverted microscope). Scale bar represents 100µm. (d) Representative flow cytometry of 
SFTPCtdTomato expression in Day 30 RUES2. RT-qPCR of pre-sort, sorted tdTomato+ (Tom+), and tdTomato- 
(Tom-) samples compared to primary Week 21 (Wk 21) human fetal distal lung control (85-90% SFTPC+). Bars 
represent mean fold change in expression (2-ΔΔCt) compared to undifferentiated (day 0) PSCs ± S.D. in n=3 biological 
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replicates from 3 differentiations separated at the day 0 stage. (e) Representative immunofluorescence microscopy after 
staining with antibodies against tdTomato (red), EPCAM, NKX2-1, proSFTPB, and proSFTPC (green) in Day 30 
RUES2 alveolospheres. Nuclei stained with Hoechst (gray). Scale bars represent 10µm. (f) Day 21 representative flow 
cytometry analysis of C17 Day 15 unsorted, sorted NKX2-1GFP+, or sorted NKX2-1GFP- outgrowth. Bars represent 
mean ± S.D., n=3 biological replicates from differentiations separated at the day 0 stage, *** p ≤ 0.001 by unpaired, 
two-tailed Student’s t-test.  
 
Figure 2.2. Targeting and validation of NKX2-1GFP and SFTPCtdTomato reporter lines.  
(a) C17 NKX2-1GFP;SFTPCtdTomato (NGST), RUES2 SFTPCtdTomato (ST), and BU3 NKX2-1GFP;SFTPCtdTomato (NGST) 
iPSC lines show normal karyotype in 20 out of 20 cells by G-banding analysis. (b) Schematic of primer binding 
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locations, gel showing PCR validation of tdTomato targeting (P3,P4; 906bp); intact endogenous SFTPC in the non-
targeted locus (P1,P2; 997bp); and excision of the puromycin resistance cassette (P5,P6; 600bp). Note: primers P1 and 
P3 bind in the endogenous genome outside of any targeting plasmids. First 4 lanes on each gel (1-4) are clones selected 
for screening, + indicates positive control for each expected PCR product, - indicates negative control, and W 
represents “water only” control. (c) Schematic of published differentiation protocol with representative 
GFP/tdTomato/phase overlay images of C17 reporter line at anterior foregut endoderm stage, Day 15, Day 31, and Day 
35 of differentiation. Black arrows indicate emergence of a loop of epithelium co-expressing NKX2-1GFP and 
SFTPCtdTomato (orange). Scale bar represents 1mm. Table shows growth factor abbreviations and concentrations. (d) 
Representative flow cytometry from C17 Day 35 differentiation. RT-qPCR of presort and sorted (NG-ST-, NG+ST-, or 
NG+ST+) populations; bars represent fold change (2-ΔΔCt compared to day 0 iPSCs) ± S.D., n=3 biological replicates 
from differentiations separate from the day 0 PSC stage.  
 
Figure 2.3. Manipulation of signaling pathways and Day 15 surface marker-based sorting in iAEC generation.  
(a) Schematic of differentiation scheme and yield of SFTPC+ cells resulting from unsorted progenitors. Bars represent 
mean percent SFTPCtdTomato+ cells ± S.D. in Day 30 RUES2 cultured from Day 15-30 in CFK+DCI media with one 
component removed in n=3 differentiations separate from the Day 0 stage. (b) C17 iPSCs differentiated in a similar 
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screening approach to that shown in A, except NKX2-1+ progenitors are sorted on day 15 for outgrowth in various 
media and analyzed at day 21 by flow cytometry. Bars represent mean percent SFTPCtdTomato+ cells ± S.D. In the far left 
graph, media consist of CFK+DCI with one indicated component added (abbreviations listed in the above table). In the 
left graph, various components were removed from CFK+DCI media in n=3 differentiations separate from the Day 0 
stage (*p ≤ 0.05, **p ≤ 0.01 compared to the CFK+DCI condition by unpaired, two-tailed Student’s t-test). In the right 
graph, CK+DCI media was supplemented with various components, in n=2 differentiations. In the far right graph, 
inhibitors of FGF signaling were added to CK+DCI media, n=2. No conditions other than CK+DCI showed a 
significant increase in Day 21 percent SFTPCtdTomato+ cells when compared to CK+DCI media, but adding the MEK 
inhibitor PD98059 did seem to increase the SFTPCtdTomato percent. (c) Representative flow cytometry of Day 15 
CD47hi/CD26lo and CD47lo populations. Top panel shows intracellular NKX2-1 protein on day 15 in unsorted, 
CD47hi/CD26lo, and CD47lo sort gates, and bottom panel shows SFTPCtdTomato expression in the Day 21 outgrowth of 
each population, sorted on day 15 for replating and 3D outgrowth until day 21 analysis. Bars represent mean ± S.D. of 
n=3 differentiations separated at the PSC stage (***p ≤ 0.001, ****p ≤ 0.0001 by unpaired, two-tailed Student’s t-test).  
 
Human putative alveolar cells derive from an NKX2-1+ primordial progenitor 
Next, we asked whether the early NKX2-1+ population represented the entire 
pool of progenitors from which SFTPC+ alveolar cells might arise. To address this 
question, we differentiated day 15 unsorted cells and sorted NKX2-1GFP+ vs NKX2-1GFP- 
cells in parallel (Figure 2.1F). We found that NKX2-1GFP+ sorted cells gave rise to 
SFTPC+ cells, whereas GFP- sorted cells were not competent to give rise to SFTPC+ 
progeny. The mixed (unsorted) population resulted in a lower efficiency of alveolar 
differentiation, suggesting that the NKX2-1GFP- population does not detectably contain a 
lineage that promotes alveolar differentiation, such as lung-specific mesenchyme (Fig. 
1F), findings consistent with our previous profiling of the iPSC-derived GFP negative 
population (Hawkins et al, in press). To extend this approach to PSCs that do not contain 
an NKX2-1 knock-in reporter, we next aimed to develop a strategy to identify AEC2-
competent NKX2-1+ progenitors in the RUES2 cell line, which has a single 
SFTPCtdTomato reporter. We have previously shown that CD47hi/CD26lo day 15 cells are 
highly enriched in NKX2-1+ lung progenitors (Hawkins et al., in press). In keeping with 
these findings, we observed that sorting RUES2 Day 15 cells based on CD47hi/CD26lo 
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gating (Figure 2.3C) resulted in ~88% NKX2-1+ cells (compared to ~62% NKX2-1+ 
without sorting and ~5% in CD47lo cells), and that CD47hi/CD26lo sorting on day 15 
identified the entirety of the SFTPC competent population, enriching the SFTPC+ yield 
in the day 21 population approximately 4 fold over unsorted cells (Figure 2.3C).  
Having demonstrated that SFTPC+ cells derive via an NKX2-1+ progenitor 
intermediate, we next sought to test whether Wnt activation was necessary and acting 
directly on these progenitors. Hence, we purified NKX2-1GFP+ cells on day 15 and 
repeated our differentiation protocol in the presence or absence of CHIR (Figure 2.3A, 
2.4A). By day 21, induction of the SFTPCtdTomato reporter was evident in 7.17 +/- 0.89% 
of cells in the presence of CHIR, whereas only rare cells (0.64 +/- 0.34%) expressed the 
tdTomato reporter in the absence of CHIR, even when the cultures were maintained up to 
day 35. These findings are consistent with our prior observation (McCauley et al. 2017) 
that CHIR distalizes NKX2-1+ human lung progenitors while suppressing proximal 
airway fates. Although KGF was dispensable for initial induction of the tdTomato 
reporter (Figure 2.3A, B), we found cells proliferated poorly in the absence of KGF or 
FGF10 (data not shown). In addition, KGF, when combined with CHIR, was more 
consistent in promoting the outgrowth of tdTomato+ cells by day 21 compared to 
FGF10+CHIR (Figure 2.3B), as predicted by prior mouse lung explant culture 
experiments (Liu et al. 2003).  
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Figure 2.4. Putative iAEC2s proliferate and differentiate in long-term culture.  
(a) Representative flow cytometry analysis on day 21 of C17 iPSCs sorted based on NKX2-1GFP+ expression on Day 15 
and replated for outgrowth from day 15-21 with or without addition of CHIR to K+DCI base media. Bars represent 
mean ± S.D., n=6 biological replicates separated from the day 0 stage, **** p ≤ 0.0001 by unpaired, two-tailed 
Student’s t-test. (b) Day 30 representative flow cytometry analysis of BU3 iPSCs sorted on Day 15 based on NKX2-
1GFP+ expression, replated for outgrowth from days 15-30 and then sorted for analysis from each gate: NKX2-1GFP- 
SFTPCtdTomato- (NG-ST-), NKX2-1GFP+ SFTPCtdTomato- (NG+ST-), and NKX2-1GFP+ SFTPCtdTomato+ (NG+ST+). RT-
qPCR of these populations, in addition to unsorted (Pre-Sort) Day 30 cells and Week 21 primary human fetal distal 
lung controls (21 Wk) is shown with bars representing mean fold change (2-ΔΔCt compared to day 0 iPSCs) ± S.D., n=3 
biological replicates differentiated separately from the day 15 stage. (c) Schematic describing experiment in which Day 
22 alveolospheres were dissociated for cell sorting and SFTPCtdTomato+ cells were sorted either into 3D culture in 
CK+DCI media or 2D culture (tissue culture-treated plastic) in 10%FBS media. Representative phase/brightfield and 
tdTomato fluorescence microscopy of live cells after 7 days in either culture condition, scale bars represent 50µm, 
		
76 
arrow indicates tdTomato expression in 2D cultured cells. RT-qPCR of 3D vs 2D cultured cells with bars representing 
mean fold change (2-ΔΔCt compared to day 0 PSCs) ± S.D., n=3 biological replicates from differentiations separate from 
the day 0 stage, *p ≤ 0.05, ***p ≤ 0.001 by unpaired, two-tailed Student’s t-test. (d) Representative confocal 
immunofluorescence microscopy of Edu (green) and anti-tdTomato (red) after 24 hour EdU incubation. Nuclei were 
stained with Hoechst. Representative flow cytometry analysis of Day 38 BU3 iPSC-derived alveolospheres shows co-
expression of EPCAM and tdTomato proteins (e) Graph showing cell number at consecutive passages of 1x104 BU3 
SFTPCtdTomato+ sorted cells plated on Day 22 in 3D CK+DCI culture. Passages were 10 and 14 days apart, respectively. 
Representative flow cytometry and live cell imaging of Day 66 RUES2-derived alveolospheres from the outgrowth of 
SFTPCtdTomato+ cells sorted on Day 22 and passaged 3 times. Scale bars represent 100µm.  
 
Having established a protocol for the derivation of SFTPC+ putative distal lung 
cells we next sought to determine whether other lung lineages were co-developing in 
these cultures, focusing in particular on profiling the frequent NKX2-1+/SFTPC- cells 
that were present in our differentiations. Hence, we sorted each population for profiling 
on day 30 using each combination of the NKX2-1GFP and SFTPCtdTomato dual reporters 
present in our BU3 iPSC line (Figure 2.4B). In the presence of CHIR and KGF, we 
observed significant enrichment of SFTPC in the NKX2-1GFP+/SFTPCtdTomato+ population  
(NG+ST+; Figure 2.4B) whereas NKX2-1 was expressed equally in NKX2-
1GFP+/SFTPCtdTomato+ cells compared to NKX2-1GFP+/SFTPCtdTomato- (NG+ST-) cells, as 
expected. In marked contrast we observed no expression of the airway club cell marker, 
SCGB1A1 in any population (Figure 2.4B), and enriched expression of the basal cell 
marker P63 in only the GFP- non-lung population, a finding in keeping with our 
observation that there is inefficient proximal airway patterning of iPSC-derived NKX2-
1+ progenitors in the presence of high levels of CHIR-stimulated canonical Wnt signaling 
(McCauley et al. 2017). As we have previously published, when we withdrew CHIR 
early (day 15-19) from sorted NKX2-1+ progenitors, the resulting cells in the presence of 
FGF stimulation demonstrated robust upregulation of proximal airway markers (SOX2, 
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SCGB3A2, SCGB1A1, TP63, and MUC5B) without significant expression of SFTPC or 
other distal markers ((McCauley et al. 2017) and data not shown). 
In our distalizing media (CK+DCI; Figure 2.1B and 2.4B) we were surprised to 
find little evidence of type 1 AEC (AEC1) differentiation in any population at the day 30 
time point, as evidenced by low to undetectable levels of PDPN, AGER, and AQP5 
(Figure 2.4, 2.5). Similar findings were observed for later (day 35-50) time points (data 
not shown). Considering our finding that NKX2-1+ SFTPC- cells in the day 30 
population were not proximal lung cells or AEC1s, we assessed their expression of 
additional AEC2 markers and unexpectedly found that they expressed ABCA3, and 
LPCAT1 at high levels, similar to primary fetal AECs (Figures 2.5A), raising the 
possibility that the NKX2-1+/SFTPC- population may represent a less mature distal lung 
population compared to tdTomato+ cells which express significantly higher levels of 
SFTPC.  
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Figure 2.5. Expression of alveolar transcripts pre- and post- alveolosphere passaging.  
(a) Representative flow cytometry of Day 30 BU3 iPSCs, sorted based on GFP expression on day 15 for replating and 
outgrowth until Day 30 differentiation. RT-qPCR of day 30 “presort” population vs cells sorted from each indicated 
quadrant (NG-ST-, NG+ST-, or NG+ST+); bars represent mean fold change (2-ΔΔCt compared to day 0 iPSCs) ± S.D., 
n=3 biological replicates from differentiations separate from the Day 15 sort stage (**p≤ 0.01, ***p ≤ 0.001 by 
unpaired, two-tailed Student’s t-test). (b) RT-qPCR of Day 66, passage 3 alveolospheres (unsorted outgrowth from Day 
38 sorted SFTPCtdTomato+ cells); bars represent fold change (2-ΔΔCt compared to iPSCs) ± S.D., n=3 biological replicates 
from differentiations separate from the Day 38 sort stage. See also main figure 2. 
 
Putative iAEC2s display self-renewal and differentiation capacities 
Given the absence of AEC1 differentiation in our alveolospheres in distal 3D 
culture conditions, we tested the capacity of PSC-derived SFTPCtdTomato sorted cells to 
differentiate when transferred to conditions that have been published as generating 
AEC1s from primary AEC2s, such as 2D culture in serum-containing media without 
CK+DCI (Borok et al. 1998; Dobbs 1990). In contrast to parallel control SFTPCtdTomato+ 
cells maintained in 3D distal conditions, we observed that sorted PSC-derived 
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SFTPCtdTomato+ cells replated in these “AEC1 culture conditions” for 1 week rapidly 
flattened into squamous-like cells, significantly downregulated SFTPC, lost visible 
tdTomato reporter gene expression, and significantly upregulated PDPN and AGER (Fig. 
2.4C).  
In addition to the capacity to differentiate, proliferation is a well-characterized 
property of both fetal and adult AEC2s (Barkauskas et al. 2013; Desai et al. 2014), 
though long-term in vitro AEC2 proliferation has been shown to require mesenchymal 
feeders. We found that in the absence of mesenchymal cells, with only the inductive 
signals provided in CK+DCI media, iPSC-derived SFTPCtdTomato+ cells within 
alveolospheres showed proliferative potential, as evidenced by their capacity to label with 
Edu (Figure 2.4D). In addition, tdTomato+ cells sorted to purity on day 22 continued to 
increase in number during subsequent serial passaging and to re-form alveolospheres 
after each passage (Figure 2.4E). After passaging, the resulting alveolospheres were 
composed of both tdTomato+ and tdTomato- cells providing direct evidence of a lineage 
relationship between the two populations. Both whole (unsorted) alveolar organoids and 
sorted SFTPCtdTomato+ cells maintained expression of the SFTPCtdTomato reporter in a subset 
of cells as well as mRNA expression of alveolar transcripts after multiple passages and 
freeze-thaw cycles (Figures 2.4E, 2.5B, and data not shown) further indicating significant 
self-renewal potential of PSC-derived SFTPC+ cells. 
Putative iAEC2s express lamellar bodies that synthesize and secrete surfactant 
The in vivo ultrastructural and biochemical characteristics of developing fetal and 
adult alveolar epithelia have been studied for more than 40 years, providing an extensive 
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in vivo roadmap against which to compare iAEC2s (Williams 1977). Though alveolar 
progenitors express SFTPC or other surfactant markers in vivo as early as week 12-15 of 
human gestation (Otto-Verberne et al. 1988; Khoor et al. 1994), they do not express 
functional lamellar bodies (LBs), the classic marker of AEC2 maturity, until after week 
24 (Figure 2.6A). Hence, we assessed whether putative iAEC2s express these highly 
specialized organelles. Semi-thin plastic sections of PSC-derived alveolospheres revealed 
small inclusions clustering in the apical (luminal) side of the alveolosphere monolayer in 
a subset of cells (Figure 2.6B), and ultrastructural analysis by transmission electron 
microscopy (TEM) showed these to be lamellar body-like inclusions (LBLs; Figures 2.6C 
and 2.74). As has been reported for adult AEC2 in vivo, LBLs in alveolospheres were 
approximately 1 micrometer in diameter, with some LBLs expressing central dense cores, 
a characteristic found in human but not rodent AEC2s. Even after multiple passages, Day 
70 alveolospheres contained LBLs (Figure 2.7A), further supporting the self-renewing 
capacity of putative iAEC2s. Within the cytoplasm of most cells, regardless of the 
presence of LBLs, we observed large areas reminiscent of the glycogen rich regions 
(Figures 2.6B,C and 2.7) known to be expressed in fetal AEC2s just prior to birth 
(Ridsdale & Post 2004; Have-Opbroek et al. 1988). PAS staining confirmed the presence 
of cytoplasmic glycogen in the majority of cells within CD47hi/CD26lo- alveolospheres 
(Fig 2.7B), further suggesting putative iAEC2s may resemble late fetal AEC2s.  
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Figure 2.6. Putative iAEC2s express lamellar bodies that contain surfactant.  
(a) Schematic describing temporal expression of NKX2-1 and SFTPC during human fetal lung development. (b) 
Representative image of live Day 30 RUES2-derived alveolospheres (scale bar, 100µm) and fixed plastic-section 
stained with toluidine blue. Arrows indicate cells with putative lamellar-body-like inclusions, gl = putative glycogen 
lake. (c) Transmission electron microscopy of Day 30 RUES2-derived alveolospheres. Lbl=lamellar body-like 
inclusion, desm=desmosome, gl=glycogen lake. Scale bars represent 800nm, 1µm and 2µm, as indicated. (d) 
Immunogold labeling of mature SFTPB and SFTPC in Day 30 RUES2 alveolospheres. Scale bars represent 0.2µm. 
Significance of relative labeling index was calculated by comparing observed counts in each cellular compartment with 
expected counts by χ2 statistics and contingency table analyses. *p-value< 0.05, RLI>1, and compartment χ2 value 
>25% of the total χ2 value for this study.  
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Figure 2.7. Ultrastructural analysis of alveolospheres.  
(a) Representative TEM images of Day 70 BU3 alveolospheres (outgrowth from cells sorted on day 30 for 
SFTPCtdTomato expression and passaged 3 times). Scale bar represents 500nm. (b) Periodic acid-Schiff (PAS) stain of 
Day 30 RUES2 alveolospheres, with pink staining indicating glycogen positive cytoplasmic regions. (c) Additional 
TEM images of Day 30 RUES2 alveolospheres.  
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preferentially localize to LBLs and their precursor organelles, multivesicular bodies 
(MVBs) within alveolospheres (Figure 2.6E), findings consistent with those reported for 
mature AEC2 in vivo (Brasch, Johnen, et al. 2004; Korimilli et al. 2000).  
To further test the functionality of putative iAEC2s, we asked whether the cells 
were able to process proSFTPB protein to its fully mature 8kD form (Fig. 2.8A). 
(Guttentag et al. 1998), because the last cleavage step in proSFTPB processing occurs in 
the functional MVBs and LBs of post-week 24 gestation human AEC2s (Brasch, Johnen, 
et al. 2004). Importantly, we found iAECs expressed high levels of the genes required for 
proSFTPB proteolysis (Foster et al. 2004), including PGC, Napsin A (NAPSA), and 
Cathepsin H (CTSH) (data not shown). Hence, we analyzed a time series of protein 
extracts prepared from RUES2 cells during distal lung differentiation in vitro. Western 
blots immunostained with antibodies able to discern fully processed mature 8 kD SFTPB 
(PT3 antibody) vs proSFTPB precursor forms (NFLANK antibody; Figure 2.8A,B) 
revealed increasing production of both the precursor and mature forms of SFTPB 
beginning on day 22 of differentiation and increasing over time through day 36 (Figure 
2.8B). Compared to primary fetal human AEC2 controls, PSC-derived cells similarly 
expressed 42 kD, 23 kD, and 10 kD precursor forms as well as mature 8 kD SFTPB 
protein. Moreover, as with primary controls, SFTPB appeared to be efficiently processed 
in alveolospheres as the predominant SFTPB form detected was the mature form (Figure 
2.8B). The larger precursor SFTPB forms were only visible when the “NFLANK” 
specific antibody was used to detect the proSFTPB region that is present prior to final 
cleavage into the mature form. 
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To determine whether putative iAEC2s synthesize and secrete surfactant-specific 
32:0 dipalmitoyl phosphatidylcholine (DPPC), we performed lipidomic analysis on both 
the intracellular and extracellular material from iPSC-derived alveolospheres. Since these 
spheres appear to be polarized with the apical surface pointing inwards, we first 
dissociated them with dispase and trypsin in order to free the secreted products, and then 
performed the analysis on the supernatant fractions and the cells separately (Figure 2.8C). 
Both the relative and absolute amounts of DPPC were significantly higher in the 
intracellular and extracellular material from the alveolospheres generated from PSCs via 
NKX2-1+ progenitors (isolated by CD47hi/CD26lo sorting) compared to control spheres 
generated from endodermal progenitors depleted of NKX2-1+ cells. Taken together, 
these results show that PSC-derived alveolospheres contain cells with functional lamellar 
bodies that synthesize, store, and secrete surfactant, suggesting that they contain 
phenotypically mature AEC2-like cells, hereafter referred to as iAEC2.  
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Figure 2.8. Putative iAEC2 lamellar bodies function to synthesize and secrete surfactant.  
(a) Schematic showing cellular compartments in which proSFTPB processing into mature SFTPB occurs. (b) Western 
blot of a timecourse of alveolosphere differentiation (Day 0, 16, 22, 29, and 36) and 6 day DCI-cultured primary week 
21 human fetal distal lung (HFL DCI-D6) as a positive control. Top panel uses anti-N Flank antibody that binds to the 
N-pro region of pro-SFTPB (present in the 42, 25, and 10kD intermediates), and bottom panel uses anti-mature SFTPB 
antibody (PT3) that binds all SFTPB forms, including the 8kD mature form. (c) Schematic showing dissociation 
protocol for isolation of intracellular and extracellular components of alveolospheres. Both absolute (nmol lipid/µg 
DNA in cell samples) and relative (nmol lipid/nmol total diacyl phospatidylcholine) are shown for both surfactant-
specific 32:0 DPPC and nonspecific 34:1 PC. Surfactant index was calculated as the sum of the surfactant-specific 30 
and 32 PCs divided by the sum of non-surfactant specific 36 PCs. Bars represent mean ± S.D. for each analysis, n=3 
biological replicates from wells separate from the Day 15 sort stage, *p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 
0.0001 by unpaired, two-tailed Student’s t-test.  
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Global transcriptomic profiling of PSC-derived lung progenitors and their 
differentiated iAEC2 progeny 
We next sought to define the global transcriptomes of PSC-derived lung 
progenitors and their SFTPC+ and SFTPC- progeny in an unbiased way by performing a 
time-series analysis using RNA sequencing (RNA-Seq). We analyzed 3 different 
timepoints in the RUES2 differentiation: 1) Day 0 undifferentiated cells, 2) Day 15 lung 
progenitors highly enriched in NKX2-1+ cells by CD47hi/CD26lo sorting (hereafter 
CD47+), and 3) the outgrowth of these purified progenitors in 3D culture sorted again on 
Day 35 based on SFTPCtdTomato+ (Tom+) and SFTPCtdTomato- (Tom-) gating (Figure 2.9A). 
For comparison to primary cells, we simultaneously sequenced RNA from purified 
primary fetal (21 week gestation) distal alveolar epithelial progenitors and sorted adult 
human AEC2s. In order to evaluate the effect of cell culture on primary fetal alveolar 
cells, parallel samples of the fetal cells were also exposed to 4 days of culture in DCI 
media.    
		
87 
 
Figure 2.9. Global transcriptomic profiling of PSC-derived lung progenitors and their differentiated iAEC2 
progeny.  
(a) Schematic of timepoints in alveolosphere differentiation from which samples were taken for RNA-Sequencing. (b) 
Principal component analysis (PCA) of gene expression variance across all samples based on 30,000 transcripts. (c) 
Log2 expression of SFTPC across all samples, with the dotted line representing “noise,” since these levels of 
expression are not consistently detected by RT-qPCR. Lower right panel shows RT-qPCR of each sample, with mean 
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fold change (2-ΔΔCt compared to day 0 PSCs) ± S.D., n=3 biological replicates from separate differentiations (RUES2 
samples), cells isolated for RNA separately (Wk 21), cells cultured for 4 days separately (Wk 21 DCI), and cells from 
separate lungs (Adult AEC2), *p ≤ 0.05, ** p ≤ 0.01 by unpaired, two-tailed Student’s t-test. (d) Heatmap of row-
normalized expression of selected lineage markers across PSC-derived and primary samples. (e) Heatmap of top 10 
genes upregulated in day 35 Tom+ cells vs day 15 progenitors (ranked by fold change, FDR≤0.05). Known AEC2 
genes are in bold.  (f) Heatmap of top 50 genes differentially expressed in day 35 Tom+ cells vs day 15 cells (ranked by 
FDR, FDR≤0.01). Known AEC2 genes are in bold. (g) Heatmap of supervised hierarchical clustering based on top 300 
genes differentially expressed in day 35 Tom+ vs day 15 cells (ranked by absolute fold change, FDR≤ 0.01). (h) Left 
panel shows experimental design, middle panel shows Western blot for IkB-alpha, phospho-Stat3 (Tyr705), and pan-
actin. Bottom panels show RT-qPCR of each sample, with fold change (2-ΔΔCt compared to day 0) ± S.D., n=3 
biological replicates from differentiations separate from the day 35 passaging stage, *p ≤ 0.05, ** p ≤ 0.01 by unpaired, 
two-tailed Student’s t-test.  
 
Figure 2.10. Global transcriptomic profiling of iAEC2s compared to early timepoints in differentiation and 
primary AEC controls.  
(a) List of all Hallmark Gene Set Enrichment Analysis (GSEA) pathways upregulated in adult AEC2s vs Tom+ cells 
(ranked by FDR, FDR≤0.05), with pathways related to immune signaling highlighted in yellow and pathways related to 
oxidant stress highlighted in orange. (b) Left panel shows a Venn diagram of genes upregulated in Adult AEC2s vs Day 
C
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15 cells and genes upregulated in Tom+ cells vs Day 15 cells (FDR≤0.05), with selected AEC2 genes shown in the 
overlap region. In each non-overlapping region, the top 10 upregulated genes ranked by fold change are shown. Right 
panel shows a Venn diagram of genes upregulated in Tom+ vs Day 15 cells and genes upregulated in Tom- cells vs 
Day 15 cells (FDR≤0.05). In each non-overlapping region, the top 10 upregulated genes ranked by fold change are 
shown. Note: the Tom+ and Tom- cells largely upregulate the same genes from Day 15-35, including many AEC2 
genes. (c) List of all Hallmark Gene Set Enrichment Analysis (GSEA) pathways upregulated in Tom+ cells vs. day 15 
cells (ranked by FDR, FDR≤0.05), with the TNFa signaling via NFkB and IL6/Jak/Stat3 pathways (the top signaling 
pathways differentially expressed) highlighted. (d) Heatmap of log2 expression of selected genes in Day 0, Day 15, 
Day 35 Tom-, Day 35 Tom+, week 21 AEC, and adult AEC2 populations. (e) List of all Hallmark Gene Set 
Enrichment Analysis (GSEA) pathways upregulated in Tom- cells vs. Tom+ cells (ranked by FDR, FDR≤0.05), with 
the Wnt/bCatenin signaling pathway (the top developmental signaling pathway differentially expressed) highlighted. 
 
By principal component analysis (PCA) of 30,000 transcripts in each sample, we 
found that PSC-derived cells after 35 days of differentiation clustered closer to primary 
cells on the PC1 axis (Figure 2.9B). In addition, on both PC1 and PC2 axes, fetal primary 
cells clustered closer to PSC-derived cells after cell culture in DCI media, whereas sorted 
adult AEC2 clustered separately from all other samples. In keeping with this finding, 
profiling of both the canonical marker, SFTPC (Figure 2.9C) as well as a selected set of 
22 markers of AEC2s, AEC1s, and early lung endoderm (Figure 2.9D), showed that 
expression patterns most closely resembled primary AECs in the sorted PSC-derived 
cells at day 35. To identify genes differentially expressed in Tom+ cells with 
differentiation, we compared the sorted day 35 Tom+ cells with their day 15 precursors 
(Figures 2.9E,F, G and 2.10C). Notably, we found the set of 50 most differentially 
expressed transcripts in day 35 Tom+ cells were highly enriched in AEC2-specific 
marker genes (ranked by absolute fold change and FDR<0.01; Figure 2.9F). Strikingly, 7 
out of the top 10 most differentially upregulated genes in Tom+ cells encoded proteins 
related to surfactants or lamellar body biogenesis (Figure 2.9E). Furthermore, comparing 
expression levels across all samples, these genes were expressed in PSC-derived Tom+ 
cells at levels similar to adult AEC2s (Figure 2.9E). Indeed, hierarchical clustering 
analysis of all samples based on the top 300 differentially expressed genes in the Tom+ 
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population indicated that these cells clustered closest to adult AEC2 (Figure 2.9G). 
Unexpectedly, Tom+ and Tom- cells displayed similar gene expression profiles by both 
PCA of all 30,000 transcripts and hierarchical clustering analyses of the top 300 genes 
upregulated from Day 15 to 35 in Tom+ cells (Figures 2.9B, G and 2.10B, D), and they 
expressed multiple AEC2 marker genes at levels similar to adult AEC2s with the 
exception of SFTPC, which was significantly upregulated in the Tom+ vs the Tom- 
population (Figure 2.9C and 2.10D). 
  We next focused on potential gene expression differences between the various 
samples. First, we looked at the transcriptomic differences between PSC-derived Tom+ 
cells and primary cells, expecting to see major differences in global gene expression in 
iAEC2s when compared to primary adult AEC2s due to the effects of accelerated 
development of iAEC2s outside of the alveolar niche in submerged sterile cultures vs the 
effects of life-long maturation of adult AEC2s in an air breathing, multilineage, non-
sterile environment. Not surprisingly GSEA analysis of Tom+ cells v. adult AEC2s 
revealed that the gene sets differentially expressed in adult AEC2s involved upregulation 
of immune pathways and oxidant stress (Figure 2.10A,C).  
Focusing next on the gene expression differences between day 15 and day 35 
Tom+ cells, GSEA revealed the JAK/STAT3/IL6 and TNFa/NFkB signaling pathways 
comprised the top 2 upregulated signaling pathways in the day 35 Tom+ population and 
were in the top 13 of all upregulated Hallmark pathways overall (Figure 2.10C). To 
determine whether iPSC-derived day 35 cells are capable of functional signaling through 
these canonical pathways, we stimulated PSC-derived alveolospheres with cytokines 
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known to activate each pathway in pulmonary epithelial cells (Quinton et al. 2007; 
Quinton et al. 2008; Traber et al. 2015): oncostatin M (OSM) for the JAK/STAT3 
pathway, and TNFa/IL1b for the TNFa/NFkB pathway. Exposure to OSM ligand resulted 
in significant and rapid activation of STAT3 signaling, indicated by increased 
phosphorylated STAT3 protein and downstream SOCS3 mRNA expression, whereas 
exposure to TNFa and IL1b activated NFkB signaling, as evidenced by a rapid decrease 
in IkB protein and an increase in the expression of NFkB-dependent cytokines, IL8 and 
GM-CSF (Figure 2.9H). Taken together, these results indicate that iAEC2s are capable of 
performing another important function of AEC2s: immune signaling in response to 
canonical ligands.  
Last we focused on the few and subtle gene expression differences between PSC-
derived day 35 Tom+ and Tom- cells (Figure 2.11A). Only 203 genes were differentially 
expressed between Tom+ and Tom- cells and of these only 30 were upregulated in the 
Tom+ population, including SFTPC (FDR<0.05; Figure 2.11A). The 173 genes 
downregulated in Tom+ compared to Tom- cells were enriched in transcripts encoding 
non-lung endodermal markers, such as hindgut marker, CDX2, stomach marker CHGA, 
and hepatic markers APOA2 and APOB2, implying that Tom+ sorting depleted the iAEC 
population of these alternative endodermal lineages. Because the global transcriptomic 
profiles of iPSC-derived Tom+ and Tom- cells were so similar when each population 
originated from sorted day 15 lung progenitors, we further considered the possibility that 
each population was largely composed of closely related distal alveolar epithelia. 
Consistent with this possibility, replating each population in pure form (sorted Tom+ 
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cells vs Tom- cells) gave rise to alveolospheres each composed of a mixture of Tom+ and 
Tom- cells, recreating the diversity of cells and implying a lineage relationship between 
the two populations. 
 
Figure 2.11. Temporal regulation of Wnt signaling promotes iAEC2 maturation and proliferation.  
		
93 
(a) Heatmap of top 10 upregulated and top 10 downregulated genes in Day 35 Tom+ vs Tom- populations (ranked by 
fold change, FDR≤ 0.05). (b) Heatmap of selected differentially expressed genes downregulated in Tom+ vs Tom- 
populations (FDR≤ 0.05) from the MSigDB v5.1 Hallmark Wnt/b-Catenin Signaling database. RT-qPCR of Day 15, 
Day 35 Tom- and Day 35 Tom+ samples, with fold change (2-ΔΔCt compared to day 0) ± S.D., n=3 biological replicates. 
(c) Schematic showing late CHIR withdrawal experiment. Representative flow cytometry analysis of Day 38 sort gates 
and Day 50 outgrowth of the BU3 NKX2-1GFP+/SFTPCtdTomato- population cultured with or without CHIR from Day 40-
50. Bars show mean ± S.D., n=3 biological replicates separate from the Day 38 sort stage. (d) RT-qPCR of Day 50 +/- 
CHIR populations and week 21 human fetal distal lung, with bars representing fold change (2-ΔΔCt compared to iPSCs) 
± S.D., n=3 biological replicates from differentiations separate from the Day 38 sort stage, *p ≤ 0.05, **p ≤ 0.01, ***p 
≤ 0.001 by unpaired, two-tailed Student’s t-test. (e) Schematic of CHIR addback experiment, representative images of 
live RUES2 alveolospheres (brightfield/tdTomato overlay;  -CHIR week 4-5 (Day 32-39), +/-CHIR addback week 5-6 
(Day 39-48). Bar graphs show percent SFTPCtdTomato+ and total cell number in Day 48 populations +/- CHIR 
withdrawal and +/- CHIR addback. Bars represent mean +/- SD of n=3 differentiations separate from the Day 32 
passaging stage, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 by unpaired, two-tailed Student’s t-test. (f) Schematic of putative 
effects of Wnt stimulation on lung epithelial differentiation.  
 
 
 
Figure 2.12. Transcript expression in whole alveolospheres after CHIR addback.  
(a) Schematic of CHIR addback protocol and representative RUES2 Day 48 flow cytometry. (b) RT-qPCR of alveolar 
transcripts in Day 48 alveolospheres differentiated using the protocol in Figure 2.12A compared to primary fetal 
alveolar epithelial control cells (week 21 gestation; “Wk 21”); bars represent mean fold change (2-ΔΔCt compared to 
iPSCs) ± S.D., n=3 biological replicates from differentiations separate from the Day 15 sort stage.  
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Temporal regulation of Wnt activity promotes iAEC2 maturation. 
Based on the significantly higher SFTPC expression in the otherwise similar 
Tom+ vs Tom- cells on day 35, we considered the possibility that Tom+ cells might 
represent a more mature state of iAEC2s compared to Tom- cells. GSEA analysis to 
screen for developmental pathways that might distinguish the two populations revealed 
that Wnt signaling was the top differentially expressed developmental pathway (Figure 
2.10E). Although both cell populations were cultured in the presence of CHIR, Wnt 
signaling was unexpectedly downregulated in Tom+ cells, compared to Tom- cells, with 
significantly decreased expression of LEF1 and NKD1 (Figure 2.11B), two Wnt targets 
most associated with canonical Wnt signaling levels in our PSC-lung model system based 
on our previous publication (McCauley et al. 2017). Hence, to test the hypothesis that 
decreased Wnt signaling regulates maturation of iAECs, we sorted the distalized NKX2-
1GFP+/SFTPCtdTomato- population on day 38 for further 3D culture in the presence of 
absence of continued Wnt stimulation with CHIR (Figure 2.11C). We found that 
withdrawal of CHIR for 10 days (days 40-50) resulted in markedly increased efficiency 
of differentiation into SFTPC+ progeny (68.7% +/- 2.8), with significant upregulation of 
SFTPC mRNA as well as other markers of AEC2 maturation, LAMP3 and SLC34A2 
(Figure 2.11C,D).  
Notably, following this period of CHIR withdrawal, we observed decreased 
proliferation and size of alveolospheres (data not shown) and hence repeated these 
experiments adding back CHIR following a 1-week period of withdrawal (Figure 2.11E).  
We found that subsequent re-exposure to CHIR resulted in maintained expression of the 
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SFTPCtdTomato reporter and increased proliferation, evident as increased cell numbers of 
the resulting SFTPCtdTomato+ cells (Figure 2.11E), findings consistent with the recently 
reported post-natal proliferative effects of Wnt activation in AEC2 in vivo in mouse 
models (Frank et al. 2016). Thus, alveolospheres (derived from sorted CD47hi/CD26lo on 
day 15; week 2) exposed to CK+DCI media from weeks 2-6 with CHIR withdrawn from 
week 4-5 and added back from week 5-6, displayed at least 40% SFTPCtdTomato+ cells and 
expressed high levels of alveolar transcripts SFTPC, SFTPB, ABCA3, and additional 
AEC2 maturation transcripts, SLC34A2 and LAMP3, with only LAMP3 being expressed 
at a lower level than primary (week 21) human fetal lung alveolar cell controls (Figures 
2.11E and 2.12). Taken together, these results suggest that though Wnt stimulation is 
required for distal lung epithelial differentiation from primordial NKX2-1+ progenitor 
cells, long-term sustained Wnt stimulation may prevent these distal cells from 
committing to a fully mature AEC2 phenotype, and temporal modulation of Wnt 
signaling promotes AEC2 maturation and self-renewal.   
Discussion 
Our results demonstrate the differentiation of phenotypically mature AEC2-like 
cells, referred to as iAEC2s, from human ESCs as well as from patient-specific iPSCs.  
Formed in 3D cultures via an NKX2-1+ endodermal lung progenitor intermediate, the 
resulting cells express distal lung alveolar epithelial mRNAs and proteins, as well as 
functional lamellar bodies that process, store, and secrete surfactant. Contrary to prior 
reports of the necessity of feeder cells for culturing primary adult AEC2s, we were able 
to derive and serially passage “epithelial-only” alveolospheres without using 
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mesenchymal feeders, differentiating populations of sorted NKX2-1+ primordial 
progenitors into alveolar cells. We found the emergence of SFTPC+ cells from NKX2-1+ 
precursors in culture occurred rapidly in the presence of Wnt stimulation via CHIR 
within 2-7 days (17-22 total differentiation days) and was augmented by the additional 
presence of stimulants of FGF signaling together with corticosteroids and cyclic AMP 
(“DCI media”), consistent with studies that have previously shown that: a) Wnt signaling 
rapidly promotes distal airway patterning and alveologenesis in vivo (Mucenski et al. 
2005; Shu et al. 2005; Frank et al. 2016) or in vitro (McCauley et al. 2017), b) KGF 
promotes distal epithelial outgrowth ex-vivo (Liu & Hogan 2002), and c) hormones, such 
as corticosteroids, promote AEC2 maturation (Gonzales et al. 2002; Ballard et al. 2010). 
We also found that the early-stage iPSC-derived NKX2-1+ cells represented the entire 
progenitor pool from which SFTPC+ cells are later derived, consistent with mouse 
developmental studies (Minoo 1999) and further validating our recently published human 
directed differentiation findings (Hawkins et al. 2017).  
Though we did observe lamellated inclusions in the cytoplasm of alveolospheres, 
lamellated inclusions that are not enriched in surfactant proteins or phospholipid can be 
mistakenly referred to as AEC2 lamellar bodies, and they have been known to occur in a 
variety of cell types that neither display an AEC2 phenotype nor package surfactant in 
culture, such as A549 cells (Mason & Williams 1980). Only phenotypically mature 
pulmonary AEC2s are known to have true lamellar bodies enriched in surfactant. Based 
on their functional capacity to process SFTPB protein to its 8kD isoform and produce 
DPPC surfactant phospholipid, we conclude that iAEC2s express true lamellar bodies and 
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represent a maturity level comparable to primary AEC2s post-week 24 of gestation, a 
benchmark that has not been demonstrated before in reports of in vitro alveolar directed 
differentiation. We found PSC-derived alveolospheres to be composed of a mixture of 
lung epithelial cells, likely of varying states of maturity. Despite the presence of a subset 
of relatively mature cells, the unsorted alveolospheres as well as their sorted SFTPC high 
or low components can be sequentially passaged and maintain proliferative capacity over 
weeks to months. Though we do not generally detect AEC1 markers within 3D 
alveolospheres, when SFTPCtdTomato+ iAEC2s are plated in 2D culture they 
downregulated SFTPC and upregulated the AEC1 markers PDPN and AGER, as has 
been shown in primary AEC2 culture. These capacities of self-renewal and differentiation 
are key features that have defined primary AEC2 in vivo as the progenitors of the distal 
lung and are required for the survival of air breathing mammals.  Future studies are 
needed, however, to understand both the signaling pathways and the developmental time-
windows involved in AEC2-to-AEC1 conversion in vivo and in vitro during directed 
differentiation.  
On a whole transcriptome level, iAEC2s clustered closer to cultured primary fetal 
AECs than to adult or fetal AEC2s. Although iAEC2s are more similar to adult AEC2 
when compared based on supervised hierarchical clustering using AEC2 specific gene 
sets, still these similarities should not be overstated. Not surprisingly there are many 
ways in which iAEC2s, differentiated in submerged culture over only 30-35 days in vitro 
are not identical to primary AEC2s exposed to a lifetime of air breathing in adults. 
Several of the gene sets enriched in primary adult AEC2s compared to iAEC2s appeared 
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to involve immune responses and oxidant stress pathways, and it is expected that these 
transcriptomic networks would be underrepresented in iAEC2s. However, we found 
iAECs treated with immune cytokines do respond by activating the IL6/JAK/STAT3 and 
TNF/NFkB pathways. Since AEC2s are known to be important immune modulators in 
vivo, it is important that iAEC2s allow for studies of immune function.  
Though we were surprised to find that SFTPCtdTomato+ and SFTPCtdTomato- cells 
cluster so closely together by PCA as well as supervised hierarchical clustering analyses, 
it is likely that these populations, both deriving from NKX2-1+ lung endoderm in 
distalizing conditions, represent very similar cells, some of which have progressed to 
express high levels of SFTPC and others which may remain “stuck” as less mature cell 
types expressing significantly lower levels of SFTPC, even though most other AEC2-
specific genes are expressed similarly in both populations. Though we did not see robust 
evidence of increased expression of AEC1 or proximal lung epithelial markers in the 
SFTPCtdTomato- cells, we did see expression of markers of the gut, liver, and stomach, 
suggesting that there are also some non-lung cells present in the SFTPC negative 
population. Since NKX2-1+/SFTPC- cells at a late timepoint in differentiation are still 
capable of maturation into SFTPC+ cells, there is likely still fluidity between SFTPC-
expressing and non-expressing states, and there may be a higher percent of lower SFTPC-
expressing AEC2-like cells in the NKX2-1+ population than the SFTPCtdTomato reporter 
indicates at any given time. 
Interestingly, GSEA analysis showed that the Wnt/bCatenin signaling pathway 
was downregulated in SFTPCtdTomato+ cells, and late CHIR withdrawal resulted in both a 
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dramatic increase in percent SFTPCtdTomato+ cells in the previously SFTPCtdTomato- 
population and an increase in expression of mature AEC2 transcripts within this 
population. This finding suggests that overstimulation with CHIR may actually inhibit 
full alveolar differentiation. We have previously shown that early CHIR withdrawal (Day 
15) results in proximalization of NKX2-1+ lung progenitors (McCauley et al., in press), 
and we now see that late withdrawal of CHIR, following distalization, promotes alveolar 
differentiation, consistent with the low-Wnt pre-alveologenesis stage of AEC2 
development recently reported in mice by Frank and colleagues (Frank et al. 2016). 
Furthermore, as predicted by these mouse studies, adding back Wnt stimulation following 
maturation stimulates proliferation of the resulting human iAEC2s. 
Overall, our work shows generation of phenotypically mature iPSC-derived 
alveolar organoids that represent a robust in vitro model of human alveolar development, 
providing a platform by which new insights can be made into the effects of genetic and 
environmental insults on AEC2 biology.  
 
COMPUTATIONAL ANALYSIS OF PSC-DERIVED AEC2S COMPARED TO 
PRIMARY ALVEOLAR CELLS  
 
Rationale 
 Since human alveolar cells are relatively inaccessible during neonatal 
development, mouse developmental models have informed much of our understanding of 
human alveolar development. We collected cell samples from various timepoints in 
human development, both in vitro and in vivo, enabling analysis of the transcriptomic 
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expression patterns that distinguish different stages of alveolar development so that we 
can better determine where iAEC2s fall in the developmental continuum.  
Primary AEC2 ex vivo culture has proven challenging for decades because 
AEC2s do not maintain their phenotype over long periods of time in culture. Because we 
have found that iAEC2s can maintain their phenotype for several passages in CK+DCI 
media, we thought it was important to evaluate the ability of primary AEC2s to maintain 
AEC2 phenotype in these conditions as well. We cultured week 21 AEC2s in either DCI 
media, as described in previous studies (Gonzales et al. 2002; Ballard et al. 2010) or 
CK+DCI media and evaluated AEC2 gene expression in both conditions.  
Finally, we used several variations of the alveolosphere protocol over time, either 
sorting CD47hi cells to enrich for NKX2-1+ progenitors at Day 15 or not; and either 
passaging alveolospheres in dispase to prevent them from becoming too confluent on Day 
30 or not. We also wanted to ask whether these changes in differentiation technique, 
without altering the growth factors or culture conditions, could cause important changes 
in gene expression.  
Methods 
All samples were collected as described in Chapter 2. “Early” samples represent 
distal cells from one week 16 gestation lung and 2 separate week 17.5 lungs obtained 
from Dr. Susan Guttentag’s lab under protocols approved by the Institutional Review 
Board of CHOP at the University of Pennslyvania and subsequently reviewed by 
Vanderbilt University. “Late (Week 21 gestation)” samples correspond to the week 21 
samples from Chapter 2, and “Day 15 (RUES2 CD47+),” “Adult (Primary AEC2),” and 
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“DCI (Week 21 gestation cultured in DCI for 4 days)” samples are the same as listed in 
Chapter 2. “CK+DCI” samples represent week 21 cells cultured using an identical 
protocol to that for the DCI samples, except for that they were cultured for 4 days in 
CK+DCI media. “+D15 sort +Pass” samples are the same as “Day 35 Tom+” samples in 
Chapter 2. “-D15 sort +Pass” samples were differentiated identically to “+D15 sort +Pass 
cells except for that at Day 15, rather than being sorted for CD47hi expression, they were 
simply replated after trypsinization, as described in Chapter 2. “-D15 sort -Pass” samples 
were differentiated identically to “-D15 sort +Pass cells except for that at Day 30, they 
were not passaged. Passaging, in this case, involves leaving alveolospheres in 2mg/ml 
dispase for 30 minutes-1 hour, mechanically pipetting to release alveolospheres, allowing 
them to settle for 5 minutes, washing twice with DMEM/F12, and resuspending in 2-3 
times as much Matrigel as was originally used. Matrigel is then allowed to settle at 37C, 
and CK+DCI media is added after 20-30 minutes.  
RNA-Sequencing was performed as described in Chapter 2. All scatter plot 
graphs represent log2 expression transformed as described in Chapter 2. All GSEA 
pathway analysis represents all pathways up- or downregulated in each pairwise 
comparison with an FDR < 0.05.  
Results 	
A transcriptional timecourse of AEC2 development 	
		
102 
	
Figure 3.1. PCA plot of all RNA Sequencing Samples.  
3 small dots represent biological triplicates and 1 larger dot represents the average of the triplicates.  
 Principal component analysis of all sequenced samples shows that triplicate 
samples cluster relatively close to each other, and that the differentiation stage, whether 
in vivo or in vitro, strongly influences gene expression (Figure 3.1). Focusing specifically 
on the following samples, we can view this RNA Seq data as an opportunity to analyze a 
timecourse of human alveolar development: (1) Day 15 CD47hi RUES2 cells represent 
primordial lung progenitors; (2) Samples from 3 separate lungs at gestational age week 
16-17.5 represent “early” distal lung progenitors; (3) Separate samples from 1 lung 
represent “late” distal lung progenitors; and (4) Samples from 3 separate adult lungs 
represent a pure population of HT2-280 sorted adult AEC2s (Figure 3.2).  
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Figure 3.2. PCA with arrows showing timecourse of AEC2 development.  
As expected, expression of mature AEC2 markers increases with age (Figure 3.3), 
albeit with different kinetics. For example, SFTPB , SLC34A2, and NAPSA increase the 
most from the primordial progenitor stage to the early fetal lung stage, SFTPC and 
LAMP3 increase steadily but plateau at week 21, and SFTPA1, SFTPA2, PGC, and 
CTSH remain low and are increased between the week 21 and adult stages (Figure 3.3). 
When we look at expression of earlier markers of proximodistal patterning (SOX2 
proximal and SOX9 distal) or early distal lung bud markers (ETV4, ETV5, BMP4), there 
is a decrease in SOX2 in the primordium-to-early distal lung transition, and a decrease in 
SOX9 in the late distal lung-to-adult lung transition. ETV4, ETV5, and BMP4 all peak 
during fetal development and decrease in the adult cells. Interestingly, the samples vary 
considerably in their WNT-responsiveness, with Day 15 being high in WNT 
responsiveness (likely because of culture in CHIR), with a dip in responsiveness in early 
In vivo 
“differentiation”
Day 0
Wk 16-18
Wk 21
DCIAdult
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distal lung that goes back up in late distal lung and becomes low again in adult AEC2s 
(Figure 3.4).  
 
 
Figure 3.3. Expression of mature AEC2 markers throughout development.  
“Week 15” refers to CD47hi  sorted cells from Day 15 of a RUES2 differentiation. “Early” refers to week 16-17.5 
gestation distal lung, “Late” refers to week 21 distal lung. “Adult” refers to adule HT2-280 sorted AEC2s. Values 
represent log2 normalized mRNA expression.  
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Figure 3.4. Expression of early lung markers throughout development.  
“Week 15” refers to CD47hi  sorted cells from Day 15 of a RUES2 differentiation. “Early” refers to week 16-17.5 
gestation distal lung, “Late” refers to week 21 distal lung. “Adult” refers to adule HT2-280 sorted AEC2s. Values 
represent log2 normalized mRNA expression.  
 
 To determine which pathways were changed over the course of AEC2 
differentiation, we next performed GSEA analysis on “Early” v “Day 15,” “Late” v 
“Early,” and “Adult” v “Late” populations. We found that inflammatory pathways 
including the interferon alpha and gamma pathways seems to be upregulated with 
differentiation and that Myc and E2F targets as well as the unfolded protein response 
pathways were downregulated with differentiation. Between the “late” and “adult” 
groups, the WNT, TGFb, and SHH signaling pathways were downregulated (Appendix 
A), suggesting that these pathways play a more significant role in alveolar development 
than in adult alveolar homeostasis.  
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CK+DCI media maintains AEC2 transcriptional program in vitro 
 In the previous chapter we show that iAEC2s can maintain AEC2 phenotype for 
several passages in CK+DCI media. For the RNA-Sequencing analysis, we also cultured 
week 21 distal lung cells for 4 days in either DCI media, the usual method of culture, or 
CK+DCI media, to determine the extent to which either media promoted AEC2 gene 
expression maintenance or maturation. Strangely, though we would expect to see an 
increase in WNT responsiveness as measured by expression of AXIN2, LEF1, and NKD1 
in cells culture with CHIR, and we did see an increase in AXIN2 in CK+DCI cells, there 
was no increase in expression of LEF1 or NKD1 (Figure 3.5). SOX2 expression was low 
in both culture conditions, SOX9 expression was lower, and ETV4 and 5 expression was 
higher in CK+DCI cultured cells when compared to DCI cultured cells.  Expression of 
3/4 AEC1 genes was higher in DCI conditions than CK+DCI conditions, possibly 
suggesting different propensity to transdifferentiate or to upregulate different AEC1 
transcripts (Figure 3.5). Expression of all AEC2 genes analyzed was higher in CK+DCI 
conditions than in DCI conditions, though expression of IL-8 was notably low in both 
cultured cell samples (Figure 3.6).  
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Figure 3.5. Expression of Wnt responsive genes, early lung markers, and AEC1 markers in Primary and 
Cultured Cells.  
“Late” refers to week 21 distal lung samples, “DCI refers to these samples cultured for 4 days in DCI media, and 
“CKDCI” refers to these samples cultured in CK+DCI media for 4 days. Values represent log2 normalized mRNA 
expression.  
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Figure 3.6. Expression of mature AEC2 markers in Primary and Cultured Cells.  
“Late” refers to week 21 distal lung samples, “DCI refers to these samples cultured for 4 days in DCI media, and 
“CKDCI” refers to these samples cultured in CK+DCI media for 4 days. Values represent log2 normalized mRNA 
expression.  
 
 When we performed GSEA on the “Late,” “DCI,” and “CKDCI” groups, 
pathways upregulated in both DCI and CK+DCI conditions included cholesterol 
homeostasis, adipogensis, glycolysis, and protein secretion, possibly pointing to 
maturation of the surfactant pathway. We also found downregulation of inflammatory 
signaling pathways possibly reflecting adaptations to cell culture away from immune 
Lat
e
DC
I
CK
DC
I
10
12
14
16
18
log
2 
Ex
pr
es
sio
n
SFTPA1
Lat
e
DC
I
CK
DC
I
6
8
10
12
14
16
log
2 
Ex
pr
es
sio
n
SFTPA2
Lat
e
DC
I
CK
DC
I
18
19
20
21
22
23
log
2 
Ex
pr
es
sio
n
SFTPB
Lat
e
DC
I
CK
DC
I
10
12
14
16
18
20
log
2 
Ex
pr
es
sio
n
SFTPC
Lat
e
DC
I
CK
DC
I
10
11
12
13
14
15
log
2 
Ex
pr
es
sio
n
SFTPD
Lat
e
DC
I
CK
DC
I
10
12
14
16
log
2 
Ex
pr
es
sio
n
LAMP3
Lat
e
DC
I
CK
DC
I
14
16
18
20
log
2 
Ex
pr
es
sio
n
SLC34A2
Lat
e
DC
I
CK
DC
I
10
12
14
16
18
20
log
2 
Ex
pr
es
sio
n
IL-8
Lat
e
DC
I
CK
DC
I
13
14
15
16
17
18
19
log
2 
Ex
pr
es
sio
n
ABCA3
Lat
e
DC
I
CK
DC
I
10
12
14
16
18
20
log
2 
Ex
pr
es
sio
n
PGC
Lat
e
DC
I
CK
DC
I
13
14
15
16
17
18
log
2 
Ex
pr
es
sio
n
NAPSA
Lat
e
DC
I
CK
DC
I
13
14
15
16
17
18
log
2 
Ex
pr
es
sio
n
CTSH
		
109 
signals from non-epithelial cells. Several signaling pathways were decreased in 
expression in CK+DCI conditions compared to DCI, including TGFb, SHH, and Notch 
signaling, as well as, very surprisingly, WNT signaling. Epithelial-to-mesenchymal 
transition pathways were also lower, possibly pointing to the reason why CK+DCI cells 
better maintained their AEC2 epithelial gene expression (Appendix B).  
Transcriptional effects of passaging alveolospheres 
 While optimizing the AEC2 differentiation protocol, we had observed that 
passaging alveolospheres increased expression of the SFTPCtdTomato reporter as well as 
AEC2 gene expression within the SFTPCtdTomato+ cells (Figure 3.7).  
 
Figure 3.7. Effects of Passaging on SFTPC reporter and AEC2 transcript expression 
Left shows expression of SFTPCtdTomato reporter in Day 35 alveolospheres with or without passage at Day 30. Right 
shows expression of various AEC2 trasncripts in Day 0, Day 35 SFTPCtdTomato+ cells from alveolospheres passaged on 
Day 30, Day 35 SFTPCtdTomato+ cells from alveolospheres that were not passaged, and week 21 distal lung as a primary 
control.  
 
 In the RNA Sequencing analysis, there were three groups of SFTPCtdTomato+ cells 
that were cultured using three different methods before sorting: 1) “-D15 sort -Pass” cells 
that were neither sorted at Day 15 nor passaged at Day 30, 2) “-D15 sort  +Pass” cells 
that were not sorted at Day 15 but were passaged at Day 30, and 3) “+D15 sort  +Pass” 
cells that were sorted CD47hi/CD26lo on Day 15 and passaged on Day 30. These groups 
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come from separate differentiations and Day 35 sorts making direct comparisons 
difficult. This may explain why contrary to the above results from cells differentiated 
simultaneously, in these separate runs, it seems that the –D15 sort  –Pass cells express 
higher levels of AEC2 transcripts in general than the other groups, though SFTPC 
expression is lower. SFTPA1, SFTPA2, and NAPSA seem to be expressed at higher 
levels in both Day 15 unsorted groups compared to the Day 15 sorted Day 30 passaged 
group. Expression of distal bud genes SOX9, ETV4, and ETV5 are also highest in the –
D15 sort  –Pass group (Figure 3.8).  
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Figure 3.8. Effects of Day 15 Sorting and Day 30 Passaging on AEC2 transcript expression 
Log2 transformed mRNA expression of various AEC2 trasncripts in SFTPCtdTomato+ cells from alveolospheres passaged 
on Day 30 (-D15 sort  +Pass), sorted for CD47hi cells on Day 15 and passaged on Day 30 (+D15 sort  +Pass), neither 
sorted on Day 15 nor passaged on Day 30 (-D15 sort  –Pass). These three samples are from three different 
differentiations.   
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By GSEA, Day 15 sorted and/or Day 30 passaged cells were lower in expression 
of several inflammatory pathways as well as hypoxia and glycolysis pathways than cells 
that had been through neither protocol (Appendix C). Though it is difficult to determine 
exactly what differences might be due to manipulations to the protocol and which are due 
to run-to-run variability, these findings may suggest that putting the cells through fewer 
passaging events improves expression of some AEC2 markers (with the exception of 
SFTPC), possibly because they are less stressed throughout differentiation.  
Discussion 
 Analyzing the whole transcriptomes of these primary and in vitro-derived cell 
populations gives us important insights into the gene expression patterns that characterize 
particular developmental stages. It is interesting to see that SOX2, a marker of the early 
proximal lung, expression decreases prior to week 16, while SOX9, ETV4, and ETV5, 
markers of the early distal lung, continue to decrease in expression after week 21. The 
WNT responsive genes AXIN2, LEF1, and NKD1 seem to oscillate in expression, with 
lower expression in the week 16-17.5 samples, higher in the week 21 samples, and lower 
again in the adult samples. All of the known AEC2 genes analyzed increased in 
expression over developmental time, but SFTPA1, SFTPA2, PGC, and CTSH spiked 
between week 21-adult, suggesting that they are markers of more mature AEC2s. There 
is an overall increase in inflammatory GSEA hallmark pathways with increasing age, as 
well as a decrease in unfolded protein response (UPR), which suggests that early AEC2s 
may be more biosynthetically active and prone to UPR activation. Between week 21 and 
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adult lung, there is also a decrease in TGFb, WNT, and SHH signaling perhaps pointing 
to the pathways downregulated after development that could be reactivated upon injury.  
Though this data does allow us to make interesting observations about temporal gene 
expression during in-vivo differentiation, a timecourse with more timepoints to analyze 
would be ideal to truly evaluate trends in gene expression.  
 Overall, the increased expression of AEC2 surfactant-related genes and generally 
low expression of AEC1 markers suggests that CK+DCI media would be able to maintain 
AEC2 phenotype better than DCI media alone, and indeed may even be able to mature 
AEC2s in vitro based on higher expression of SFTPA1, SFTPA2, SFTPB, SFTPD, 
SLC34A2, ABCA3, and the surfactant processing enzymes PGC, NAPSA, and CTSH. 
GSEA analysis reveals a decrease in inflammatory pathways and an increase in fatty acid 
synthesis related pathways with culture in either DCI or CK+DCI. Interestingly, there is a 
decrease in the EMT pathway as well as the TGFb, WNT, SHH, and Notch pathways in 
CK+DCI compared to DCI, suggesting that these signaling pathways may suppress 
AEC2 maturation or promote differentiation into other lineages. The decrease in Tgfb 
pathway expression may be related to the decrease in EMT, since Tgfb is known to cause 
EMT in vitro (J. Xu et al. 2009). The decrease in WNT signaling in the presence of CHIR 
is surprising and could represent very high levels or spontaneous WNT signaling in the 
DCI cultured cells or a cellular response to overactive WNT that involves decreasing 
WNT response pathways in the CK+DCI cultured cells. These studies may be worth 
repeating with more ultrastructural and protein-level analysis, and perhaps in a 3D culture 
model as well. Since this sequencing was performed on cells that were only in culture for 
		
114 
4 days, it would be important to evaluate whether primary AEC2s in CK+DCI media 
could be maintained for longer periods of time in culture or even passaged. Finally, it 
would be interesting to see whether adult AEC2s perform better in CK+DCI media as 
well.  
 Though the effect of differences in differentiation methods in gene expression in 
SFTPCtdTomato+ cells is likely an important factor to study, the results from this RNA-
Sequencing showing decreased expression of many AEC2 genes contrasts with qPCR 
data from cells differentiated at the same time + or – Passaging. Though it is possible that 
the CD47lo cells express a signal that improves maturity within the SFTPCtdTomato+ 
population, another experiment would need to be done comparing cells sorted on Day 15 
or unsorted on Day 15 in gene expression from the same differentiation. Day 15 sorting 
and continuous passaging when alveolospheres reach confluence clearly increases the 
consistency and efficiency of the protocol, but only as long as the resulting cells are 
similar in expression of AEC2 markers and phenotype. This is an important point to 
consider when adopting new changes in the protocol, like CHIR oscillation, as described 
in Chapter 2. We should likely repeat some of the characterization studies done in 
Chapter 2 on alveolospheres from the most recent protocol.  	
MODELING ALVEOLAR DISEASE WITH PSC-DERIVED AEC2S  	
Rationale 	
 Though we have shown previously that alveolospheres are phenotypically similar 
to primary AEC2s, their utility depends in some ways on our ability to use them to model 
human disease. Children’s interstitial lung disease is caused by genetic mutations and can 
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lead to neonatal respiratory distress or early onset pulmonary fibrosis. SFTPB and 
SFTPC mutations in particular would ideally be studied in primary patient-derived 
AEC2s, but access to patient samples is complicated by several factors. 1) These are rare 
diseases and very few patients would be available for research; 2) Access to AEC2s in a 
patient involves a lung biopsy, a highly invasive procedure unlikely to be repeated 
multiple times; 3) By the time a lung biopsy is taken, several other disease processes like 
inflammation, infection, ventilator induced injury and fibrosis have set in, complicating 
study of the initial AEC2 insult vs the subsequent insults; 4) Ex vivo, there have been no 
reports of long term AEC2 culture from lung disease patients, so studies have to be 
performed over short periods of time; and 5) primary cells have a low proliferative 
capacity and are therefore less likely to be amenable to gene-editing.  
 Patient iPSC-derived alveolospheres could address several of these issues if we 
can prove that they at least recapitulate the known aspects of alveolar disease pathology. 
In addition, they can provide an opportunity to determine whether diseases believed to be 
monogenic are truly monogenic- if the known mutation is corrected with the rest of the 
patient’s genetic background kept constant and the cells are still dysfunctional, there may 
be an underlying additional genetic factor involved. In this chapter, we generate iPSCs 
from a patient with an SFTPB mutation known to cause children’s interstitial lung 
disease (chILD). We correct the mutation using CRISPR-Cas9 technology and 
differentiate the pre- and post-corrected iPSCs into alveolospheres. Pre-corrected iPSC-
derived alveolospheres recapitulate key pathological features of SFTPB deficiency, while 
post-correction, these alveolospheres display reconstitution of surfactant processing. We 
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also show that iPSC-derived alveolospheres from a patient with the SFTPCI73T mutation 
show accumulation of misprocessed isoforms of proSFTPC similar to those seen in a 
mouse model of the same mutation. This human model system thus is likely to facilitate 
disease modeling, developmental studies, drug screening, and future regenerative gene or 
cell therapies for a variety of adult and childhood lung diseases affecting lung alveoli.  
Methods 	
ESC/iPSC Line Generation and Maintenance 
The iPSC line SP212 was derived by reprogramming dermal fibroblasts (see 
below) of a patient with respiratory distress syndrome resulting from documented 
homozygous 121ins2 mutations (c.397delinsGAA (p.P133Efs*95), hg19) in the 
surfactant protein B (SFTPB) locus. The Institutional Review Board of Washington 
University, St. Louis, MO, approved procurement of fibroblasts with documented 
informed consent. The iPSC line SPC1 and SPC2 were derived by reprogramming 
dermal fibroblasts of a patient with a documented G182R mutation in the SFTPC locus 
and a documented I73T mutation in the SFTPC locus, respectively.  
Reprogramming to generate SFTPB 121ins2 iPSCs 
Reprogramming of patient-specific dermal fibroblasts (Figures 4.1 and 4.2) was 
performed with a single-integrated excisable copy of the floxed hSTEMCCA lentiviral 
reprogramming vector (Somers et al. 2010) followed by excision with transient Cre 
recombinase-exposure. Ten iPSC colonies were mechanically isolated 30 days after 
lentiviral transduction and expanded on MEF feeders in human “iPSC media” (Somers et 
al., 2010), composed of DMEM/F12 (Sigma-Aldrich) with 20% KnockOut Serum 
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Replacement (Invitrogen), 1mM nonanimal L-glutamine (Sigma-Aldrich), 0.1mM Β-
mercaptoethanol, and 10 ng/ml FGF2 (R&D Systems) on 0.1% gelatin (Sigma-Aldrich) 
coated plates preseeded with mitomycin C-inactivated or irradiated mouse embryonic 
fibroblast (MEF) feeder cells. Integrated hSTEMCCA copy number was assessed by 
Southern blot of BamHI-digested gDNA extracts probed for the lentiviral WPRE cassette 
(Somers et al. 2010), and only iPSC clones with single copy hSTEMCCA integrations 
were selected for vector excision and further study. The single copy hSTEMCCA 
lentiviral cassette was removed from two iPSC clones (SP212-1 and SP212-5) via 
transient transfection of pHAGE2-Cre-IRES-PuroR plasmid DNA (Somers et al. 2010; 
Addgene #30205) using Hela Monster transfection reagent (Mirus, Madison, WI, 
www.mirusbio.com) according to the manufacturer’s instructions (Somers et al. 2010). 
Approximately 11-14 days later, colonies were picked and gDNA from each subclone 
was screened for vector excision by PCR using the following primers and conditions: 
cMYC F5’-GGA ACT CTT GTG CGT AAG TCG ATA G-3’; WPRE R5’-GGA GGC 
GGC CCA AAG GGA GAT CCG-3’; 95° C for 3 minutes; followed by 33 cycles of 
94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute; followed by a single 
cycle of 72°C for 5 minutes. Vector excision was then confirmed by Southern blot using 
BamHI digested gDNA probed for the WPRE element (Somers et al. 2010) to identify 
two iPSC lines (each generated from the two separately picked clones (renamed SP212-1-
Cr3 and SP212-5-Cr3 to reflect successful vector excision; Figure 4.2).  
CRISPR-based gene correction of SFTPB 121ins2 mutation 
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We used CRISPR/Cas9 technology to target the region adjacent to the 121ins2 
mutation (also known as c.397delinsGAA (p.P133Efs*95), hg19) in the human SFTPB 
gene locus (4.2) with a guide RNA (specifically recognizing the 121ins2 mutation but not 
wild-type) that had the following sequence: 5’ TTG ACG ACT ACT TCG AAC CCT 
GG 3’. gRNA sequences were commercially cloned into the pD1321-AD plasmid 
backbone (DNA 2.0 ATUM) that contains a M-dasher-GFP sequence fused to Cas9. 
Delivery of this plasmid to iPSCs enabled co-expression of Cas9, gRNA, and a GFP 
reporter. To accomplish footprint-free correction of the SFTPB mutation, a short single 
stranded DNA oligo (sequence 5’-GAA GCT GCT CAT GCC CCA GTG CAA CCA 
AGT GCT TGA CGA CTA CTT CCC CCT GGT CAT CGA CTA CTT CCA GAA 
CCA GAT TGT GAG GCT G-3’) was used as a donor template containing the wild type 
SFTPB sequence. SP212 cells maintained in feeder-free conditions in mTeSR1 media 
were treated with 10µM Y-27632 (Tocris) for 3 hours, dissociated in Gentle Cell 
Dissociation Reagent (GCDR, StemCell Technologies) for 10 minutes at 37°C and 
counted using a Luna-II Automated Cell counter (Logos Biosystems, Annandale, VA). 
Approximately 5x106 cells were centrifuged at 200g x 5 minutes, resuspended in a 
mixture containing P3 solution and supplement (Lonza, Basel, Switzerland) as well as 
5ug CRISPR/Cas9 plasmid and 5ug oligo donor, and nucleofected using program code 
CB-150 in the 4-D nucleofector system (Lonza). Nulceofected cells were replated on 2 
wells of a matrigel-coated 6 well plate in mTeSR1 media, and 10uM Y-27632 was added 
for 24 hours.  After 48 hours, cells were prepared for sorting. They were treated with 
10uM Y-27632 for 3 hours, dissociated into single cell suspension with GCDR for 10-15 
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minutes at 37°C, centrifuged at 200g x 5 minutes, resuspended in mTeSR1 media + 
10uM Y-27632, and filtered through a 30 uM filter (Falcon). GFP+ cells were sorted into 
recovery media (1 part mTeSR1 and 1 part conditioned mTeSR1 supplemented with 
0.7ng/ml FGF2, plus 10uM Y-27632) using a high-speed cell sorter (MoFlo Legacy, 
Beckman Coulter, Brea, CA). 1x104 cells GFP+ sorted cells were plated into a 10cm 
tissue culture treated dish pre-coated with growth factor-reduced matrigel. Recovery 
media was changed every other day for the first 5 days, with 10uM Y-27632 added for 
the first 24 hours. After 5 days, mTeSR1 was used to feed the cells, and after 10 days, 
colonies that emerged were of sufficient size for picking for clonal expansion and 
screening. Individual colonies were picked and screened for correction using the 
following primers: ACT CCT TGG CAC TCG TGA AC, GGG TGC TGT GTG TTT 
GTG TC. In pre-correction SP212, there is a BstB1 restriction site created by the 121ins2 
mutation, and after enzyme digestion, 2 bands at 230bp and 191bp appear. Post-
correction, the BstB1 site disappears, and only the uncut 430bp band is seen on a gel. 
After PCR screening, colonies with the uncut band were further analyzed for correction, 
which was confirmed by DNA sequencing, resulting in the SP212Corr line.  
TALENs targeting of RUES2 and SPC1 with SFTPC/GFP fusion plasmids 
 TALENs targeting was performed as described above, with donor vectors that had 
the tdTomato cassette replaced by wt SFTPC/GFP, delta exon 4 SFTPC/GFP, I73T 
SFTPC/GFP, or G182R SFTPC/GFP. Endogenous SFTPC allele and puromycin cassette 
excision screening was performed using the same primers as listed in Chapter 2. 
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Targeting was verifying using the following primers: 5’-AAC TTG TGG CCG TTT ACG 
TCG-3’ and 5’-GGG TGA GTG AGC TGA TTC GAG-3’.  
 
Differentiation and Analysis of Alveolospheres 
 Differentiation, immunostaining, RT-qPCR, and ultrastructural analysis was 
performed as described in Chapter 2, with the addition of NPRO-SFTPC (dilution 
1:3,000, Beers et al. 1994), b-actin (dilution 1:10,000, Sigma) antibodies used for 
Western.  
Results 	
Modeling SFTPB deficiency with iPSCs 
We sought to derive iAEC2 from disease-specific iPSCs made from a child 
carrying homozygous SFTPB mutations (121ins2), a monogenic cause of neonatal 
respiratory distress that requires lung transplantation for survival (Figure 4.2A). Based on 
prior work, SFTPB mutations do not perturb SFTPB locus transcription, but the unstable 
mutant mRNA in patients is only detectable at 8% of normal levels and carries a 
premature stop codon with consequent loss of detectable SFTPB protein, inability to form 
lamellar bodies, misprocessing of SFTPC protein, failure to synthesize or secrete 
surfactant, and, ultimately, neonatal respiratory distress (Nogee et al. 1994);(Beers et al. 
2000). To date it has not been possible to correct the mutation in primary AEC2s from 
patients to definitively prove that all changes result intrinsically in human AEC2s as the 
direct consequence of the mutation rather than from additional or downstream secondary 
effects from diseased bystander cells within the lung. To develop a novel in vitro model 
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of this disease, based on patient-specific cells, we reprogrammed dermal fibroblasts from 
a patient homozygous for the 121ins2 SFTPB mutation employing a single integrated 
copy of our previously published Cre-excisable STEMCCA-loxP lentiviral vector 
(Somers et al. 2010) (Figure 4.1A). Following excision of the STEMCCA cassette, the 
resulting “transgene-free” iPSC line (SP212) underwent footprint-free correction by gene 
editing both mutant SFTPB alleles using CRISPR/Cas9 technology together with a short 
oligo donor to replace the mutant 2bp insertion in exon 4, resulting in a corrected line 
with two normal SFTPB alleles (hereafter SP212Corr) (Figures 4.2B and 4.1B-E). We 
differentiated both lines via CD47hi/CD26lo sorted progenitors into alveolospheres 
expressing similar levels of SFTPC mRNA (Figure 4.2C) in order to perform head-to-
head comparisons of the pre- vs post-gene corrected cells (SP212 vs SP212Corr).  We 
observed that SP212 alveolospheres expressed lower levels of SFTPB transcript than 
SP212Corr alveolospheres (Figure 4.2C), no detectable SFTPB protein, and no detectable 
lamellar bodies by TEM (Figures 4.2D-F). Notably, in 2/3 differentiations, we observed 
the appearance of an aberrant, misprocessed 6-10 kD proSFTPC protein form in SP212 
alveolospheres, a form resulting from the residual N terminal flanking dodecapeptide that 
cannot be cleaved from proSFTPC in the absence of lamellar bodies (Figure 4.2F).  In 
SP212Corr alveolospheres, correction of the SFTPB mutation resulted in increased 
SFTPB mRNA, the appearance of detectable lamellar bodies, reconstitution of the mature 
8kD form of SFTPB protein, and disappearance of the aberrant proSFTPC protein form, 
verifying that all deficiencies were the direct result of the SFTPB121ins2 mutation 
(Figures 4.2C-F).  
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Figure 4.1. Reprogramming of dermal fibroblasts to generate patient-specific iPSCs carrying homozygous 
121ins2 SFTPB mutations.  
(a) Left panel shows reprogramming approach to generate iPSCs free of any residual exogenous reprogramming 
factors. Schematic indicates approach for reprogramming the subject’s dermal fibroblasts using the hSTEMCCA-loxP 
lentiviral vector, encoding the 4 human factors, OCT4, KLF4, SOX2, and cMYC, with methods previously detailed 
(Somers et al., 2010). Right panel shows table with patient clinical information. (b, c, and d) Southern blotting of 
BamH1-digested gDNA from each iPSC clone was used to quantify the number of copies of integrated reprogramming 
vector per clone, detected as a single integrated STEMMCA copy visualized with a probe against the WPRE lentiviral 
element. This single floxed-STEMCCA copy was then excised by transient exposure to Cre recombinase with 
validation by both PCR (b) and Southern blotting (d) of gDNA. Ethidium bromide stained Southern blot indicates 
similar loading and BamH1 digestion of all clones. Red font indicates each subclone after transient Cre exposure. 
Normal karyotype (c) was confirmed by G-banding analysis, and this analysis was repeated, confirming normal 
karyotype after correction of the 121ins2 mutation (SP212Corr). (e) Immunostaining characterization of stem cell 
marker expression was performed for each clone with expected positive staining for SSEA4, TRA1/81, and TRA1/60. 
SSEA1 staining (expected to be negative in human stem cells) was included as a negative control stain. 
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Figure 4.2. iPSC-derived AEC2s enable in vitro modeling of genetic alveolar disease.  
(a) Chest radiograph of child from which iPSCs were generated, showing diffuse pulmonary infiltrates. Schematic 
showing the process of correcting both alleles carrying the homozygous 121ins2 SFTPB mutations in iPSCs derived 
from dermal fibroblasts, resulting in pre-correction (SP212) and post-correction (SP212Corr) iPSC lines. (b) SFTPB 
exon4 genomic sequence, with 121ins2 C -> GAA mutation in red, CRISPR guide RNA target sequence in green, PAM 
cutting site in blue, oligo-based donor design with corrected base in red. Pre- and post- correction DNA sequencing 
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chromatograms with yellow boxes showing 121ins2 mutation site sequence. (c) RT-qPCR of Day 35 SP212 and 
SP212Corr alveolospheres, with bars representing fold change (2-ΔΔCt compared to day 0 iPSCs) ± S.D., n=3 biological 
replicates differentiated separately from the day 0 stage, **p ≤ 0.01 by unpaired, two-tailed Student’s t-test. (d) Top 
panel shows a western blot for mature SFTPB (immunoblotted with PT3 antibody) on SP212 and SP212Corr 
alveolospheres (n=3), as well as RUES2 alveolospheres cultured separately from Day 15, 6 Day DCI cultured week 21 
human fetal distal lung (HFL DCI-D6), and lung samples from a different patient with the same SFTPB121ins2 mutation. 
Bands showing mature 8kD SFTPB are present only in normal week 21 controls, RUES2 alveolospheres, and 
SP212Corr alveolospheres (closed arrowhead). Bottom panel shows western blots for mature SFTPB (PT3) and 
proSFTPC (NPRO-SFTPC) in 2 different alveolosphere samples of SP212, and 1 sample of SP212Corr, all 
differentiated separately from the day 0 stage, with ~6-10kD abnormal/misprocessed proSFTPC band (closed 
arrowhead) present only in the SP212 samples, and 8kD mature SFTPB (open arrowhead) present only in the cultured 
week 21 and SP212Corr samples. (e) Representative immunofluorescence microscopy of proSFTPB (magenta), NKX2-
1 (green) in SP212 and SP212Corr alveolospheres. Nuclei were stained with Hoechst dye; scale bars represent 50µm. 
(f) Representative TEM images of SP212 and SP212Corr alveolospheres; scale bars represent 500nm. 
 
121ins2 SFTPB deficiency patient history. 
 
Female infant twin B was born at 35 weeks gestation (birth weight 2173g, 10-50th 
percentile) via cesarean section due to non-reassuring antenatal surveillance of male twin 
A.  Pregnancy was notable for diamniotic/dichorionic twin gestation and chronic 
hypertension for which mother received methyldopa.  Apgars were 8 at 9 and 1 and 5 
minutes of life, respectively.  The infant developed respiratory distress and cyanosis 
within minutes of birth and required intubation, mechanical ventilation, and surfactant 
replacement therapy.  Her respiratory status stabilized and she was extubated on day of 
life 4 to continuous positive airway pressure.  However, she developed progressive 
respiratory failure prompting reintubation, additional surfactant replacement therapy, 
high frequency oscillatory ventilation with FiO2 1.0 and nitric oxide to maintain adequate 
arterial saturations. She was also treated with glucocorticoids (methylprednisolone, 
hydrocortisone) and diuretics (aldactazide and furosemide).  Lung biopsy at 1 month of 
age demonstrated interstitial pneumonitis and type II pneumocyte hyperplasia.  Genetic 
testing revealed homozygous, loss of function mutations (c.397delinsGAA 
(p.P133Efs*95), hg19; also known as “121ins2”) in the surfactant protein B gene 
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(SFTPB). The infant underwent bilateral lung transplantation at 4 months of age. Lung 
explant histology revealed abnormal small air space development, marked hypertrophy of 
smooth muscle with extension into the lung periphery, type II pneumocyte hyperplasia, 
evidence of alveolar proteinosis, and vascular changes consistent with pulmonary 
hypertension.  She is alive 8 years post lung transplant and doing well at the time of 
manuscript submission. 
 
 
 
Modeling SFTPC mutations with iPSCs 
 We designed a donor vector with the same arms of homology as the tdTomato 
targeting vector used above, but with the SFTPC cDNA coding sequence fused to a GFP 
tag. This fusion construct has been used to study trafficking of SFTPC mutants via 
transient overexpression in heterologous cell lines, and has been shown to colocalize with 
proSFTPC protein in these models (Maguire et al. 2012; Beers et al. 2011). We targeted 
RUES2 lines with this construct, as well as an iPSC line (SPC1) from a patient with an 
SFTPC G182R BRICHOS mutation (Figure 4.3-4.5).  
      
 
Figure 4.3. SFTPC/GFP fusion TALENs targeting strategy and table of PSC lines that have been targeted to 
date.  
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Figure 4.4. SFTPC/GFP fusion targeting screening in RUES2.  
Row 1 shows a targeting screen, with a band at 960bp representing a targeted allele. Row 2 shows an intact endogenous 
allele screen, with a band at 906bp representing an intact endogenous allele. Expression of both bands should indicate 
monoallelic targeting. Row 3 shows one clone targeted with each SFTPC form listed above (RUES2 GFP/WT SPC-2, 
RUES2 GFP/I73T SPC-3, and RUES2 GFP/delta-exon4 SPC-1) screened for puromycin cassette excision, with a band 
at 600bp representing an intact puromycin cassette (no excision). After gDNA sequencing the region from the left arm 
of homology to the GFP transcription start site, I selected RUES2 GFP/WT SPC 2Cr2, RUES2 GFP/I73T SPC 3Cr1, 
and RUES2 GFP/delta exon 4 SPC 1Cr3 to further expand and try to differentiate.  
 
 
Figure 4.5. SFTPC/GFP fusion targeting screening in SPC1.  
Row 1 shows a targeting screen, with a band at 960bp representing a targeted allele. Left panel shows targeting with 
wt-SFTPC/GFP fusion and right panel shows targeting with G182R SFTPC/GFP fusion (the patient’s own mutation). 
Row 2 shows an intact endogenous allele screen, with a band at 906bp representing an intact endogenous allele. 
Expression of both bands should indicate monoallelic targeting. After gDNA sequencing the region from the left arm of 
homology to the GFP transcription start site, I froze down all of the above clones for storage at -150.  
 
 
 After confirming targeting by sequencing the gDNA, I differentiated these fusion 
targeted lines without sorting to enrich for CD47hi cells or passaging, and did not see 
expression of GFP by fluorescence microscopy or flow cytometry or RT-qPCR though 
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RT-qPCR did reveal low-level expression of SFTPC in these putative alveolospheres 
(Figure 4.6). This suggests that something about the fusion protein targeting results in 
different regulation of gene expression at the SFTPC locus than the simple fluorescent 
reporter allele, since expression of SFTPC mRNA does not correlate with expression of 
GFP mRNA or protein. The efficiency of differentiation was likely very low in these 
initial analyses and perhaps in a more efficient protocol (with CD47hi enrichment, 
passaging, or CHIR oscillation), these reporters might be expressed. Southern blot 
analysis or outgrowth from single cells would determine whether there were issues of 
mosaicism in these clones as well.  
 
Figure 4.6. SFTPC/GFP fusion differentiation results. 
Left panel shows flow cytometry analysis for GFP expression in 2 wells of the Day 28 wtSFTPC/GFP RUES2 fusion 
construct, with no discernable expression of GFP+ cells. Right top panel shows expression of SFTPC mRNA in Day 0 
iPSCs, Day 28 whole well wtSFTPC/GFP RUES2, presort for Day 34 C17, with around 1% of cells expression 
SFTPCtdTomato, Day 34 C17 sorted SFTPCtdTomato+ cells, and week 21 fetal lung cells. Right bottom panel shows 
expression of eGFP mRNA in Day 0 iPSCs, Day 28 Day 28 whole well wtSFTPC/GFP RUES2, presort for Day 34 
C17  with around 17% of cells expressing GFP, and Day 34 C17 NKX2-1GFP+ sorted cells.  
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Despite not having a working SFTPC/GFP fusion line, I was able to differentiate 
the SPC2 iPSC line (from a patient with the SFTPCI73T mutation) into alveolospheres 
after CD47hi enrichment for NKX2-1 expression and found robust expression of SFTPC, 
SFTPB, and NKX2-1 mRNA, as well as SFTPC protein in a pattern that resembles the 
misprocessed bands present in mouse models of SFTPCI73T expression (Figure 4.7). This 
suggests that a similar pathogenic process may be occurring in iPSC-derived SFTPCI73T 
expressing cells as what occurs in primary cells, and provides a strong rationale for 
further exploring this disease model.  
 
Figure 4.7. mRNA and protein expression in chILD iPSC-derived alveolospheres. 
Top panel shows qPCR for SFTPC, SFTPB, and NKX2-1 mRNA expression in alveolospheres from the following 
iPSC lines SP300 (E690K ABCA3 mutation), SP212 (121ins2 SFTPC mutation), and SPC2 (I73T SFTPC mutation), 
as well as a week 21 primary control. Bottom left shows western blot for NPRO-SFTPC, with primary control of 6 day 
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DCI cultured week 21 lung (HFL AT2 DCI) and alveolospheres from (1) SP212 iPSCs, (2) SP212Corr iPSCs, (3) 
SP212 iPSCs, (4) BU3 NGST iPSCs, (5) SP300 iPSCs, and (6) SPC2 iPSCs. Bottom right shows NPRO-SFTPC and 
bActin western blot in lung tissue from a mouse that expresses the SFTPCI73T allele. Red arrows indicate similar 
abnormally processed proSFTPC intermediates. (Western blot is from Mike Beers lab). 
 
 
Discussion 	
The ultimate test of iAEC2s as a clinically relevant surrogate for primary AEC2s 
is whether they can recapitulate human alveolar disease in vitro. Primary cells from 
patients with alveolar disease are difficult to access and do not proliferate well in culture, 
severely limiting studies into the pathogenesis of these diseases. Despite this, the 
pathogenesis of SFTPB deficiency has been documented as resulting in unstable SFTPB 
mRNA, lack of production of SFTPB protein and lamellar body agenesis (Nogee et al. 
1993; Beers et al. 2000). Indeed, in our studies, iAEC2s generated from a child with 
severe lung disease due to homozygous 121ins2 SFTPB mutations recapitulated known 
aspects of this disease, which were rescued in gene-corrected iAEC2s from the same 
patient. This finding shows that iAEC2s can provide a robust model for human alveolar 
disease that avoids the issues of patient access and safety, the low proliferative capacity 
of primary AEC2s, and the barriers to efficient gene editing of primary cells. Now, 24 
years after Nogee et al.’s original report of two brothers with neonatal respiratory distress 
and SFTPB deficiency suggestive of a genetic cause of the disease (Nogee et al. 1994), 
patient-specific iAEC2s and their gene-corrected progeny provide a sophisticated in vitro 
disease model, carrying each patient’s own genetic background. This new model both 
recapitulates the original observations, and demonstrates their reversal with gene editing 
technologies. We extend this disease modeling method to the SFTPCI73T mutation that 
causes early-onset interstitial lung disease, and find expression of misprocessed forms of 
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proSFTPC protein, absent in non-SFTPCI73T expressing alveolospheres, similar to the 
forms expressed in a mouse model of SFTPCI73T disease that leads to spontaneous 
fibrosis. This suggests that SFTPCI73T iAEC2s may be useful in modeling epithelial 
dysfunction. If this iPSC line were gene-edited in a similar way to the SFTPB121ins2 line, 
we could model this disease controlling for genetic background. SFTPC/GFP fusion 
proteins should simplify visualization of proSFTPC trafficking, but if problems with GFP 
expression continue, a strategy using just the tdTomato knockin reporter to knock out 
either the normal or diseased allele would allow for the same type of analysis. These 
models of SFTPB and SFTPC mutation related disease should now facilitate delineation 
of the disease-causing mechanisms previously studied by our community using 
heterologous systems and mouse genetic models (Clark et al. 1995; Melton et al. 2003; 
W. E. Lawson et al. 2011; Maguire et al. 2012).  
 
DISCUSSION 
Future Directions in Improving AEC2 Differentiation 
Though this work represents a significant advance toward a more accessible 
source of clinically relevant AEC2s, PSC-derived alveolospheres are not identical to 
mature primary AEC2s. The differentiation protocol could be improved in many ways to 
address some of these key differences.  
Efficiency 
What prevents 100% of NKX2-1+ derivatives from becoming SFTPC reporter+ 
cells? Though Chir withdrawal and addback does improve efficiency, the highest percent 
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we have seen is 70% Tomato+, with many runs continuing to be around 10% Tomato+. 
Previous data in the lab shows that 100% of NKX2-1+ progenitor cells can express 
SFTPC when cultured with distal lung mesenchyme (Hawkins et al. 2017). It would be 
interesting to repeat this experiment with the dual reporter line. If again 100% of the cells 
express SFTPCtdTomato reporter, that would suggest that there is a key factor missing in the 
differentiation media, or that there is a key inhibitor present that arrests the differentiation 
of some cells. Our lab has plans to perform a large screen of soluble factors on NKX2-1+ 
sorted outgrowth that might point to what the missing factors or inhibitors might be. 
Since we have seen positive immunostaining of SFTPCtdTomato- cells for proSFTPC 
protein, is important to note the possibility that the SFTPCtdTomato  reporter is not 
completely sensitive, that there is monoallelic expression of SFTPC, that incomplete 
PGK-puromycin resistance cassette excision results in promoter interference at the 
targeted SFTPC locus, or that loss of the endogenous polyA regulatory sequence inhibits 
transcription at the targeted locus. Since lower seeding densities result in a higher percent 
of cells expressing the SFTPC tdTomato reporter (Hawkins et al. 2017 and unpublished 
data) and passaging the cells when they reach a high density improves the SFTPC+ cell 
yield, there may be a paracrine factor secreted by the cells themselves that prevents 
maturation, or cell-cell contacts that inhibit maturation. Putative factors other than Wnt 
signaling that may inhibit alveolar differentiation from immature distal lung cells include 
Notch signaling and Fgf signaling. Overactive Fgf signaling has been shown to 
upregulate SOX9 expression in the distal lung and decrease expression of mature markers 
of AEC2s and AEC1s (Chang et al. 2013). Inhibition of Notch signaling has been shown 
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to augment the differentiation of mature alveolar epithelial cells from lineage negative 
epithelial progenitor cells that repopulate the lung after influenza injury (Vaughan et al. 
2015). I have previously added both Notch inhibitors (DAPT) and FGF MAPK inhibitors 
to the CK+DCI differentiation media and found no difference in SFTPCtdTomato% with 
DAPT but an increase in SFTPCtdTomato% with inhibition the PI3K arm of FGF signaling.  
Since we do see high levels of SFTPC expression even in the SFTPCtdTomato- 
population, it would also be worth addressing what level of SFTPC expression correlates 
with reporter expression. The cells also seem to be very fluid in reporter expression at 
late timepoints in differentiation, with sorted Tomato+ or Tomato- cells either losing or 
gaining expression of the reporter over the course of 2-3 days. Single cell sequencing of 
the Tomato+ and Tomato- cells could clarify the identities of these cells. Since the 
efficiency of the protocol has reached up to 70% in some cases, it seems likely that with a 
combination of soluble factor screens and single cell sequencing, we could develop a 
consistently highly efficient protocol, similar to the hepatocyte, cardiomyoctye, and 
neuronal differentiation protocols.  
Surfactant Function 
How many of the cells in alveolospheres express functional lamellar bodies? Do 
alveolospheres secrete surfactant in an organized manner capable of generating a surface 
film that reduces surface tension and can contract and expand? Currently, it seems that 
though mature SFTPB is highly expressed in alveolospheres, proSFTPC protein is harder 
to detect. Possible hypotheses to explain this could be (1) reporter lines are 
haploinsufficient for SFTPC which could reduce proSFTPC protein expression, (2) 
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SFTPC functions at low tidal volumes in the human lung and without the cyclical stretch 
that the lung is exposed to in utero, protein expression may be reduced, and (3) it is 
possible that SFTPC processing (similar to SFTPB processing) is so efficient in these 
cells that the proSFTPC form is not detected. Interestingly, when I differentiated iPSCs 
from a patient with an I73T SFTPC mutation, we found high levels of proSFTPC 
expression, suggesting that SFTPC can accumulate in alveolospheres, and that perhaps in 
non-SFTPC mutant iPSC lines we are less likely to see proSFTPC buildup. Since SFTPC 
is not required for surfactant function except for at very low tidal volumes, and mutant 
proSFTPC still accumulates as predicted in previous studies, perhaps the level of SFTPC 
expression is sufficient for the study of most diseases.  
Though we have determined that alveolospheres express relatively surfactant-
specific DPPC and can secrete it into the interior of the sphere, there are additional 
techniques that would allow us to determine the surface-activity of alveolosphere 
surfactant as compared to actual surfactant. A diagram of some of these techniques 
follows (Figure 5.1):  
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Figure 5.1. Biophysical techniques used to evaluate surface activity of surfactant preps in vitro (From Serrano et 
al. 2006).  
 Though the 3D culture system is not optimal for these analyses, growing 
alveolosphere cells in 2D air-liquid interface (ALI) might provide a better model to 
assess surfactant function.  Since cyclical stretch of the lung is a constant factor in late 
fetal development, it could be interesting to see how stretch of an ALI membrane could 
influence gene and protein expression as well as surfactant function and differentiation 
efficiency.  
 How many cells within an alveolosphere express lamellar bodies? Since LAMP3 
expression is low in alveolospheres, it is unclear whether we would get a strong readout 
by immunostaining for LAMP3 and identifying cells that express a classical vesicular LB 
pattern. Staining with a dye like lysotracker which identifies organelles of low pH, both 
with and without Chir oscillation, would help clarify this issue in both SFTPCtdTomato+ and 
SFTPCtdTomato- cells.   
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Global Transcriptomic Differences between PSC-derived AEC2s and Primary AEC2s 
 What are the transcriptomic differences between PSC-derived AEC2s and 
primary AEC2s and how will they impact our ability to use these engineered cells as 
surrogates for primary cells? A preliminary analysis suggests that pathways differentially 
upregulated in primary adult AEC2s are related to inflammation, oxidant stress, and 
aging. The only known AEC2 gene that is significantly lower in PSC-derived AEC2s vs. 
primary cells is LAMP3, and LAMP3 expression could be an important marker of 
maturation in this system. It could also be valuable to compare PSC-derived AEC2s to 
primary AEC2s on a single cell level, so that we can identify subsets of primary AEC2s 
and which genes are expressed differentially in those cells vs. ours without concerns of 
non-AEC2 contaminants in either population. Though cells differentiated in vitro over 
only 30 days, without being surrounded by the mesenchymal cells in the alveolar niche 
and the exogenous and innate immune signals present in the air-breathing lung are 
unlikely to fully recapitulate the global transcriptome of primary AEC2s, PSC-derived 
AECs can still reflect important primary cell biology in the context of development and 
disease. Chasing after gene-expression may distract greatly from more important 
functional studies, and it would be more valuable to focus on the gene expression 
differences that correlate with a lack of AEC2 functionality.  
Cell surface markers 
 Can we develop a cell surface marker specific enough for SFTPC-expressing cells 
that we could replace the knockin tdTomato reporter? Though I have screened several 
possible cell surface markers (data not shown), I have not found one that it detects the 
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majority of SFTPCtdTomato+ cells or is particularly specific to this population. Single-cell 
sequencing of SFTPC+ vs SFTPC- cells might shed light on whether a surface marker 
exists, and it would be worth attempting to use the HT2-280 antibody that has been 
reported to bind to the apical surface of AEC2s in vivo (Gonzalez et al. 2010). Though 
the CD47hi/CD26lo sort algorithm works well to identify NKX2-1+ cells at early 
timepoints, we cannot use this algorithm at later timepoints until we have a better 
understanding of the heterogeneity within the NKX2-1+ SFTPC- population and whether 
these cells represent immature distal cells or another cell type entirely.  
Optimal culture conditions for AEC2s 
 Once AEC2s have been derived from PSCs, how can they be cultured in a way 
that is amenable to our research interests? Though we have emphasized differentiating 
AEC2s in mesenchyme-free conditions to better understand the signaling pathways that 
act directly on the epithelium, most previous reports of AEC2 culture have included co-
culture with mesenchymal feeders from endothelial cells to fetal lung fibroblast cell lines. 
It would be interesting to culture PSC-AEC2s with lung mesenchymal lineages and 
evaluate differences in proliferation and maturation. However, it is unclear whether 
mesenchymal feeders are alive or proliferative in the previously published studies 
(Barkauskas et al. 2013; Lee et al. 2014), and it is unlikely that mesenchymal cells will 
grow in 3D culture in CK+DCI media. We should evaluate PSC-AEC2 survival and 
differentiation in alternate medias, such as MTEC media or SAGM media, which have 
been shown previously to support AEC2/mesenchymal co-culture.  
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ALI culture is an alternative to culturing AEC2s in 3D culture that might help 
maintain their AEC2 phenotype and make the system more amenable to certain analyses, 
like barrier function, surfactant secretion, in vivo protein trafficking. Since the apical side 
of ALI cultures can also be washed with medias other than CK+DCI, this might allow us 
to understand how AEC2 secreted signals influence non-epithelial cells without the 
complications of finding a media for co-culture. Another advantage of ALI culture would 
be the ability to expose the apical side of the culture to environmental toxins like 
cigarette smoke, microbial infection, and bleomycin, among others. Finally, ALI culture 
would allow us to simulate a possible route of gene-based therapy for monogenic 
diseases. For example, we could add CRISPR/Cas9 plasmids and oligo donors to the 
apical surface of the ALI culture and evaluate the efficacy of this gene editing technique.   
Another interesting culture technique for these cells would be culture on a matrix 
that resembled actual alveolar structure. Though our lab has attempted this before by 
injecting mouse ESC-derived cells into a decellularized lung and culturing a slice of the 
lung in-vitro (Longmire et al. 2012), it would be worthwhile to attempt this technique 
again with more well defined SFTPC-expressing cells. Other groups have attempted to 
recapitulate alveolar structure using alginate beads to form mesenchymal organoids 
though do not appear to have successfully formed organoids with both mesenchymal and 
epithelial components or endothelial tubes (Wilkinson et al. 2017). Finally, there have 
been reports of “lung-on-a-chip” in which epithelial and endothelial cells are seeded on 
opposing sides of a membrane, forming an epithelial-endothelial interface. This method 
has allowed for measuring barrier function and the effects of stretch on both cell layers, 
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and would allow for culture of each cell in a separate media, and could be useful for 
studying PSC-AEC2 models of ARDS or infection (Huh et al. 2010).  
Correlations to mouse models of development and disease 
 The key findings from this in vitro model of development are 1) that WNT, 
BMP4, and RA agonists are the minimal required agonists for differentiation of NKX2-
1+ lung progenitor cells from anterior foregut endoderm cells, 2) that WNT agonism and 
dexamethasone/cAMP activation are required for differentiation of ~week 24 gestation 
AEC2s from lung progenitors and that KGF augments proliferation, 3) that a period of 
reduced WNT activity is important to allow immature lung progenitor cells to progress to 
a high SFTPC-expressing stage, and 4) that AEC2s increase proliferation in response to 
WNT activation.   
 The WNT/BMP4/RA findings relates directly to a recent study published by 
Rankin et al. showing that RA regulates the competence of anterior foregut endoderm to 
respond to WNT and BMP4 signaling from the adjacent mesoderm, promoting the 
specification of NKX2-1+ lung progenitors. WNT activity has long been associated with 
distalization of the lung primordium (Mucenski et al. 2005; Shu et al. 2005), and it is not 
surprising that activation of WNT greatly increases expression of SFTPC. However, it is 
unclear why dexamethasone is required for expression of the SFTPCtdTomato reporter, 
especially since they are not required to specify SFTPC+ cells in mouse models 
(Longmire et al. 2012) (Serra et al. in revision). They have been shown to increase 
expression of surfactant proteins and generation of lamellar bodies in AEC2s ex vivo, 
however, and it is possible that our distalized cells express low levels of SFTPC mRNA 
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but do not express the SFTPC reporter until that expression level is increased by DCI. 
Another possibility is that because the cells survive poorly without DCI, human cells 
simply have different survival requirements than mouse cells.  
 The idea that a decrease in WNT activity could promote maturation is supported 
by a recent finding by Frank et al. showing an initial dip in WNT responsiveness at the 
end of branching morphogenesis followed by an increase in WNT signaling during the 
alveologenesis stage, marked by a population of Axin2-expressing AEC2s (Frank et al. 
2016). It is possible that the dip in WNT signaling coincides with the dip in FGF 
signaling and Sox9 expression observed by Chang et al. at the end of branching 
morphogenesis (Chang et al. 2013). It would be interesting to evaluate the effects of FGF 
signaling inhibition at this timepoint and the expression of SOX9 with or without 
withdrawal. Surprisingly, though Frank et al. found an increase in AEC1 differentiation 
when AEC2s were cultured in the absence of CHIR, I did not find an increase in AEC1 
markers in this condition, and found it difficult to find expression of these markers in any 
condition I cultured these AEC2s in. Perhaps they are highly committed to an AEC2 fate 
in CK+DCI media or they are missing an important signal that drives AEC2-to-AEC1 
differentiation. Contrasting reports have shown that p300/b catenin signaling via Protein 
Kinase C is the key factor that promotes AEC2 differentiation, and it would be worth 
culturing AEC2s in CK+DCI media with ICG-001, which would inhibit CBP/b catenin 
interactions to test whether augmenting p300 activity would result in AEC1 marker 
expression (Rieger et al. 2016). We do not find any evidence of coexpression of SFTPC 
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and PDPN, suggesting existence of a “bipotent progenitor” in this system, though single 
cell sequencing should allow us to further explore this possibility.  
 Finally, the increase in proliferation in response to WNT agonism via CHIR was 
shown both in vivo and ex vivo in the Frank et al. paper, and was not unexpected since 
WNT is known to increase proliferation in many cell types. It does seem that CK+DCI 
media in contrast to DCI media maintains expression of surfactant proteins much better 
even in primary cells, suggesting that this media might be advantageous for primary 
AEC2 culture as well.  
 Our findings correlate well with mouse models of human disease, specifically 
SFTPB deficiency and SFTPC I73T expression. In iPSC-alveolospheres from an 
SFTPCI73T patient, we found similar patterns of expression of misprocessed SFTPC by 
Western blot to those seen in the lungs of mice expressing the same mutant allele. In 
iPSC-alveolospheres from an SFTPB121ins2 patient, we found similar phenotypes at the 
mRNA, protein, and ultrastructural levels, and we found that all of these phenotypes 
could be reversed in iPSC-alveolospheres from the same patient with the disease allele 
corrected. All current in vivo and in vitro models of alveolar disease, however, have 
generally proven inadequate to predict therapeutics that work for patients, possibly due to 
differences in cell phenotype or genetic background. iPSC-alveolospheres could represent 
the first steps toward a high throughput screening model for patient-specific therapeutics.  
 For SFTPB deficiency, though mouse models have given us a strong 
understanding of the surfactant related pathology of the disease; it remains unclear 
whether there is an additional injury intrinsic to AEC2s that is unrelated to lack of 
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surfactant. Performing transcriptome-wide analysis of pre- and post- SFTPB correction 
alveolospheres would be a good first step toward finding interesting pathways that may 
be different due to the mutation, but either a lineage-specific reporter, sort marker, or 
single cell sequencing would likely be required to determine the effect on AEC2s as 
opposed to other lineages. One aspect of the disease that we have not yet addressed is the 
lipidomics within the cells and secreted material, which could make for the most 
straightforward readout for a drug screen, especially if these cells could be cultured in 
2D.  
Future Plans for Modeling Alveolar Disease 
 Using PSC-derived alveolospheres to model the epithelial contribution to 
pulmonary fibrosis would be a clear next step. SFTPC mutations are likely the best place 
to start due to their specificity to AEC2 expression and clear link to pulmonary fibrosis, 
but other mutations such as SFTPA mutations and TERT or TERC mutations more 
associated with adult onset fibrosis would be interesting to study as well. Starting with 
epithelial perturbations, we could analyze iAEC2s controlled for genetic background 
using analysis of the global transcriptome, single cell transcriptomes, protein 
mistrafficking, ER stress pathway, and apoptosis activation. We could also analyze 
secreted signals using cytokine arrays or mass spectrometry.  
Since fibrosis likely involves several cells of the lung from the epithelium, 
mesenchyme, and endothelium, it would be interesting to culture any of these other cell 
types from primary human or mouse tissue with the AEC2 secretions or in a co-culture 
model and evaluate their changes in gene or protein expression.  
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Other ways in which iAEC2s could model alveolar disease include exposure to 
cigarette smoke, any number of bacterial, viral, or fungal infections, environmental 
toxins, bleomycin injury, hypoxia or hyperoxia, overexpression of KRas to model the 
early adenocarcinoma, and many more. 
Implications for future gene-based or cell-based therapy 
 Some of the most exciting applications for this model would be in true lung 
regeneration though gene-editing to correct monogenic diseases or cell based therapy to 
replace lost alveolar epithelium.  
 Since we have a CRISPR/Cas9 system working that effectively corrects the 
SFTPB121ins2 mutation and reverses disease pathology, we could attempt to use this same 
CRISPR/Cas9 guideRNA and oligo donor to correct the mutation in iAEC2s either in 3D 
culture or, to better mimic polarity in the developing embryo, ALI culture. Similar 
strategies could be used for NKX2-1, ABCA3, or HPS mutations. For SFTPC mutations, 
since the pathogenic allele is a dominant negative, and since total loss of SFTPC is not 
associated with a severe phenotype in patients, gene therapy could involve simple 
knockout of the SFTPC gene, possibly with only one CRISPR targeted to the 5’ portion 
of the transcript.  
 Could iAEC2s ever be used for cell-based therapy? Of course that would be the 
end goal of this type of work- generating AEC2s from patient iPSCs that could be 
transplanted back into the patient and recover lung function. There are multiple avenues 
by which this could be achieved. First, we could engraft AEC2s into areas of lung injury. 
In the past 2 years we have seen the first believable report of engraftment of a lineage 
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negative distal lung cell capable of repopulating both the airway and alveolar 
compartments after influenza A injury (Vaughan et al. 2015). Though we do not have 
evidence thus far of having generated this “LNEP” cell in vitro, it is possible that since 
iAEC2s have much higher proliferative capacity in vitro than has been previously 
reported for primary AEC2s, these cells could still be capable of engrafting in an injury 
model. Less mature Day 15 NKX2-1+ lung progenitors or proximalized cells might also 
be an alternative source of engraftable cells. These techniques would have to be 
performed in a humanized mouse model, which might complicate the influenza infection 
response, and another injury model might need to be evaluated.  
 Another strategy would be to re-seed a decellularized mouse or rat lung with 
epithelial and endothelial cells in the air spaces and vascular network, respectively, 
transplant it into a mouse or rat that had been pneumonectomized, and see whether gas 
exchange could occur, as our lab has attempted in the past (Ott et al. 2010). The main 
obstacle to this method is the cell number required to recellularize the lung epithelium- 
we have not yet expanded differentiation capacity to 100 million cells or more, but this 
should be an achievable goal, and it would be fascinating to see whether the cells in the 
right matrix differentiate into AEC1s and can perform gas exchange.  
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Figure 5.2 Future plans for using the iPSC-derived AEC2s to better understand and treat disease. 				
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APPENDIX 
Appendix A. GSEA Analysis of AEC2 Developmental Timecourse 
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Appendix B. GSEA Analysis of Week 21 Distal Lung Culture 
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Appendix C. GSEA Analysis of Passaging Alveolospheres 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DOWN WITH SORTING AND PASSAGING FDR
HALLMARK_HYPOXIA 1.1E-12
HALLMARK_GLYCOLYSIS 9.4E-07
HALLMARK_TNFA_SIGNALING_VIA_NFKB 2.3E-05
HALLMARK_MTORC1_SIGNALING 6.8E-05
HALLMARK_INFLAMMATORY_RESPONSE 5.6E-03
HALLMARK_IL6_JAK_STAT3_SIGNALING 8.4E-03
HALLMARK_IL2_STAT5_SIGNALING 3.2E-02
HALLMARK_KRAS_SIGNALING_UP 4.6E-02
DOWN WITH SORTING ONLY FDR
HALLMARK_HYPOXIA 0.0001
HALLMARK_TGF_BETA_SIGNALING 0.0143
HALLMARK_GLYCOLYSIS 0.0143
HALLMARK_PANCREAS_BETA_CELLS 0.0147
HALLMARK_IL6_JAK_STAT3_SIGNALING 0.0304
HALLMARK_INFLAMMATORY_RESPONSE 0.0422
DOWN WITH PASSAGING FDR
HALLMARK_HYPOXIA 6.1E-12
HALLMARK_GLYCOLYSIS 1.4E-07
HALLMARK_MTORC1_SIGNALING 1.3E-05
HALLMARK_TNFA_SIGNALING_VIA_NFKB 3.1E-05
HALLMARK_E2F_TARGETS 6.8E-03
HALLMARK_MYC_TARGETS_V1 2.2E-02
HALLMARK_INFLAMMATORY_RESPONSE 3.7E-02
HALLMARK_IL6_JAK_STAT3_SIGNALING 3.7E-02
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Appendix D. Key Resources Table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit monoclonal to NKX2-1 (clone EP15847) Abcam Cat.# ab76013 
Mouse monoclonal to NKX2-1 (clone 8G7G3/1) Abcam Cat.# ab72876 
Rabbit polyclonal to Pro-SFTPB Seven Hills Cat.# WRAB-55522 
Rabbit polyclonal to Pro-SFTPC Seven Hills Cat.# WRAB-9337 
Rabbit polyclonal to Mature SFTPB Seven Hills Cat.#	r28031 
Rabbit polyclonal to Mature SFTPC Seven Hills Cat.#	r76694 
Mouse monoclonal to EPCAM (clone AUA1) Abcam Cat.# ab181853 
Mouse monoclonal to CD26, PE conjugated 
(clone BA5b) 
Biolegend Cat.# 302705 
Mouse monoclonal to CD47, PerCP-Cy5.5 
conjugated (clone CC2C6) 
Biolgend Cat.# 323110 
Mouse monoclonal to red fluorescent protein 
(RFP) 
Abcam Cat.# 65856 
Rabbit monoclonal to red fluorescent protein 
(RFP) 
Rockland Cat.# 600-401-379 
Anti-mature SFTPB (PT3) Guttentag/ 
Beers Lab  
(Beers, et al. 1992) 
Anti-NFLANK SFTPB Guttentag Lab  (Korimilli, et al. 2000) 
Anti-NPRO SFTPC Beers Lab  (Beers, et al. 1994) 
Anti-pan actin Cell Signaling Cat.# 8456 
Anti-GAPDH Chemicon Cat.# MAB374 
Anti-bActin Sigma Cat.# A1978 
Anti- phosphoStat3 Cell Signaling Cat.# 9131 
Anti IkB Santa Cruz Cat.# sc-371 
AffiniPure Donkey Anti-Rabbit IgG (H+L), 488 
conjugated 
Jackson 
Immunoresearch 
Cat.# 711-225-152 
AffiniPure Donkey Anti-Rabbit IgG (H+L), Cy3 
conjugated 
Jackson 
Immunoresearch 
Cat.# 711-165-152 
AffiniPure Donkey Anti-Rabbit IgG (H+L), 
AlexaFluor 647 conjugated 
Jackson 
Immunoresearch 
Cat.# 711-605-152 
AffiniPure Donkey Anti-Mouse IgG (H+L), 
AlexaFluor 647 conjugated 
Jackson 
Immunoresearch 
Cat.# 715-605-150 
AffiniPure Donkey Anti-Mouse IgG (H+L), 
AlexaFluor Cy3 conjugated 
Jackson 
Immunoresearch 
Cat.# 715-165-150 
AffiniPure Donkey Anti-Goat IgG (H+L), 
AlexaFluor 647 conjugated 
Jackson 
Immunoresearch 
Cat.# 305-605-003 
   
   
Biological Samples 
   
Chemicals, Peptides, and Recombinant Proteins 
Growth Factor Reduced Matrigel Corning Cat.# 356230 
SB431542 Tocris Cat.# 1614 
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Dorsomorphin Stemgent Cat.# 04-0024 
CHIR99021 Tocris Cat.# 4423 
Recombinant human FGF10 R&D Systems Cat.# 345-FG-025 
Recombinant human KGF R&D Systems Cat.# 251-KG-010 
Recombinant human BMP4 R&D Systems Cat.# 314-BP 
Retinoic acid Sigma Cat.# R2625 
Y-27632 dihydrochloride Tocris Cat.# 1254 
Recombinant human FGF2 R&D Systems Cat.# 233-FB 
Recombinant human TGFβ R&D Systems Cat.# 240-B 
DAPT Sigma Cat.# D5942 
Dexamethasone Sigma Cat.# D4902 
8-bromoadenosine 3’,5’-cyclic monophosphate 
sodium salt (cAMP) 
Sigma Cat.# B7880 
3-Isobutyl-1-methylxanthine (IBMX) Sigma Cat.# I5879 
Recombinant mouse Noggin R&D Systems Cat.# 1967-NG 
Recombinant mouse EGF R&D Systems Cat.# 2028-EG-200 
Hoechst Thermo Fisher 
Scientific 
Cat.# H3570 
Puromycin Dihydrochloride Thermo Fisher Cat.# A1113802 
Geneticin Sulfate Life Technologies Cat.# 11811-023 
0.05% trypsin-EDTA Invitrogen Cat.# 25300-120 
Defined Fetal Bovine Serum Thermo Fisher Cat.# NC0652331 
Calcein blue Life Technologies Cat.#	C1429 
Recombinant human TNFa R&D Systems Cat.# 210-TA-005 
Recombinant human IL1-b R&D Systems Cat.# 201-LB-005 
Recombinant human OSM R&D Systems Cat.# 295-OM-
010/CF 
 
Dispase Thermo Fisher Cat.#	354235 
Glutaraldehyde Ladd Research Cat.# 20100 
Osmium Tetroxide Polysciences Cat.# 0223D 
Uranyl Acetate Electron 
Microscopy 
Sciences 
Cat.# 22400 
EMbed 812 Electron 
Microscopy 
Sciences 
Cat.# 14120 
14:0 PC (DMPC)  Avanti Polar 
Lipids 
Cat.#	850345 
Paraformaldehyde Electron 
Microscopy 
Sciences 
Cat.# 19208 
   
Critical Commercial Assays 
RNeasy Mini Kit Qiagen Cat.# 74104 
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QIAzol Lysis Reagent Qiagen Cat.# 79306 
TaqMan Fast Universal PCR Master Mix (2X), 
no AmpErase UNG 
Thermo Fisher  Cat.# 4364103 
High-Capacity cDNA Reverse Transcription Kit Applied 
Biosystems 
Cat.#	4368814 
   
Deposited Data 
Generation of mature lung alveolar epithelial 
cells from human pluripotent stem cells 
 GEO#: GSE96642 
 
   
Experimental Models: Cell Lines 
Normal donor induced pluripotent stem cell 
(iPSC) line (BU3) 
Kotton Lab 
(Hawkins et al. in 
press) 
www.bumc.bu.edu/ 
stemcells 
Normal donor iPSC line targeted with NKX2-
1GFP (BU3GFP) 
Kotton Lab 
(Hawkins et al. in 
press) 
www.bumc.bu.edu/ 
stemcells 
Cystic fibrosis donor iPSC line targeted with 
NKX2-1GFP (C17) 
Gift from Dr. 
Brian Davis, 
Houston, TX 
 
SFTPB deficiency donor iPSC line (SP212) This paper  
Corrected SFTPB deficiency donor iPSC line 
(SP212) 
This paper  
RUES2 embryonic stem cell line Gift from Dr. Ali 
H. Brivanlou, 
Rockefeller 
University 
 
Experimental Models: Organisms/Strains 
   
Recombinant DNA 
EF1a-TALEN_HD, EF1a-TALEN_NN This paper  
p1303-DV-SFTPC-tdTomato This paper  
pHAGE2 EF1a-Cre-IRES-NeoR-W This paper  
pHAGE2-Cre-IRES-PuroR  Kotton Lab 
(Somers et al. 
2010) 
Addgene #30205 
pD1321-AD- SFTPB121ins2 DNA 2.0 ATUM  
   
Sequence-Based Reagents 
TaqMan Gene Expression Assay Primer/Probe 
Sets 
Thermo Fisher   
SFTPC Thermo Fisher Hs00161628_m1 
SFTPB Thermo Fisher Hs01090667_m1 
ABCA3 Thermo Fisher Hs00975530_m1 
LAMP3 Thermo Fisher Hs00180880_m1 
NKX2-1 Thermo Fisher Hs00968940_m1 
SLC34A2 Thermo Fisher Hs00197519_m1 
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LPCAT1 Thermo Fisher Hs00227357_m1   
PDPN Thermo Fisher Hs00366766_m1 
AGER Thermo Fisher Hs00542584_g1 
AQP5 Thermo Fisher Hs00387048_m1 
SCGB1A1 Thermo Fisher Hs00171092_m1 
P63 Thermo Fisher Hs00978340_m1 
SOCS3 Thermo Fisher Hs02330328_s1 
IL-8 Thermo Fisher Hs00174103_m1 
GMCSF Thermo Fisher Hs00531296_g1 
NKD1 Thermo Fisher Hs00263894_m1 
LEF1 Thermo Fisher Hs01547250_m1 
eGFP Thermo Fisher Mr04329676_mr 
   
Software and Algorithms 
ImageJ National 
Institutes of 
Health 
Imagej.nih.gov/ij/ 
   
Other 
StemDiff Definitive Endoderm Kit StemCell 
Technologies 
Cat.# 05110 
mTeSR1 StemCell 
Technologies 
Cat.# 05850 
Glutamax Life Technologies Cat.# 35050-061 
Gentle Cell Dissociation Reagent StemCell 
Technologies 
Cat.# 07174 
Click-iT® EdU Alexa Fluor® 488 Imaging Kit  Thermo Fisher Cat.# C10337 
EZ-TAL TALE Assembly Kit System 
Bioscience 
Cat.# GE120A-1 
Lipfectamine LTX Kit Thermo Fisher Cat.# 15338100 
P3 Primary Cell 4D-Nucleofector® X Kit S  Lonza Cat.#	V4XP-3032 
PAS Kit Sigma Cat.# 395b 
Hela Monster transfection reagent  Mirus Cat.# MIR 2904 
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